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Abstract11
In patients with early-stage cancer, ctDNA detection rates can be low due to the presence of12
few or no copies of any individual mutation in each sample. Sensitivity may be increased13
by collecting larger plasma volumes, but this is not feasible in practice. Although cancers14
typically have thousands of mutations in their genome, previous analyses measured only15
individual or up to 32 tumour-specific mutations in plasma.16
Here, we demonstrate that sensitivity can be greatly enhanced for any given input DNA17
mass by analysing a large number of mutations via sequencing. We sequenced in plasma18
102-104 mutated loci per patient, using custom capture panels, whole exome (WES) or19
whole genome sequencing (WGS). We developed a method for INtegration of VAriant Reads20
(INVAR) that aggregates reads carrying tumour mutations across multiple mutant loci, and21
assigns confidence to error-suppressed reads based on mutation context, fragment length and22
tumour representation. This workflow combines a number of concepts in a novel approach in23
order to quantify ctDNA with maximal sensitivity.24
We applied INVAR to plasma sequencing data from 45 patients with stage II-IV melanoma25
and 26 healthy individuals. ctDNA was detected to 1 mutant molecule per million, and tu-26
mour volumes of ~1cm3. We show that this algorithm is applicable across targeted and27
untargeted sequencing methods. In patients with stage II-III melanoma who relapsed after28
resection, ctDNA was detected within 6 months post-surgery and prior to relapse in 50% of29
cases, compared to 16% in a similar cohort analysed with digital PCR. In addition, INVAR30
may enhance detection of ctDNA in samples with limited input or sequencing coverage by31
iv
aggregating signal across a large number of mutations. Using low-depth WGS (0.6x), ctDNA32
was detected to 1 mutant per 10,000 molecules. Given that 60 genome copies of cfDNA may33
be obtained from 1 drop of blood (50-75µL), we suggest that INVAR may enable cancer34
monitoring from limited samples volumes.35
36
As tumour sequencing becomes more widespread allowing identification of a large37
number of mutations per patient, this method has potential to quantify ctDNA with enhanced38
sensitivity, and to enable routine cancer monitoring using low-depth sequencing, potentially39
from low-volume blood samples that might be self-collected.40
Lay Abstract41
Cancer cells release their contents into the bloodstream when they die. This includes mutated42
DNA fragments from the cell nucleus, which can be called circulating tumour DNA (ctDNA).43
Therefore, cancer can be detected from blood tests by identification of ctDNA through44
methods such as DNA sequencing. The fraction of DNA fragments that are mutated in a45
patient’s blood corresponds to the extent of cancer in their body. Thus, in patients with low46
disease burden, for example post-surgery or in response to treatment, there are few mutant47
DNA molecules in the bloodstream. This results in ctDNA molecules being missed when48
blood is sampled and tested for specific mutations.49
Cancers can have up to 102 to 104 mutations in their genome, each in different regions of50
the genome. Each mutation gives rise to a ctDNA fragment, representing an opportunity to51
detect cancer. DNA sequencing-based approaches have so far targeted up to 40 mutations52
per patient in order to improve sensitivity for ctDNA compared to methods targeting single53
mutations. In order to target multiple mutations efficiently, These mutations may be identified54
per patient if tumour sequencing is performed prior to ctDNA analysis, which is possible in55
the disease monitoring setting, and may allow improved detection or monitoring of cancer.56
In this study, we studied patients with early or advanced melanoma skin cancer and57
identified up to 5,073 tumour mutations per patient, then sequenced patients’ blood samples.58
To achieve high sensitivity detection, we developed a method called ‘INtegration of VAri-59
ant Reads’ (INVAR) that aggregates signal across thousands of mutations, and considers60
biological and technical features of ctDNA sequencing. This method detects low levels of61
vi
ctDNA, down to a single mutant molecule per million circulating DNA molecules. ctDNA62
was detected in 100% of advanced melanoma patients, and disease was monitored to the63
limit of CT imaging. Within 6 months post-surgery, this method detected ctDNA in 50%64
of stage II-III melanoma patients who later relapsed within 5 years. Furthermore, sensitive65
detection of ctDNA can be achieved from samples where little starting material, or limited66
(low-depth) sequencing data, is available. We show that this method can monitor ctDNA to 167
mutant molecule per 10,000 using limited input and low-depth WGS. These data could be68
generated from ~1 genome copy, indicating that cancer monitoring from droplet volumes of69
blood with high sensitivity may be possible.70
71
As tumour and plasma sequencing becomes increasingly routine, INVAR could enhance72
detection of residual disease and could enable cancer monitoring using low-depth sequencing,73
or from limited sample volumes such as blood droplets, which might enable self-collection74
at home.75
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1.1 Attribution408
This chapter is adapted from a review article which we published in 2017:409
410
Wan, JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S,411
Baird R & Rosenfeld N (2017). Liquid biopsies come of age: towards implementation of412
circulating tumour DNA. Nature Reviews Cancer, 17(4), 223-238.413
414
In this thesis, I have adapted the manuscript to expand upon Section 1.9 (Enhancing detection415
of residual disease).416
For this chapter, I performed the literature review wrote the draft manuscript, under417
the supervision of Nitzan Rosenfeld and Richard Baird. Following feedback from Nature418
Reviews Cancer to increase the level of discussion throughout the manuscript, I rewrote419
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much of the manuscript, synthesising ideas across the cfDNA field. This involved linking420
ideas between non-invasive prenatal testing and ctDNA, and linking potential applications421
between cfDNA, cfRNA and other circulating nucleic acids. Nitzan oversaw this re-writing,422
corrected the wording throughout the Review. The published version is attached.423
Given the focus of my thesis on the sensitivity of methods for ctDNA, I added Section 1.10424
‘Enhancing detection of residual disease’, which I drafted and Nitzan Rosenfeld approved.425
This section allowed the inclusion of studies published on ctDNA detection since the time of426
our Review being written.427
1.2 Abstract428
Improvements in genomic and molecular methods are expanding the range of potential429
applications for circulating tumour DNA (ctDNA), both in a research setting and as a430
‘liquid biopsy’ for cancer management. Proof-of-principle studies have demonstrated the431
translational potential of ctDNA for prognostication, molecular profiling and monitoring.432
The field is now in an exciting transitional period in which ctDNA analysis is beginning433
to be applied clinically, although there is still much to learn about the biology of cell-free434
DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to435
consider their applications in personalised oncology and in cancer research.436
1.3 Introduction437
The presence of fragments of cell-free nucleic acids in human blood was first described in438
1948 by Mandel and Métais [1]. The origins and characteristics of cell-free DNA (cfDNA)439
were studied intermittently in subsequent decades [2]. In healthy individuals, cfDNA concen-440
tration tends to range between 1-10ng/millilitre (ml) in plasma [2, 3], and raised cfDNA levels441
were first reported in the serum of cancer patients in 1977 [2]. cfDNA concentration can442
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also be raised by other illnesses or conditions, such as acute trauma [4], cerebral infarction443
[5], exercise [6], transplantation [7], and infection [8]. Furthermore, the identification of444
fetal DNA sequences in maternal plasma by Dennis Lo and colleagues in 1997 [9] has led445
to multiple applications of cfDNA in prenatal medicine including sex determination [10],446
identification of monogenic disorders [11], and non-invasive prenatal testing (NIPT) for447
aneuploidies such as Down’s Syndrome (trisomy 21), which was first demonstrated in 2007448
by Lo et al. [12] and has moved rapidly into widespread clinical use [13, 14].449
In 1989, Stroun, Anker et al. identified that at least some cfDNA in the plasma of cancer450
patients originates from cancer cells [15]. In 1992, Vogelstein, Sidransky and colleagues451
showed that DNA from urinary sediments (cell pellets) from patients with invasive bladder452
cancer carried mutations in TP53, setting the stage for the use of genomic analysis methods453
in liquid biopsy applications [16]. KRAS mutations were soon found in stool or sputum454
that matched mutations from colorectal , pancreatic [17], or lung cancers [18, 19]. In 1994,455
mutated KRAS sequences were first reported to be detected in plasma cfDNA of patients456
with pancreatic cancer using polymerase chain reaction (PCR) with allele-specific primers457
[20]. For each patient, the KRAS mutation found in the plasma was identical to that found in458
the patient’s tumour, thereby confirming that the mutant DNA fragments in plasma were of459
tumour origin. Mutations in cfDNA are highly specific markers for cancer, which gave rise460
to the term circulating tumour DNA (ctDNA).461
In the following decades, ctDNA was explored as a prognostic or predictive marker462
[21, 22] and for cancer detection [23]. Such studies confirmed the potential of ctDNA,463
though the levels of ctDNA in different clinical contexts were not yet accurately defined.464
These studies nonetheless could demonstrate potential clinical applications, for example465
detection of KRAS mutations in plasma as a potential prognostic factor in colorectal cancer466
[24]. The introduction of a digital PCR (dPCR) method in 1999 by Vogelstein and Kinzler467
enabled the accurate identification and absolute quantification of rare mutant fragments468
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[25]. A modification of this technique using beads in emulsions [26] and flow cytometry469
allowed the quantification of the mutant allele fraction of cancer mutations in the plasma470
of patients with different stages of colorectal cancer [27]. Diehl, Diaz and colleagues then471
showed in 2008 that ctDNA is a highly specific marker of tumour dynamics, and may be472
able to indicate residual disease [28]. In parallel, allele-specific PCR and other methods473
were devised and tested for their ability to identify epidermal growth factor receptor (EGFR)474
mutations in serum or plasma of lung cancer patients, following the elucidation of the role of475
such mutations in predicting response to treatment with molecularly targeted inhibitors.476
The development of next generation sequencing-based technologies has facilitated the477
interrogation of the genome at a broader scale. In 2012, deep sequencing of multiple genes in478
cfDNA was demonstrated using panels of tagged amplicons, which allowed the identification479
of mutations directly in the plasma of cancer patients, and monitoring of multiple tumour-480
specific mutations in a single assay [29]. This method was subsequently applied to monitor481
ctDNA in a cohort of patients with metastatic breast cancer [30]. Shortly thereafter, whole-482
genome sequencing (WGS) of plasma cfDNA was first shown to identify tumour-derived483
chromosomal aberrations [31], focal amplifications [32] and gene rearrangements [33], and484
hybrid-capture sequencing was introduced as a non-invasive method to analyse the evolving485
genomic profile of mutations in cancer across the entire exome [34].486
1.4 cfDNA and ctDNA biology487
cfDNA is thought to be released from cells mostly through apoptosis and necrosis, and488
possibly also active secretion [35–39]. Outside of the blood circulation, cfDNA has been489
detected a variety of body fluids including urine [40–43], cerebrospinal fluid (CSF) [44–46],490
pleural fluid [47] and saliva [48]. Genetic and epigenetic modifications of cfDNA molecules491
reflect the genome or epigenome of the cell of origin [49–51] (Figure 1.1). Methylation492
analysis has revealed that the majority of cfDNA in plasma is released from haematopoietic493
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cells in healthy individuals [50–52]; these have been suggested to be the source of cfDNA494
release following intense exercise [53]. Observational studies have determined the half-life495
of cfDNA in the circulation as between 16 minutes and 2.5 hours [28, 44, 54, 55] which496
allows ctDNA analysis to be considered as a ‘real-time’ snapshot of disease burden. Other497
observational studies indicate that cfDNA is cleared from the circulation via nuclease action498
[55, 56] and renal excretion into the urine [57, 40]. In addition, cfDNA uptake in the liver499
and spleen, followed by degradation by macrophages, may also contribute [27, 58]. The500
stability of individual fragments in the circulation may be increased through association with501
cell membranes, extracellular vesicles or proteins [35].502
Fig. 1.1 Origins and spectrum of alterations in cell-free DNA
Cells release cfDNA through a combination of apoptosis, necrosis, and secretion. cfDNA
can arise from cancerous cells but also from cells in the tumour microenvironment, immune
cells, or other body organs. In the bloodstream cfDNA may exist as either free, or associated
with extracellular vesicles such as exosomes [35]. Multiple classes of genetic and epigenetic
alterations can be found in cfDNA. Taken from Wan et al. [59].
Nearly two decades ago, the modal size of cfDNA was determined using gel electrophore-503
sis as ~180 base pairs (bp), indicating that cfDNA was likely to be nucleosome-associated504
[60]. Sequencing-based approaches have since refined this measurement, by identifying a505
prominent peak at 166bp [61, 62], corresponding to the length of DNA wrapped around a506
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nucleosome (~147bp), plus linker DNA associated with histone H1. Fragment size traces507
of cfDNA show a 10bp ladder pattern [39, 57], ostensibly caused by nucleases cleaving the508
DNA strand at periodically exposed sites with each turn of the DNA double-helix. The frag-509
mentation patterns of cfDNA differ between plasma and urine [57], potentially contributed510
to by a higher nuclease activity in urine [63].511
ctDNA molecules (i.e. mutant cfDNA fragments) are shorter than non-mutant cfDNA in512
plasma, demonstrated by PCR [3, 64] and sequencing [51, 65]. Animal xenograft experiments513
[62, 64–66] provide an elegant means to interrogate ctDNA, since any human DNA sequences514
must have originated from the tumour xenograft. The modal length of ctDNA fragments has515
been measured in a rat xenograft model as between 134-144bp [65], though the cause of this516
shortening is not clear. Shortening of fragments is also observed in fetal cfDNA relative to517
maternal cfDNA [61], and between non-haematopoetically-derived vs. haematopoietically-518
derived cfDNA fragments in transplant patients [67, 68]. Differences in nucleosome wrapping519
or nuclease action between haematopoietic cells, which contribute most to the cfDNA pool,520
and other tissues may play a role. Long cfDNA fragments (>1,000bp) have been observed in521
healthy individuals using long-read sequencing techniques [69], and may be released into522
the circulation in association with exosomes [36, 37], or by tumour cells via necrosis [38].523
Current extraction methods often poorly recover these long fragments [6, 70]. Commonly524
used library preparation methods introduce further biases. Single-stranded DNA (ssDNA)525
library preparation [71] can recover DNA fragments with damaged ends, and when applied526
to cfDNA [49, 72] uncovered a large proportion of fragments shorter than 100bp. Diverse527
extraction and sequencing methods can therefore yield complementary data; combining those528
with histological analysis of corresponding tissue samples could provide new insights into529
the biological determinants of cfDNA fragmentation, and the biological origins of cfDNA.530
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1.4.1 Physiological and pathological considerations531
cfDNA has been proposed as a ligand for Toll-like receptor 9 (TLR9) [73, 74], which is532
a sensor of exogenous DNA fragments that is found primarily in tissues rich in immune533
cells. In mice, obesity-related adipocyte degeneration was shown to release cfDNA, which534
contributed to macrophage accumulation via TLR9 activation and led to adipose tissue535
inflammation and insulin resistance [75]. Another study has suggested that cfDNA may536
inhibit pro-apoptotic caspases via TLR9-dependent signalling [74] which could imply a537
potential immunomodulatory role for cfDNA.538
In vitro experiments suggest that cfDNA may be internalized by cells [75, 76, 35], which539
raises the possibility that cfDNA molecules could mediate the horizontal transfer of genes or540
DNA. One report showed that NIH-3T3 mouse cells that were in contact with samples of541
plasma from patients with KRAS-mutant colorectal cancers underwent in vitro transformation,542
despite being separated to avoid tumour cell contamination [77]. Another study demonstrated543
the integration of ctDNA into the nuclear DNA of recipient cells and suggested that this may544
occur through non-homologous end-joining [76]. A similar phenomenon has been observed545
for mitochondrial DNA [78]. The evidence for this potential phenomenon of genometastasis546
is, at present, limited to a small number of studies and report and so further investigation is547
required before conclusions can be drawn. In sum, it is clear that there is a lot to learn about548
the biology of cfDNA and ctDNA, and improved knowledge could have an important impact549
on their potential applications in oncology.550
1.5 Pre-analytical considerations for ctDNA analysis551
In low-burden disease, or certain cancer types, the concentration of ctDNA molecules may be552
low and any loss of sampled material could reduce the sensitivity of molecular profiling. For553
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quantitative applications, reproducibility of measurement is essential to achieving a robust554
result, and so the following pre-analytical factors should be considered:555
• Samples should be collected in tubes containing an anticoagulant that is compatible556
with PCR, with EDTA being preferred. Plasma from heparinised blood leads to557
inhibition of PCR [79], although some studies have successfully utilised such samples558
[80].559
• It is important that the first centrifugation of the blood is done within a few hours of560
the blood draw in order to remove blood cells that may lyse and release germline DNA561
which would dilute ctDNA [52, 81–83]. Tubes containing fixative agents may stabilise562
cells and prevent lysis for several days at room temperature [82, 84–86], including563
during shipping [86, 87] .564
• Following centrifugation, buffy coat DNA from the same tubes can be used as a source565
of germline DNA, although this may contain small or trace amounts of ctDNA.566
• From a blood draw, plasma is preferred over serum for ctDNA analysis [83]. Serum567
also contains ctDNA [88], but blood cell lysis during the preparation of serum samples568
releases DNA from non-cancerous cells, which would dilute any ctDNA signal. Other569
body fluids or cytological specimens may be used, and may contain a higher amount570
or concentration of tumour DNA depending on tumour proximity.571
• cfDNA extraction may be carried out with affinity-column, magnetic bead, polymer,572
and phenol-chloroform methods. Different methods show variation in their ability to573
recover particular fragment sizes [6, 70], which could have implications for ctDNA574
detection, given the differences in size between cfDNA and ctDNA.575
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1.6 Approaches for ctDNA analysis576
Analysis of ctDNA ranges in scale from single mutations to whole-genome analyses (Fig-577
ure 1.2, Table 1.1). Appropriately designed assays for individual mutations can achieve high578
sensitivity using a simple workflow. Allele-specific PCR methods have been applied since579
the mid-2000s for detection of hot-spot mutations in serum and plasma, and some assays580
are available as kits that are approved for clinical use [89, 90], but have limited analytical581
sensitivity. dPCR assays on microfluidic platforms are quantitative and highly sensitive, and582
are used extensively to quantify ctDNA levels [26–28, 42, 91–94]. Improved detection at583
selected loci has been demonstrated by methods such as single-base extension or enrichment584
for mutant alleles by electrophoretic methods [95, 96], nuclease activity or modified PCR585
[97, 98]. The multiplexing capacity of such assays, that rely on differential binding affinities586
of mutant and wild type alleles, and for the most part require primers or probes that are587
specific to a defined mutation or targeted locus, is limited. These are therefore generally588
suited to investigating a small number of mutations, and are often applied to analysis of589
cancer hot-spot mutations. If samples need to be split into multiple reactions, this increases590
the likelihood of sampling error, and may impair the overall performance of an assay for very591
low copy numbers of mutant DNA.592
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Fig. 1.2 Scales of analysis of ctDNA
The analysis of cfDNA can range from the interrogation of individual loci, to analysing
the whole genome. Off-the-shelf dPCR assays can achieve high sensitivity with a simple
workflow, but are limited by a low multiplexing capability. Targeted sequencing can allow the
interrogation of multiple loci with high sensitivity, using methods that suppress background
noise [99]. The targeted sequencing image is modified with permission from [29] and the
whole genome sequencing image was kindly provided by Dennis Lo, based on data published
in ref. [100]. Taken from Wan et al. [59].
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In order to interrogate a larger number of loci, targeted sequencing using PCR amplicons593
or hybrid-capture have been employed [29, 34, 111, 108]. Regions for sequencing may range594
from individual exons of interest (kilobases), to the entire exome (~50 megabases). Current595
off-the-shelf panels for gene sequencing can detect mutations with an allele fraction greater596
than 1% [108, 109]. Amplicon-based assays that have been optimised for the purpose of597
ctDNA analysis use bespoke analytical and statistical processes, thereby targeting dozens598
to hundreds of amplicons across multiple kilobases [29, 112, 104]. Hybrid-capture-based599
approaches can increase the genomic region studied to dozens or hundreds of kilobases600
[111, 105–107]. The sensitivity for ctDNA detection can be further enhanced, even with601
limited amounts of input material, by using multiplexed patient-specific panels in combination602
with targeted sequencing methods [29, 106, 113].603
Shallow WGS (sWGS) has been employed to detect fetal aneuploidies [32], and it can604
also be used to detect cancer-specific copy number alterations [31, 32, 114]. Amplifications605
and deletions may be identified through low-depth (~0.1x coverage) sequencing of the whole606
genome, with comparison of the relative number of sequencing reads between equally sized607
genomic regions across a sample or between samples and controls [110]. sWGS has a limit608
of detection of between 5%-10% mutant allele fraction [115], and so has limited sensitivity609
for profiling earlier stage disease. If molecular profiling of a small number of recurrent copy610
number alterations is desired, higher sensitivity may be achieved through targeted sequencing611
of single nucleotide polymorphisms, which may detect copy number alterations as low as612
0.5% [116].613
The limit of detection for assays will vary based on whether the individual’s disease614
status, and tumour mutations, are already characterised. Tumour burden in plasma has615
often been assessed by quantifying mutations (or other alterations) that were previously616
identified in the patient’s tumour sample [27, 28]. Prior knowledge of the mutation profile617
from tumour sequencing data enables the detection of known patient-specific mutations618
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above the background error rate, as opposed to calling mutations de novo [29, 111]. For619
mutation calling across a panel of genes or hotspots, the risk of false positives increases with620
the size of the panel due to multiple hypothesis testing [117], and filters need to be applied to621
increase specificity, which erodes sensitivity for rare variants. Thus, sequencing-based assays622
can be used as sensitive and quantitative tools for ctDNA measurement and monitoring, in623
addition to their use for mutation profiling [29, 30, 111].624
ctDNA can be quantified using different metrics, such as mutant allele concentration (i.e.625
copies per ml) or mutant allele fraction [118]. Each of these metrics would be affected in a626
different way by analytical, pre-analytical, and physiological characteristics. For example,627
metabolic changes to the rate of ctDNA turnover would affect the concentration of mutant628
alleles more than the mutant allele fraction, whereas pre-analytical factors affecting release629
of germline DNA from blood cells would reduce the mutant allele fraction to a greater extent.630
Analysis of ctDNA (both fraction and concentration) [101], as well as total cfDNA and631
cfDNA fragmentation [3, 101], could therefore provide complementary information, and632
may have advantages in different applications or in combination.633
1.7 Clinical utility of liquid biopsies in oncology634
There is a clear clinical need for novel diagnostic and molecular tools in oncology. For635
example, conventional sampling methods such as needle biopsies are subject to procedural636
complications in up to one in six biopsies [119], difficulty in obtaining sufficient material637
of adequate quality for genomic profiling (reported failure rates range from <10% to >30%638
of cases) [120, 121], and sampling biases arising from genetic heterogeneity [109, 122–639
125]. Detection and monitoring of disease over time relies on body fluid-based markers that640
often lack specificity [126], and imaging which exposes patients to ionising radiation [127]641
and has limited resolution (in both time and space). Recent advances in ctDNA research642
highlight the potential applications of liquid biopsies at each stage of patient management643
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(Figure 1.3a). These potential applications primarily arise from two types of information644
obtainable through ctDNA analysis: quantification of disease burden, and genomic analysis645
of cancer (Figure 1.3b). These may be combined and/or leveraged through serial sampling in646
order to monitor disease burden and clonal evolution.647
Fig. 1.3 Applications of ctDNA analysis during the course of disease management
(a) A schematic time course for a hypothetical patient who undergoes surgery (or other
initial treatment) has a disease relapse, and then undergoes systemic therapy. The potential
applications of liquid biopsies during this patient’s care are indicated. The patient starts
with one single disease focus, but clonally distinct metastases emerge following treatment,
depicted in different colours.
(b) The information extracted from ctDNA may be classified, broadly, into quantitative
information (i.e. tumour burden) or genomic information. Quantification of ctDNA at a
single time point may allow disease staging and prognostication, and genomic analysis can
inform selection of targeted therapies. Therefore, longitudinal analysis allows the quantitative
tracking of tumour burden, such as response monitoring; and by comparing genomic profiles
over time, clonal evolution may be monitored. Taken from Wan et al. [59].
1.8 ctDNA detection648
The concentration of ctDNA in plasma has been shown to correlate with tumour size [62, 128]649
and stage [129]. A study of 640 patients with various cancer types and stages [129] found a650
100-fold increase in median ctDNA concentration between patients with Stage I and Stage IV651
disease. Measuring individual tumour mutations in each patient, patients with Stage I disease652
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had fewer than 10 copies per 5 ml of plasma. In sharp contrast, patients with advanced653
prostate, ovarian and colorectal cancers had a median concentration of 100-1,000 copies per654
5 ml of plasma. ctDNA levels vary greatly even within patients with the same type and stage655
of disease. This variability in ctDNA concentration is partially explained by differences in656
extent of metastatic spread or disease burden. In a recent report that compared ctDNA levels657
with tumour volume assessed by imaging in patients with relapsed high-grade serous ovarian658
cancer, ctDNA levels and disease volume were significantly correlated (Pearson r = 0.59,659
p < 0.001) [118]. Mutant alleles in plasma increased in fraction by approximately 0.08%,660
and in concentration by 6 mutant copies/ml, for every cm3 of disease [118]. Despite these661
correlations, substantial variation in ctDNA concentration may arise from inter-individual662
differences. For example, poor tumour vascularisation could hamper ctDNA release into663
the bloodstream, or conversely, could promote ctDNA release via producing hypoxia and664
cell death. Histological differences could forseeably influence both the rate and type of cell665
death. Patients with primary brain tumours have very low levels of ctDNA, with a median666
concentration for individual mutations of less than 10 copies per 5 ml of plasma [129],667
while the fraction of tumour DNA in CSF was found to be significantly higher [45, 46, 129].668
Although not directly proven, the blood-brain barrier has been suggested to impede the669
movement of cfDNA fragments into the circulation [45, 46, 129].670
The relationship between ctDNA levels and cancer stage suggests prognostic utility for671
ctDNA. Patients with detectable ctDNA have been shown to have worse survival outcomes672
than those without [24, 130–133]. For example, the 2-year overall survival rate for patients673
with colorectal cancer who had detectable ctDNA was 48%, as opposed to 100% for patients674
without [24]. In patients with detectable ctDNA, it has been found to be a more significant675
prognostic predictor than commonly used tumour markers [30, 118], where an increasing676
concentration of ctDNA correlates with poorer clinical and radiological outcomes [30,677
118, 129, 134, 135]. For example, in patients with metastatic breast cancer, a significant678
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inverse correlation was shown between ctDNA concentration and overall survival up to 2000679
copies/ml, with a uniformly poor prognosis above this level [30]. In addition to ctDNA levels,680
mutational patterns identified in ctDNA can help group patients into molecular subtypes with681
different prognosis [136].682
1.8.1 Molecular profiling of ctDNA683
At present, the European Medicines Agency (EMA) and the US Food and Drug Adminis-684
tration (FDA) approve the use of information from ctDNA analysis to help select patients685
with EGFR-mutant NSCLC for gefitinib (EMA) [137], erlotinib (FDA) [90] or osimertinib686
[90, 138] therapy in the event that a tumour sample is not evaluable, as it provides an alterna-687
tive source of material. This could offer a pragmatic solution to provide molecular profiling688
information for patients, while avoiding repeat biopsies for some individuals. Current rec-689
ommendations [90, 138] state that if liquid biopsies are carried out in advance of a tumour690
biopsy, ctDNA detection may abrogate the need for tissue biopsy, but if ctDNA analysis is691
negative, a tissue biopsy may still provide valuable genomic information.692
Molecular profiling using ctDNA may have particular utility for stratifying patients in693
‘basket trials’, which enrol patients independent of tumour histology, or ‘umbrella trials’,694
which assign patients to multiple investigational drugs or treatment options [139]. For695
example, a 54-gene panel detected ctDNA in 58% of patients across multiple cancer types696
[107]. Of the patients with alterations, 71.4% had at least one mutation actionable by an697
FDA-approved drug. This panel is being used to test the feasibility of matching patients with698
different metastatic cancer types to targeted therapies in a prospective clinical trial. In another699
study presented at the 2016 Molecular Analysis for Personalised Therapy meeting, a 34-gene700
panel identified mutations in 79% of 174 patients with NSCLC, allowing 28 patients (17%)701
to receive personalised treatment based on ctDNA molecular profiling [140]. Personalised702
therapy selection presents challenges: even if mutations are successfully detected using703
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ctDNA in patients, an efficacious molecularly targeted agent may not exist. However, data704
from a prospective clinical trial presented at the 2016 Molecular Analysis for Personalised705
Therapy meeting demonstrated that selecting therapies based on genomic analysis can706
improve outcomes for cancer patients, even when patients with well-established actionable707
targets (for which approved drugs are available) were excluded [141].708
Improvements in the analytical sensitivity of molecular profiling tools could further709
increase detection and concordance rates or allow for sensitive multiplexed analysis (Table710
1.1), though biological factors and heterogeneity may reduce sensitivity in some cancer types711
and stages [129, 142, 143]. The utility of ctDNA should, therefore, be assessed for different712
clinical indications. However, benchmarking ctDNA against individual tumour biopsies may713
be confounded by sampling error, as rare private mutations may be sampled in the biopsy,714
but release insufficient ctDNA into the bloodstream to be detectable.715
1.8.2 Analysis of tumour heterogeneity716
The extent of genetic heterogeneity has been confirmed over recent years as multi-regional717
sequencing studies have demonstrated clear differences in mutation profiles between different718
tumour regions in the same patient [144, 145] and between different specimens from primary719
and metastatic sites [146]. Although the potentially confounding effects of heterogeneity720
are recognised, it is often neither feasible nor desirable to perform multiple tumour biopsies721
on patients to try to account for this. Analysis of an individual biopsy might not accurately722
reflect the genomic architecture of a patient’s cancer, introducing bias to the selection and723
efficacy of personalised medicines. Furthermore, in a recent study of patients with lung724
cancer treated with an EGFR inhibitor, the tumour EGFRT790M allele fraction correlated725
with the degree of tumour shrinkage [147], suggesting that the current paradigm of treatment726
selection based on mutation presence or absence alone may be suboptimal.727
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Liquid biopsies sample ctDNA released from multiple tumour regions, and may thereby728
reflect both intratumour heterogeneity [46, 123, 124] and spatially separated disease foci729
[123, 125, 148]. While individual tumour biopsies from different tumour regions may differ730
in mutation profile due to intratumour heterogeneity [149, 150], ctDNA analysis has detected731
mutations missed in corresponding tissue samples [123, 125, 142, 151]. Multi-region tumour732
sequencing data show that stem mutations (shared by all tumour regions) show a higher allele733
fraction in plasma compared to private mutations [149, 150]. Therefore, for tracking tumour734
burden in plasma, stem mutations would provide the most reliable detection. Alternatively,735
tracking a large set of mutations may compensate for potential biases of individual private736
mutations.737
1.8.3 Sensitivity of hot-spot mutation assays and gene panels738
By comparing mutation detection in plasma against matched tumour samples, the sensitivity739
of ctDNA analysis has been estimated in retrospective studies as between 65%-98% [92,740
94, 101, 142, 148]. For profiling specific loci, for example in order to stratify patients for741
matched molecular therapies, international studies have begun to demonstrate that large-scale742
testing is feasible and may be standardised, although the use of assays with limited analytical743
sensitivity resulted in low detection rates of ctDNA [152, 139, 153]. Using assays developed744
specifically to detect low levels of ctDNA [3], a blinded prospective study demonstrated745
sensitivity for KRAS and BRAF mutations in metastatic colorectal cancer of 92% and 100%,746
respectively, with concordance rates of 96% and 100% for each [101].747
Significant attention has been devoted to analysis of EGFR mutations in patients with748
NSCLC, as it is often challenging to obtain tissue biopsies to help inform treatment [119, 120].749
Meta-analysis of 27 studies published between 2007-2015 [154], comprising altogether nearly750
4,000 patients, resulted in a pooled sensitivity of 60% and specificity of 94% for detection751
of EGFR mutations in plasma or serum, with a variety of methods. In a phase IV study of752
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the EGFR inhibitor gefitinib, mutation status was compared between tumour and plasma753
samples from 652 patients. The sensitivity and specificity for detecting mutations in plasma754
were determined as 65.7% and 99.8%, respectively [153, 155], likely affected by the limited755
analytical sensitivity of the allele-specific PCR method used [89], as the version of the kit756
used in that study had a limit of detection (at >95% analytical sensitivity) of 1.64% and 1.26%757
for EGFR deletions and L858R mutations [153]. Low rates of concordance of EGFRT790M758
status were also observed in a recent phase III trial of osimertinib [156], in which tissue759
testing was compared to an allele-specific PCR assay for ctDNA analysis that has a limit of760
detection (with >95% analytical sensitivity) of 100 copies of EGFRT790M per ml of plasma761
[90]. Using methods based on droplet digital PCR (ddPCR), higher sensitivity in plasma762
was obtained. Sensitivity in plasma for the EGFRT790M mutation (which confers resistance763
to gefitinib and erlotinib, and frequently emerges following initial treatment with those764
EGFR tyrosine kinase inhibitors) was lower than the sensitivity for EGFR L858R and EGFR765
Ex19del, which occur earlier in the development of disease (70% vs. >90%) [142, 157].766
Initial data suggests that this may be due to heterogeneous presence of resistance mutations767
at disease relapse [142].768
In retrospective analyses, despite limited concordance rates of EGFR mutation status769
between plasma and tumour samples observed in some studies, response rates for patients770
who were plasma positive for mutations in EGFR were similar to response rates of patients771
who were tissue positive [142, 153, 155–157]. Data showing the response of patients treated772
solely on the basis of ctDNA analysis are starting to emerge: patients who were treated with773
osimertinib based on detection of EGFRT790M in plasma showed response rates similar to774
the those of patients treated based on tissue analysis [140]. Interestingly, objective responses775
were also seen in patients with very low allele fractions of mutant EGFRT790M in plasma776
(<0.5%) [140].777
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1.8.4 Detection of structural variants778
Copy number alterations can be detected in cfDNA using WGS [31, 32, 110, 158], amplicon-779
based [104, 114, 159, 160], and hybrid-capture approaches [34, 111, 161]. In patients with780
hepatocellular carcinoma, WGS was able to identify amplifications and deletions in plasma781
matching those identified in tumour tissue [32, 162]. Heterogeneous copy number changes782
were also identified in a patient with synchronous breast and ovarian cancers, as copy number783
changes unique to each cancer were detected in plasma [32]. In a study of 80 patients784
with prostate cancer, androgen receptor (AR) copy number gain prior to abiraterone therapy785
predicted a worse overall survival, thus identifying patients with primary resistance [163].786
For patients with advanced disease, sWGS may provide a relatively cost-effective measure787
of ctDNA level that is applicable across cancer types. This approach may have utility as788
a sample screening step in a ctDNA analysis workflow [114], where high-burden patient789
samples are triaged for exome sequencing [34].790
Chromosomal rearrangements in plasma can be identified through both WGS [31] and791
hybrid-capture sequencing approaches [33, 164], though the latter may be more economical792
due to the depth of coverage needed to confidently identify a rearrangement. In one study of793
patients with prostate cancer, sWGS was able to detect a deletion on chromosome 21 in 5794
patients, though higher-depth capture sequencing was necessary to identify a rearrangement795
between exon 1 of TMPRSS2 and exon 3 of ERG [33].796
1.8.5 Early detection797
Diagnosing cancer at an earlier stage, particularly before metastatic spread, may allow earlier798
intervention and could improve survival [165]. A number of studies have demonstrated799
the potential for non-invasive early diagnosis. Mutations have been detected in saliva and800
plasma from individuals up to two years prior to cancer diagnosis [18, 166], and there have801
been reports of incidental pre-symptomatic detection of cancers in pregnant women who802
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underwent NIPT [51, 167, 168], as WGS can identify copy number alterations of both fetal803
and tumour origin. Screening in asymptomatic populations introduces risks of over-diagnosis804
and false positives; implementation could therefore be explored in stages, and a first step805
could involve the use of ctDNA for earlier diagnosis of disease in symptomatic individuals,806
who at present may undergo lengthy investigation procedures.807
In a survey across several cancer types, ctDNA was detected in 82% of patients with808
Stage IV disease, which fell to 47% for patients with Stage I disease [129]. The method they809
applied was benchmarked as being able to detect one copy of an individual cancer mutation810
per 5ml of plasma [129]. Using a sequencing gene panel targeting a median of four mutations811
per patient, ctDNA was detected in 50% of patients with stage I NSCLC [111]. Targeting812
known tumour mutations in plasma using ddPCR assays in early-stage breast cancer showed813
a sensitivity of 93.3% [169]. An sWGS method adapted from an NIPT assay was recently814
shown to detect 6/16 (37.5%) cases of early ovarian cancer [170], though this approach may815
not perform as well in other cancer types with fewer copy number alterations. Together,816




The short half-life of cfDNA [28, 54, 55, 171], as well as the ease and reduced risk of821
repeating liquid biopsies relative to imaging [127] or tissue biopsies [119], enables liquid822
biopsies to be used for real-time monitoring of cancer burden in response to therapy. Studies823
monitoring patients during treatment have shown that ctDNA dynamics correlate with treat-824
ment response [28–30, 111, 133], and may identify response earlier than clinical detection825
[30, 172, 173]. In breast cancer, ctDNA showed the greatest range in concentration and826
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provided the earliest measure of response to chemotherapies, as well as the earliest indication827
of impending relapse compared to imaging and other blood-based cancer markers, such as828
CTCs and Cancer Antigen 15-3 (CA 15-3, also known as MUC1) [30]. In relapsed ovarian829
cancer, pre-treatment ctDNA levels and the extent of ctDNA decrease after chemotherapy830
initiation were significantly associated with time to progression, and were more informative831
than levels of CA125 (also known as MUC16) [118].832
A recent study suggested that an early spike in ctDNA levels (allele fractions of BRAF833
mutations) in the first week following the initiation of immunotherapy in melanoma patients834
may predict response [174]. This may reflect a transient increase in cell death. If these data835
are confirmed, sampling at early time points could be applied in the clinic as well as in drug836
development. However, the presence or timing of such spikes in cell death would likely vary837
based on the pharmacological properties and biological responses to treatments used. An838
early spike was not observed a few days after initiation of treatment with chemotherapy for839
patients with colorectal cancer [175] or with an EGFR inhibitor for patients with NSCLC840
[173]. If analysis of plasma immediately after the start of therapy could reliably detect the841
destruction of sensitive cancer cells, this raises an exciting possibility that the existence of842
resistant sub-clones could be identified very rapidly through differential early dynamics of843
mutations. In the context of immunotherapy, liquid biopsies may provide the opportunity844
to monitor both ctDNA and the response of the immune system, for example through the845
analysis of cfDNA released from distinct T-cell clones [176].846
1.9.2 Clonal evolution and resistance847
As discussed above, rising or falling ctDNA concentration may provide an indication of848
treatment effect on overall tumour burden. If multiple tumour mutations are interrogated,849
then the relative change between each may provide insight into molecular evolution of the850
patient’s cancer [34, 177, 178]. Ratios between the levels of different mutations in plasma851
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can indicate heterogeneity and may be informative to predict patient response to treatment852
targeting particular alterations [142, 161]. Liquid biopsies have been shown to contain ctDNA853
from multiple tumour sites [46, 123–125], can have a faster turnaround time than tissue854
biopsies [33, 94, 164], and may be less prone to biases resulting from individual tumour855
biopsies [144, 145, 179]. Studies demonstrate that ctDNA can monitor clonal evolution and856
identify resistance mechanisms to treatment [108, 151, 157, 161, 180]. Serial ctDNA analysis857
in patients with colorectal cancer demonstrates the positive selection of mutant KRAS clones858
during EGFR blockade, which later decline upon the withdrawal of anti-EGFR therapy859
[151, 181]. In NSCLC patients undergoing treatment with EGFR inhibitors, resistance-860
conferring mutations emerged in plasma ahead of clinical progression. Exome sequencing861
of plasma DNA may identify resistance mechanisms in patients across cancer types [34],862
though the sensitivity of exome sequencing currently limits its application to advanced863
cancer patients where ctDNA levels are high (>5% mutant allele fraction). Design of patient-864
specific mutation panels [29, 125, 129, 182] could be a more cost-effective alternative for865
high-sensitivity monitoring, though may miss subsequent de novo events. Serial sWGS866
analysis also demonstrates highly dynamic copy number adaptations in response to selection867
pressures, with a mean interval of 26.4 weeks between new amplifications [183].868
Serial liquid biopsies may have particular utility for adaptive clinical management,869
whereby resistance mutations are prospectively identified, and therapy adapted in real-870
time (Figure 1.4). In the clinical research setting, non-invasive monitoring could facilitate871
adaptive clinical trials, which prospectively identify efficacious treatment regimens or drug872
combinations, and identify resistance mechanisms to novel therapies. In addition, in vitro or873
in vivo experiments carried out in parallel may provide greater insight into cancer biology.874
For example, colorectal cancer cell line experiments carried out in parallel with ctDNA875
analysis showed that resistance mutations may arise from both the selection of pre-existing876
minor clones, and through ongoing mutagenesis [177]. Another study investigating resistance877
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to a pan-tropomyosin-related kinase (TRK, also known as NTRK) inhibitor in colorectal878
cancer demonstrated that simultaneous analysis of patient-derived xenografts and liquid879
biopsies may characterise resistance more comprehensively than plasma alone [184].880
Fig. 1.4 Adaptive or reactive treatment paradigms using liquid biopsies
(a) During systemic anti-cancer therapy, serial liquid biopsies may identify biochemical
response or progression. If progression is identified, the clinician may be able to switch
therapy, or select a therapy to target arising clones carrying additional mutations that were
identified by this analysis.
(b) This adaptive or reactive monitoring and treatment may continue as a loop, which would
be facilitated by a fast turnaround time for ctDNA analyses, for example through the use
of point-of-care diagnostics. The timeframes for this analysis can vary between hours and
months; the former could allow analysis of early kinetics in response to therapy. Taken from
Wan et al. [59].
1.9.3 Minimal residual disease detection881
Following surgery or treatment with curative intent, even in the absence of any other clinical882
evidence of disease, detection of ctDNA may signal the presence of minimal residual disease883
(MRD), which could identify patients who may be at a higher risk of relapse. Stratification of884
patients into high- and low-risk groups would enable adjuvant therapy to be given to patients885
who stand to benefit most, while sparing low-risk patients from unnecessary morbidity886
and risks of adverse events. In a prospective study of 230 early-stage colorectal cancer887
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patients [185], assessment of ctDNA within 4-10 weeks after surgical resection indicated888
that recurrence-free survival at 3 years was 0% for the ctDNA-positive and 90% for the889
ctDNA-negative groups. In a separate study of 55 patients with early-stage breast cancer890
[186], assessment of ctDNA showed that detection of ctDNA at first follow-up could also891
indicate poor prognosis in early-stage breast cancer. Furthermore, stratification based on892
mutation detection across serial samples improved prediction of relapse, and this and other893
studies have observed an interval of 7.9-11 months between ctDNA detection and clinical894
relapse [186, 187], similar to that identified in the metastatic setting [30].895
Instead of SNVs, patient-specific DNA rearrangements identified from sequencing tumour896
samples can be used to design assays to track tumour burden in plasma [184]. Curative897
surgery could provide an excellent opportunity to obtain tumour DNA that can be sequenced898
to guide the design of assays for post-operative monitoring. Patient-specific rearrangements899
may be detected in ctDNA at levels as low as 0.001% mutant allele fraction [188, 189],900
since rearrangements are less confounded by background noise. One of the challenges of901
individualised panel design is that sequencing an individual tumour biopsy may not sample902
every mutation in heterogeneous disease; therefore, sequencing matched body fluid and903
tumour samples may be desirable for comprehensive mutation profiling. In future, if tumour904
sequencing were to become more routine, monitoring disease using patient-specific panels905
might become viable, although regulatory issues of standardisation and assay validation906
around the design and delivery of such assays may be complex.907
With increasingly sensitive approaches, earlier and more accurate identification of patients908
likely to relapse might become possible, thereby facilitating treatment decision making. If909
levels of ctDNA were to rise sufficiently, molecular profiling for de novo mutations may be910
carried out, in order to identify molecular targets for intervention.911
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1.10 Enhancing detection of residual disease912
1.10.1 Targeting multiple patient-specific mutations913
Following the initiation of chemotherapy or following surgery, ctDNA concentration may914
decline to undetectable levels using single-locus assays, often due to there simply being915
no mutant molecules (at the locus of interest) in the plasma sample collected. Even with916
a perfectly sensitive assay, the probability of detection of ctDNA decreases as ctDNA917
concentration declines, as any single mutation of interest may not be present in a given918
volume of sample. At low ctDNA concentrations, due to sampling error, some mutations will919
be detected while others are missed (Figure 1.5). The number of DNA molecules interrogated920
by an assay thus places a hard limit on the maximum achievable sensitivity. An increase in921
the number of molecules interrogated must be accompanied with a reduction in background922
error rates in order to detect signals occurring at a lower frequency; this may be achieved923
through bioinformatic methods (Figure 1.6a).924
It should be noted that for cancers with a viral aetiology, e.g. nasopharyngeal carcinoma925
or cervical cancer, detection of the cancer-associated viral DNA that may be present in body926
fluids in many more copies than tumour DNA can enhance the identification of individuals927
with early stage disease or pre-malignant lesions with a high risk for cancer [32, 190, 191].928
Chan et al. [191] recently demonstrated in a cohort of 20,174 individuals that screening for929
Epstein-Barr Virus cfDNA can identify a group of patients that are at significantly increased930
risk for nasopharyngeal carcinoma (70% vs. 97% PFS at 3 years; HR 0.1).931
Sampling multiple pre-specified mutations in each reaction may improve detection of932
low levels of ctDNA, since every additional target provides another independent opportunity933
to test for the presence of a mutant molecule from the set of DNA molecules at that locus934
[29, 106, 113]. Prior knowledge of the mutation profile from tumour sequencing data enables935
the detection of known patient-specific mutations, and reduces the number of false positive936
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mutation calls from mutation calling across a panel of genes. By doing so, fewer filters have937
to be applied in order to improve specificity of such calls, thereby maximising sensitivity.938
Taken to a (currently impractical) extreme, ultra-deep sequencing of the entire genome could939
in the future allow sensitive detection of cancer even from small volumes of plasma [31].940
However, targeting many mutations can only improve the limit of detection to the level of the941
background error rate. Therefore, in order to achieve the highest sensitivity, it is important to942
both maximise the number of molecules available, and reduce background error rates from943
PCR and sequencing.944
1.10.2 Maximising recovery of molecules945
To increase the number of molecules available for analysis, the simplest solution may be to946
collect larger volumes of blood, though the number of blood tubes acceptable to take at once947
would eventually become limiting. This may potentially be overcome by analying multiple948
body fluids in parallel (Figure 1.6b), such as urine for bladder cancer [42, 192] or stool for949
colorectal cancers [16, 17]; or cytological specimens such as cervical smears [193], uterine950
lavage [194] , or oesophageal brushings [195] for gynaecological or oesophageal cancers,951
respectively. Alternatively, methods such as plasmapheresis or implanted devices containing952
materials that bind cfDNA might provide a solution, and similar devices have been tested for953
enhancing the yield of circulating tumour cells (CTCs) [196]. Alternatively, if it is acceptable954
and practical for the patient to have multiple blood samples taken over multiple days, this955
could further boost the number of cfDNA molecules available for detection of rare mutant956
molecules.957
Given the low number of cfDNA molecules present in an individual plasma sample,958
analytical methods should aim to minimise cfDNA molecule loss. Molecules may be959
lost at every stage of library preparation, particularly during the ligation of adaptors onto960
starting molecules or library cleanup steps [197]. To maximise library preparation efficiency,961
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Fig. 1.5 Leveraging multiple mutations to detect low-burden disease and overcome
sampling noise
Even with a perfectly sensitive assay, the probability of detection of ctDNA decreases as
ctDNA concentration declines, as any single mutation of interest may not be present in a given
volume of sample. At low ctDNA concentrations, due to sampling error, some mutations
will be detected while others are missed. Sampling multiple pre-specified mutations in
each reaction may improve detection of low levels of ctDNA, since every target provides
an independent opportunity to test for the presence of a mutant molecule in the set of DNA
molecules at that locus [29, 106]. Boxes below the graph show hypothetical examples of sets
of molecules that may be captured by each replicate in the analysis of a sample. Taken from
Wan et al. [59].
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Newman et al. [111] increased adaptor ligation time from 15 minutes to 16 hours with a962
100-fold molar excess of adaptors. As a result, recovery efficiency was improved by >300%963
to recover 49% of starting molecules, calculated based on the ratio between the number of964
unique molecules identified during sequencing compared to the number of input molecules,965
calculated based on qPCR [111].966
Fig. 1.6 Methods to improve detection of ctDNA
(a) For molecular barcoding, unique molecular sequences are added to each molecule during
library preparation so that sequencing reads originating from the same starting molecule can
be identified. By comparing all reads from the same molecule, a single consensus sequence
can be taken, which can suppress errors arising from PCR or sequencing.
(b) To improve sensitivity of analysis, for example for disease diagnosis or detection of MRD,
other body fluids may be considered in combination with, or instead of, plasma. Sampling
of body fluids or cytological specimens proximal to the tumour site may yield a higher
concentration of DNA of tumour origin.
(c) ctDNA has been shown to be shorter than cfDNA [64, 65, 68, 198]. Thus, selection
of shorter fragments experimentally or in silico may enrich for sequences of cancer origin
[65, 199] and can improve sensitivity for samples with low fractions of ctDNA. Taken from
Wan et al. [59].
1.10.3 Error-suppression967
Background error rates968
Background noise in sequencing data arises from PCR and sequencing errors, hampering de-969
tection of low levels of ctDNA even when there are sufficient molecules present to overcome970
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sampling error. During PCR, errors arise from two main sources: DNA-polymerase-catalysed971
enzymatic copying, plus errors due to DNA thermal damage (e.g. A+G depurination, oxida-972
tive damage, and deamination effects) [200]. Extension errors arising from DNA polymerases973
can be mitigated through the use of polymerases that have 3’ editing activity, though they974
are limited by their slower extension rate: Pyrococcus furiosus has an extension rate of 20975
nucleotides per second, whereas Thermus aquaticus elongates at 80 nucleotides per second.976
Using molecular barcoding [112] to suppress sequencing errors, error rates of PCR have977
been estimated at 4.5 x 10-7 errors/bp/PCR cycle [201].978
During Illumina sequencing, library molecules serve as the template for a PCR reaction979
whereby a complementary sequence is synthesised using nucleotides bound to fluorophores.980
By labelling each type of base with its own fluorophore, the synthesised sequence can be981
identified using imaging; by having multiple templates imaged in parallel, the term Massively982
Parallel Sequencing arises. Errors can arise from the synthesis of library molecules becoming983
out of phase, for example due to the lack of a terminator on a newly added base [202]. In984
addition, another error can occur if termination is not reversed during the washing cycle.985
Overall, any error due to early or late base termination during synthesis can cause a phasing986
error. To account for errors in Illumina sequencing, for every base sequenced, it is given an987
associated base quality score which quantifies the probability of it being an error.988
Illumina sequencing has been benchmarked in a large metagenomic dataset as having989
SNV error profiles of 2 x 10-3 and 4 x 10-3 in reads 1 (R1) and 2 (R2), respectively [201].990
Indels occur at a much lower frequency compared to SNVs (2.8 x 10-6 and 5.1 x 10-6, for991
R1 and R2, respectively), in part due to multiple bases having to be incorrectly read by the992
sequencer to produce an indel call. SNV error rates vary both by the type of mutation (i.e.993
mutation class) [111, 106, 201], position in the read [201], and sequence context [201]. Base994
qualities of substitutions were characterised by Schirmer et al. [201], which showed that995
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69-86% of SNVs showed low base quality scores, indicating that they were likely sequence996
artefacts.997
To mitigate the effects of sequencing error, stringent base quality filters have been applied998
for the early detection of disease across multiple cancer types using ctDNA without prior999
mutation knowledge [203]. It is possible that multiple rounds of read alignment (using1000
different alignment algorithms) may reduce mapping errors, as demonstrated by Chan et al.1001
[204], who used the Burrows–Wheeler transform and Smith–Waterman-like algorithms in1002
parallel, and compared the mutations from each. Furthermore, reads can be quality-trimmed1003
to remove lower quality bases at the end of the read, particularly R2 [201, 205]. Regarding1004
sequence context, particular trinucleotide base contexts appear to be more common than1005
others, with ‘GGG’ and ‘CGG’ being the first and second most noisy motif in each dataset1006
analysed by Schirmer et al. [201].1007
Methods of error-suppression1008
PCR and sequencing background noise can be suppressed molecular barcoding (Figure 1.6a),1009
enabling ctDNA to be detected at allele fractions below 0.1% [106, 112, 206, 104]. Molecular1010
barcoding uniquely identifies each starting molecule during the ligation step in library1011
preparation, so that each original molecule can be reconstructed using sequencing data.1012
During the reconstruction of each original starting molecule, error-suppression is achieved1013
by taking the consensus read sequence across multiple redundant sequencing reads of the1014
same molecule (the read family), which has a unique molecular barcode and a unique set of1015
genomic co-ordinates (start and stop locations).1016
Additionally, during the ligation step of library preparation, if starting molecules are1017
ligated to adaptors which identify each of the + and - strands of the original double-stranded1018
DNA molecule, upon sequencing the original duplex can be reconstructed [99]. In addition1019
to generating a consensus across the read family members, a consensus can be generated1020
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between the + and - strands, thereby reducing the error rate to a theoretical level of 3.8 x 10-10.1021
For first-round PCR errors to be incorporated into the consensus sequence, the mutation1022
would need to occur at the same base position on both strands of the dsDNA duplex, and1023
result in complementary errors. This approach has been applied to ctDNA analysis [106],1024
though the low error rate is difficult to fully utilise given the challenging of sequencing1025
sufficient molecules: starting with 5ng input (1650 genome equivalents) and a conversion1026
rate of 50%, if only one locus is targeted, having a limit of detection of better than 1 x 10-31027
would not provide any additional sensitivity. In order to increase the number of molecules1028
interrogated further, larger input or a larger number of mutations should be targeted, with1029
greater sequencing performed.1030
Instead of adding molecular barcodes, dilution or partitioning of molecules enables the1031
identification of unique molecules. For example, Hoang et al. [207] devised the bottleneck1032
sequencing system whereby molecules are diluted to such an extent that start and end1033
positions of each molecule (endogenous barcodes) can be used to uniquely identify each1034
molecule. By ligating forked Illumina adaptors to each molecule, each dsDNA duplex can1035
be recreated based on endogenous barcodes only. This approach enabled genome-wide1036
analysis of mutation rates in normal human tissue, but may not be utilised to interrogate1037
specific loci due to the limiting dilution of molecules which resulted in low or no coverage1038
for any given locus. Rosenfeld et al. [206] suggested an alternative approach of splitting1039
each cfDNA sample to be analysed into multiple replicates, each with a small number of1040
molecules (e.g. 40 molecules per reaction). By segregating molecules through partitioning,1041
any mutant molecules present would be observed at a high allele fraction in that partition,1042
whereas noise would occur at lower mutant allele fractions (except for first-cycle PCR errors).1043
Thus, this partitioning approach is analogous to molecular barcoding, in that each partition1044
and the observed AF provides information on the original starting molecules. The challenge1045
of this approach is of physically achieving a large number of replicates, since if too few1046
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replicates are performed then the total number of molecules interrogated is low and again1047
limits sensitivity.1048
1.10.4 Size selection1049
Since mutant molecules are shorter than wild-type cfDNA molecules [198], the size of a1050
cfDNA fragment may be leveraged to enhance detection of mutant molecules (Figure 1.6c).1051
Given that mutant molecules show a modal length of ~147bp [65], such molecules can be1052
selected for either through enrichment of short molecules in vitro, in silico [199], or by1053
attributing short molecules greater weight during analysis.1054
In the NIPT field, size selection has been applied to enrich for fetal cfDNA [208], which1055
increased the fetal DNA fraction, but simultaneously reduced the number of total DNA1056
molecules being counted, hampering sensitivity for confident detection of aneuploidy. Later,1057
Chan et al. [204] utilised a dynamic cut-off whereby fetal fragments were only considered1058
for genotyping of fetal-specific SNPs if the mean fragment size of mutant (candidate fetal)1059
molecules was at least 10bp shorter than the wild-type (maternal) fragments. Taken together,1060
it seems that for genotyping individual loci, any approaches that take into account fragment1061
size should take caution to not cause excessive allelic loss. This may potentially be achieved1062
through upweighting the signal from short fragments at each locus, or through size exclusion1063
approaches instead of size selection, or by interrogating a large number of loci through1064
patient-specific sequencing approaches.1065
Size selection has been shown to produce enrichment and enhanced detection of ctDNA1066
in patients with advanced ovarian cancer using sWGS [199]. sWGS is ideally suited to size1067
selection due to the molecules of interest not being limited to one particular locus, and so1068
any loss of mutant molecules is more acceptable. This combination of techniques pushes1069
the limit of detection of sWGS potentially up to an order of magnitude [199]. While this1070
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approach is broadly applicable, it may still only detect ctDNA in patients with relatively high1071
levels of disease burden.1072
1.10.5 Biological limits on sensitivity1073
Although the above technical advances may improve sensitivity for ctDNA analysis further,1074
biological and genomic factors will eventually become limiting. For confident de novo cancer1075
detection using ctDNA, detected alterations should have a high positive predictive value for1076
cancer. However, mutations known to be associated with cancer (e.g. in TP53, KRAS, and1077
Notch pathway genes) have been found at low levels in skin biopsies of healthy individuals1078
[209]. If non-tumourigenic clones were to increase to sufficient size and release mutated1079
cfDNA, they could introduce biological noise. Clonal haematopoiesis with leukaemia-1080
associated mutations has been observed in 10% of individuals older than 65 years of age,1081
though the absolute risk of conversion to haematologic cancer is 1% [210]. Genomic1082
alterations known to be associated with cancer have been found in plasma from healthy1083
individuals [106, 107, 210]. Clinical outcomes for apparently healthy individuals in whom1084
mutant DNA is detected in plasma should be characterised in order to understand the1085
biological and clinical implications of such findings.1086
1.11 Future directions for the field of liquid biopsy1087
Proof-of-concept studies provide an excellent starting point for larger prospective studies1088
into the clinical utility of ctDNA, and demonstrate that ctDNA may be a useful research tool1089
for drug development, and for the study of intratumour heterogeneity and clonal evolution.1090
Moving forwards, randomised trials comparing ctDNA-guided decision-making against the1091
standard of care would be definitive, and the EMA have outlined good practice guidelines1092
for the design of such trials [211]. Trials to test the clinical utility of ctDNA analysis for1093
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treatment monitoring are now being carried out [212]. In one trial, patients with NSCLC1094
receiving erlotinib are being prospectively monitored, and if resistance mutations emerge in1095
plasma, then additional scans to search for signs of disease progression would be carried out1096
[212]. Another clinical trial aims to demonstrate the efficacy of targeting mutations identified1097
in plasma from patients with advanced breast cancer [213], which could support the future1098
use of plasma-only mutation profiling and treatment stratification. Together, these studies1099
highlight that the field is moving from exploratory ctDNA studies, towards clinical trials1100
where ctDNA is guiding decision-making.1101
A better understanding of the origin and biology of cfDNA and ctDNA would aid the1102
implementation of liquid biopsies [35]. The relative contributions of apoptosis, necrosis1103
and active release, particularly at different time points during treatment, should be explored.1104
Our limited understanding of the release and clearance mechanisms of cfDNA hampers1105
interpretation of current studies. Studies of the dynamics and reproducibility of ctDNA1106
measurement in the absence of intervention will become increasingly important as we aim1107
to interpret ctDNA signal in response to treatment. It is also not clear whether all tumour1108
subclones contribute proportionately to the total ctDNA pool, or whether their representation1109
in the bloodstream is biased by other biological factors, such as tumour vascularity or1110
metabolic activity. In vivo cellular barcoding experiments [214] and autopsy studies [125]1111
could elucidate the contribution of individual subclones, and histological studies may clarify1112
the factors that modulate ctDNA release. The differences in size between cfDNA and ctDNA1113
fragments [51, 64, 65, 198] suggest that optimising processing and extraction methods (as1114
well as downstream assays) for recovery of short fragments may provide further improvement1115
to overall performance.1116
While ctDNA can have greater sensitivity and specificity compared to other circulating1117
biomarkers [30], taking a multi-marker approach may offer a more comprehensive insight1118
into a patient’s disease [101, 198, 215]. For example, total cfDNA concentration correlates1119
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with disease status [2, 198] and is associated with prognosis [216]. Epigenetic analysis of1120
cfDNA may identify cancer gene hypermethylation [24, 32] or the cell-type giving rise to1121
cfDNA fragments [49–51], and may provide a window into the tumour microenvironment,1122
which usually lacks somatic mutations. Other circulating nucleic acids such as mRNA and1123
microRNA can provide additional layers of information [217]. Targeting multiple types of1124
nucleic acid, with independent mechanisms of release, may increase sensitivity for detection1125
of MRD, for example through the co-isolation of both exosomal RNA and cfDNA [218].1126
Actively released nucleic acids may be preferred for the detection of mutations in subclones1127
resistant to therapy, whereas fragments arising from dying cells following the initiation of1128
therapy may identify treatment-responsive subclones. Next, although it may be possible1129
to infer gene expression patterns from cfDNA [183], sequencing RNA within exosomes1130
[219], CTCs [220] or platelets [221] could provide more direct evidence. We further echo1131
the suggestion by Gormally, Hainaut and colleagues [222], made almost a decade ago, that1132
characterisation of proteins associated with cfDNA may provide a rich source of information1133
on an individual’s disease, and the biology of cfDNA.1134
The clinical uptake of liquid biopsies will depend on the practical advantages for patients1135
and clinicians, the infrastructure required, and its cost-effectiveness. Tissue biopsies will1136
continue to play a key role in cancer management, particularly for the histological diagnosis1137
and classification of cancers. At present, specialised laboratories handle CTC and ctDNA1138
samples [223], though in future hospital laboratories may carry out analysis locally if1139
appropriate processes can be established [224].1140
Point-of-care devices for the identification of individual hotspot mutations with clinically1141
meaningful sensitivities are starting to be used for tissue and plasma samples [225, 226]. The1142
feasibility of single molecule (third-generation) sequencing of maternal plasma DNA was1143
first demonstrated in 2015 [69], and subsequently it was shown that structural variants in cell1144
line DNA can be detected [227]. The portability of such technologies was demonstrated by1145
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the real-time genomic surveillance in the field during the Ebola virus disease epidemic [228].1146
At present, such platforms are limited by a high error rate [227], making single nucleotide1147
variant and indel detection challenging. Another challenge is that of sequencing short1148
DNA fragments, which requires optimised library preparation methods [229]. Furthermore,1149
sequencing capacity is also limited (~150 megabases) [230], though this is likely to increase1150
in the near future, and specific amplicons may be targeted through real-time selective1151
sequencing [231]. These studies support the possibility of molecular profiling at the point of1152
care, especially if blood plasma can be interrogated without the relatively cumbersome and1153
time-consuming step of DNA purification [6].1154
The initial approvals by the EMA and FDA for mutation detection in plasma as a1155
companion diagnostic [90], and emerging ctDNA-guided clinical trials [212, 213], represent1156
key milestones towards the implementation of liquid biopsies in personalised oncology.1157
Improving technologies are enabling an ever-wider scope for non-invasive molecular analysis1158
of cancer, providing information that opens new avenues for genomic research and may1159
aid in clinical decisions. In order to fully exploit the potential utility of liquid biopsies, it1160
is essential that the biology of ctDNA be explored further. Thus far, liquid biopsies have1161
demonstrated the potential for utility across a range of applications, and are beginning to be1162
used for patient benefit.1163

Chapter 21164
Current progress in monitoring1165
melanoma with liquid biopsies1166
2.1 Abstract1167
Circulating tumour DNA (ctDNA) is being increasingly used to detect and monitor disease in1168
patients with both early-stage and advanced cancers. In cutaneous melanoma, liquid biopsies1169
are beginning to be used in research settings to monitor response to targeted therapies and1170
immunotherapies, and to monitor for relapse following surgery. A number of studies have1171
demonstrated that ctDNA can monitor advanced melanoma, though sensitivity is limited1172
for early-stage and low tumour-burden disease. By virtue of having a high mutation rate1173
in melanoma, additional mutations can be targeted, which may offer enhanced sensitivity.1174
Recent developments, and the barriers to clinical implementation of ctDNA, will be discussed1175
in this review.1176
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2.2 Epidemiology of melanoma1177
Cutaneous melanoma is a type of skin cancer affecting melanocytes (pigment producing1178
cells). In 2014, there were 15,400 new cases of melanoma in the United Kingdom, and1179
its incidence is rising faster than any other cancer in the UK [232]. Cutaneous melanoma1180
causes 75% of deaths related to skin cancer, and its global incidence is 15-25 per 100,0001181
individuals per year [233].1182
Increasing sun (UV) exposure is an important contributor to this rise in incidence, sup-1183
ported by the high rate of UV damage-induced C>T transitions in the genome of melanomas1184
[234]. As a result, melanomas have the highest mutation rate per megabase of all cancers,1185
with an average of 16.8 mutations/Mb [234].1186
91% of individuals diagnosed with melanoma are identified at an early stage i.e. American1187
Joint Committee on Cancer (AJCC) Stage I or II, which is characterised by the presence of1188
localised disease without regional lymph node involvement or distant metastasis (Table 2.1).1189
Patients’ outcomes are influenced by Breslow thickness, ulceration and regional nodal and1190
metastatic disease status. Stage I-II melanomas are managed primarily by surgical excision,1191
which confers 5-year survival of >98%; this falls to 62% for patients with Stage III disease,1192
i.e. disease that has spread to nearby lymph nodes (Table 2.2). For patients diagnosed with1193
Stage IV disease, 5-year survival has historically been approximately 10% [235], though1194
recent evidence using combination immunotherapy indicates that three-year overall survival1195
rates can be as high as 60% [236].1196
2.3 Management1197
2.3.1 Stage I-III melanoma1198
Surgical removal is the gold standard treatment for patients with primary cutaneous melanoma1199
with negative regional lymph nodes [239]. Following surgical resection of localised disease,1200
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Stage Description
Stage 0 Melanoma is confined to the epidermis.
Stage IA Melanoma thickness up to 1mm AND no ulceration AND it
has a mitotic rate of less than 1 mitosis per mm2
Stage IB Melanoma thickness of up to 1mm with ulceration, OR it
has a mitotic rate of greater than 1 mitosis per mm2, or it is
between 1-2mm and is not ulcerated
Stage II Melanoma thickness greater than 1mm with ulceration, or
greater than 2.0 mm without ulceration.
Stage III Regional lymph node involvement and/or presence of mi-
crosatellites, satellites or in-transit metastases, with no evi-
dence of distant metastases
Stage IV Distant metastatic spread of melanoma.






Stage not known 74.2% 79.9%
All stages 85.8% 92.2%
Table 2.2 Melanoma 5-year relative survival statistics. Taken from the Office of National
Statistics 2016 [238].
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patients undergo surveillance for tumour recurrence and additional primary melanomas1201
(which may occur in up to 8% of patients [240]).1202
During surveillance of patients with stage IA disease, any skin lesions that are new1203
or have changed, or that violates any of the ABCDE (Asymmetry of the lesion, Border1204
irregularity, Colour variability, Diameter >6 mm, Evolving) rule, should be evaluated by a1205
dermatologist or specialist, and/or removed and sent for histological assessment. For disease1206
stage IB-III, history and physical examination should be carried out every 3-6 months for1207
3 years, then 4-12 months for 2 years, then yearly [241]. The survival benefit from early1208
detection of melanoma recurrence was demonstrated in a study by Leiter et al. [242], which1209
showed a significantly improved survival among patients whose recurrent metastases were1210
detected early (40.5% overall survival) rather than late (25.6% OS, P=0.013).1211
Adjuvant immunotherapy may be provided for patients with stage III or definitively1212
treated stage IV disease and can produce significant benefit, though they carry risks of side1213
effects and negatively affect quality of life. In 2008, Bottomley et al. carried out a study on a1214
cohort with stage III melanoma after full lymphadenectomy, where patients were randomised1215
to either observation (n = 629) or pegylated interferon alfa-2b for an intended duration of 51216
years [243]. After 3.8 years of median follow-up, recurrence-free survival (RFS) risk was1217
reduced by 18% (HR = 0.82) compared to observation alone, though at a cost of significantly1218
lower global health-related quality of life (-11.6 points) based on the European Organisation1219
for Research and Treatment of Cancer Quality of Life Questionnaire C30) [243].1220
Between 2008-2011, 951 patients with stage III cutaneous melanoma were randomly1221
assigned to ipilimumab, an anti-CTLA4 immunotherapy, or placebo [244]. At a median1222
follow-up of 2.74 years, the median RFS was shown to be 26.1 months in the ipilimumab1223
group versus 17.1 months in the placebo group (HR 0.75). Although patients gained sig-1224
nificant benefit from the treatment, adverse events led to the discontinuation of treatment1225
of 245 (52%) of the 471 patients who started ipilimumab, and 5 patients (1%) died due to1226
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drug-related adverse effects. Most recently, Weber et al. [245] compared adjuvant therapy1227
with nivolumab versus ipilimumab single-agent treatment in patients undergoing resection of1228
stage III or IV melanoma. In this study of 906 patients, Weber et al. [245] demonstrated that1229
adjuvant nivolumab resulted in a significantly longer RFS and a lower rate of grade 3 or 41230
adverse events than ipilimumab.1231
2.3.2 Stage IV melanoma1232
Prior to the Food and Drug Administration (FDA) approval of ipilimumab in 2011, the1233
main treatments for stage IV melanoma were chemotherapeutic agents such as dacarbazine1234
and temozolomide [239], despite single or combination chemotherapies having never been1235
shown to improve overall survival. The introduction of targeted therapies led to improve-1236
ments in overall survival over the past decade [246]. Most recently, immunotherapies have1237
shown potential to produce long-term response [239]. Thus, immune checkpoint inhibitors1238
and targeted therapies have now largely superseded chemotherapy treatment for cutaneous1239
melanoma, although both show high rates of toxicity [239].1240
Anti-BRAF inhibitors such as vemurafenib and dabrafenib are widely approved for1241
treatment of patients with BRAF V600mut metastatic melanoma [247]. In randomised clinical1242
trials, Vemurafenib (960mg twice daily) [246] and dabrafenib (150mg twice daily) [248] both1243
showed similar response rates and improvements in PFS, reducing the risk of progression1244
by >60% relative to dacarbazine chemotherapy. In the vemurafenib trial, the risk of death1245
was reduced by 63%. The median overall suvival with dabrafenib was 20.0 months vs. 15.61246
months for dacarbazine alone, and 13.6 months vs. 9.7 months for vemurafenib compared1247
to dacarbazine, respectively. With targeted therapies, common adverse effects observed1248
were skin-related toxicity, arthralgia and fatigue [239]. In 20% of patients treated with1249
BRAF-inhibitors, secondary cutaneous squamous cell carcinomas and keratocanthomas can1250
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occur within the first 2-3 months of therapy [249]. In addition, second primary melanomas1251
occur in 2-5% of patients treated with anti-BRAF drugs [239].1252
The efficacy of ipilimumab has been demonstrated by randomised clinical trials of ip-1253
ilimumab compared to placebo [250], and as compared to a gp100 peptide vaccine, which1254
targets a glycoprotein that is highly expressed in melanocytic cells [251]; these studies1255
showed that compared to gp100, ipilimumab showed a hazard ratio of 0.66. However, one1256
of the challenges of treatment with immunotherapy is the frequency and severity of adverse1257
events. In a study of 676 patients with unresectable stage III or IV melanoma, grade 3-41258
immune related adverse events occurred in 10-15% of patients with colitis, skin rash and1259
endocrinopathies being common [251]. When ipilimumab is combined with dacarbazine,1260
the rate of grade 3-4 adverse events rises 56% [239]. For patients who show serious ad-1261
verse reactions, it is recommended to discontinue ipilimumab and to treat with high-dose1262
corticosteroids.1263
Monitoring of immunotherapy response by imaging is made particularly challenging by1264
unique response patterns of such treatments, termed pseudoprogression [252]. It was noted in1265
early immunotherapy cases that patients who showed conventional disease progression based1266
on RECIST (i.e. an increase in the sum of measures of target lesions, unequivocal increase in1267
non-target disease, or the appearance of new lesions) were found to have late but durable1268
treatment responses [253]. As a result, systematic criteria for assessing immune-related1269
responses were defined beyond those described by RECIST or WHO criteria [254], which1270
were named as Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST).1271
For patients with metastatic melanoma, disease monitoring must be able to overcome1272
the challenges posed by the now widespread use of immunotherapy, such as mitigating the1273
confounding effects of pseudoprogression, and having sufficient dynamic range to quantify1274
both high levels and residual disease levels if long-term response were to be achieved.1275
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2.4 Treatment monitoring with ctDNA1276
2.4.1 Stage IV melanoma1277
Liquid biopsies for ctDNA have been taken serially to monitor advanced melanoma alongside1278
conventional markers [133, 134, 172]. The aim of using liquid biopsies for melanoma is1279
for earlier identification of treatment response or failure, which may enable modification of1280
clinical management. ctDNA may have advantages over conventional serum biomarkers due1281
to its wide dynamic range [30] and high specificity [59]. Currently, patients are monitored1282
with imaging and prognostication is also aided by serum protein markers such as lactate1283
dehydrogenase or S100B [255]. S100B proteins, which are shed by melanoma cells, have1284
value in monitoring patients during therapy, with increasing levels correlating with progress-1285
ing disease (and vice versa) [256], and have a higher specificity for progressive disease than1286
LDH [257]. While protein markers can be informative for disease monitoring, they are less1287
sensitive than ctDNA analysis for disease progression or for non-RECIST progression events1288
[258], and do not reflect individual mutations in the tumour.1289
Aside from protein markers, ctDNA has been shown to correlate with imaging data, as1290
measured by FDG-PET (r = 0.61; P<0.001) [259, 260]. Patients were monitored using NGS1291
and dPCR for mutations in BRAF, NRAS, KIT, or TERT. Targeting KIT or TERT facilitates1292
monitoring of BRAF, NRAS and NF1 wild-type melanoma patients [261], which can contain1293
these additional hotspot mutations. McEvoy et al. [260] found that ctDNA was non-detected1294
in all patients with a low level of tumour lesion glycolysis across all lesions as measured by1295
PET/CT, highlighting that greater sensitivity that what was achieved in this study is needed1296
to detect and monitor small lesions or tumours with low levels of metabolic activity. Despite1297
this limited sensitivity, an assay with limited sensitivity can still have utility as a prognostic1298
classifier, as McEvoy et al. found that non-detected ctDNA is associated with longer PFS1299
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[260]. These studies indicate the potential for liquid biopsies to provide a minimally invasive1300
monitoring option between and in addition to imaging.1301
Immunotherapy1302
Liquid biopsies have been used to monitor patients with immunotherapy [133, 134, 262].1303
In both immunotherapy and chemotherapy patients, based on digital PCR measurement1304
of BRAF or NRAS mutations in a cohort of 48 patients with metastatic melanoma, lower1305
pre-treatment ctDNA levels were significantly associated with response to treatment and1306
prolonged PFS [133]. The dynamics of ctDNA in response to therapy appear to differ based1307
on treatment type: targeted therapy caused a steep decline in ctDNA [172], which was not1308
the case with immunotherapy [133]. These differences in ctDNA dynamics are likely related1309
to the mechanism of action of each of the treatments and the timeframes of cancer cell1310
death. Following treatment initiation with dabrafenib and trametinib, patients whose BRAF1311
V600mut ctDNA remained detectable showed significantly poorer PFS than patients whose1312
ctDNA became non-detected [172]. Rising ctDNA was able to identify clinical progression1313
on targeted therapy either at (26% of patients) or before (44%) progression [172].1314
By virtue of the high specificity and short half-life of ctDNA [59], liquid biopsies may1315
be able to identify pseudoprogression in patients receiving immunotherapies, which can1316
be observed as a clinical progression but followed by ctDNA levels immediately declining1317
[134]. A recent study comparing irRC and ctDNA in 125 patients showed that ctDNA1318
profile may predict pseudoprogression from true progression with a sensitivity of 90%, and1319
100% specificity [262]. Compared to LDH, ctDNA showed a positive predictive value of1320
100% vs. 92%. Thus, ctDNA analysis may have utility for classification of patients with1321
pseudoprogression.1322
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2.4.2 Stage I-III melanoma1323
Following radical treatment of stage I-III melanoma, recommended follow up is every 3-61324
months for up to 5 years with history, examination and imaging [263]. More frequent surveil-1325
lance imaging is performed for patients with stage III melanoma [263]. Stratifying patients1326
using ctDNA may enable more appropriate selection of patients for adjuvant treatment,1327
and could complement AJCC staging information. This is particularly relevant given the1328
evidence to support the use of ipilimumab, nivolumab and dabrafenib/trametinib for Stage1329
III melanoma [264, 245, 265].1330
In the early-stage disease setting, Lee et al. [266] used ddPCR to assess ctDNA in 1611331
patients with high-risk Stage II/III melanoma patients following surgery. Using a threshold1332
of  1 mutant ctDNA copies per sample from up to 2ml of plasma, 15/132 (11%) and 4/291333
(14%) of patients had detected levels of BRAF and NRAS ctDNA within 3 months of surgery.1334
Patients with detected ctDNA had a significantly reduced disease-free interval (Hazard Ratio,1335
HR 3.12, P<0.0001), and showed significantly worse overall survival at 5 years (HR 2.63,1336
P=0.003). Although detection of residual disease is possible following surgery in melanoma,1337
detection rates are low, due to limited technical sensitivity relative to the biological levels of1338
ctDNA.1339
Despite the low detection rate of ctDNA immediately post-surgery, assays with limited1340
sensitivity can still classify samples into those with the highest ctDNA levels vs. non-detected1341
ctDNA and thus can still have potential for prognostic utility. Studies with longitudinal1342
follow-up [185, 186] show that sensitivity for patients who relapsed is higher where multiple1343
longitudinal samples are used to classify samples. By using longitudinal samples, such1344
studies leverage a larger number of molecules and allow time to elapse, enabling ctDNA1345
levels to rise until they cross the limit of detection of that assay. Thus, only by increasing the1346
sensitivity of the assay at a given time point used can the lead-time to relapse be improved.1347
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This may partially explain why studies have shown lead-times up to 11 months but no further1348
[117, 186, 187, 267].1349
2.5 Improving detection of relapse1350
Although single-locus digital PCR assays have low false-positive rates, in order to fully1351
utilise the sensitivity of the assay, a sufficiently large number of input cfDNA molecules1352
needs to be used. Frequently used Bio-Rad ddPCR systems are capable of generating up1353
to 20,000 droplets, with an average of 70% droplets read (i.e. 30% dead volume) [268]. In1354
theory, one mutation molecule per 20,000 can be detected depending on the background1355
noise of the assay. Thus, to achieve sensitivity to 1 mutant molecule in 14,000, approximately1356
67ng of cfDNA is required as input, which would require the entire material from two blood1357
tubes, given a median cfDNA concentration of 7.8ng/ml plasma in the plasma of melanoma1358
patients [269].1359
Sampling error may be overcome, to an extent, by targeting additional mutations using1360
targeted sequencing. However, fixed gene panels may still achieve limited sensitivity in the1361
plasma of melanoma patients, as there are few recurrently mutated loci in the melanoma1362
genome [121]. For example, Siroy et al. [270] applied a 46-gene sequencing panel to tumour1363
tissue samples from 699 melanoma patients, identifying a median of 1 mutation per patient,1364
with >1 mutation being observed in 1/3 of patients [270]. If such a panel were to be applied to1365
plasma, many patients’ ctDNA level cannot be quantified due to having few or no informative1366
reads overlying loci that were mutated in that patients’ tumour (i.e. the issue is of sampling1367
error and not analytical sensitivity). To boost the median number of mutations detected in1368
plasma, even larger sequencing panels would be required. However, regardless of the panel1369
size used, the background error rate of the assay will ultimately set the limit of sensitivity.1370
By designing patient-specific sequencing panels [29, 106, 113], greater sequencing depth1371
can be achieved at loci of interest.1372
2.6 Conclusion 49
While there has been rapid progress in monitoring of melanoma using liquid biopsy, there1373
is a need for greater sensitivity in order to accurately classify patients into high- and low-risk1374
of relapse following surgery. In addition, non-invasive cancer diagnostics may potentially1375
improve the classification of patients for adjuvant therapy, which may reduce the rate of1376
overtreatment with immunotherapies that carry risk of adverse events. This information may1377
guide treatment decisions by clinicians and patients, in order to maximise patient outcomes1378
and quality of life.1379
2.6 Conclusion1380
There is increasing evidence supporting the validity of using of ctDNA for monitoring both1381
early and advanced-stage melanoma. The majority of these studies use single-locus mutation1382
assays targeting BRAF or NRAS. Despite the limited sensitivity of single-locus assays, ctDNA1383
has still been shown to be able to prognosticate in both high- and low-burden disease settings.1384
As liquid biopsies become more sensitive, potentially through targeting additional mutations1385
present in the melanoma genome, disease may be detected earlier. In order to progress these1386
findings towards implementation, future clinical trials guided by liquid biopsies are needed1387
to test whether or not the real-time, sensitive and specific nature of ctDNA may produce1388
clinical benefit for patients.1389

Chapter 31390
Targeting multiple mutations in plasma1391
improves genotyping and monitoring1392
3.1 Attribution1393
This chapter is adapted from the following manuscript, which we submitted in November1394
2016. The submitted manuscript from 2016 is as follows:1395
1396
Wan JCM, Murphy S, Gale D, Morris J, Mouliere F, Marass F, Heider K, Chandrananda D,1397
Smith CG, Bignell GR, Alifrangis CA, Parkinson C, Durrani A, McDermott U, Massie C,1398
Corrie PG, Rosenfeld N*.1399
Plasma DNA analysis mitigates biased mutation detection in tumour biopsies.1400
*Corresponding author1401
1402
Using a patient-specific sequencing approach, the first half of the manuscript suggests1403
the potential advantage of using a combined plasma and tumour data for comprehensive1404
genotyping, and the latter half discusses the potential improvement in sensitivity of detection1405
of ctDNA by targeting multiple mutations.1406
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3.2 Author Contributions1407
I performed all analyses in this Chapter. The first half of this chapter on comparison of1408
mutation profiles comprises the manuscript which we submitted in 2016, which I wrote and1409
performed all analyses, and was given feedback from co-authors. The second half of the1410
manuscript focuses on longitudinal monitoring of ctDNA by using multiple patient-specific1411
mutations with TAm-Seq.1412
3.2.1 Methods line-by-line contribution1413
• Patient cohort and sample processing. Pippa Corrie and Nitzan Rosenfeld set up1414
the MelResist sample collection. Individualised ctDNA monitoring was suggested1415
in a study previously published in the lab [29], and so this study was carried out to1416
explore individualised sequencing data using TAm-Seq to both improve sensitivity,1417
and to study tumour heterogeneity.1418
• DNA extraction. Tumour DNA extraction was performed by Graham Bignell and1419
Ultan McDermott at the Sanger Institute, and plasma DNA extraction and quantification1420
was shared between myself and Suzanne Murphy.1421
• Tumour exome sequencing. Graham Bignell and Ultan McDermott performed ex-1422
ome sequencing of tumour samples of 10 stage IV melanoma patients for a separate1423
hypothesis.1424
• Amplicon sequencing. Suzanne Murphy (wet-lab MD student) worked with Francesco1425
Marass and James Morris (bioinformatics staff) to design individualised TAm-Seq1426
(iTAm-Seq) primers for these patients based on the previously generated exome data.1427
I worked with Suzanne Murphy to perform the experimental work for TAm-Seq on1428
plasma samples using these primer pairs.1429
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• Shallow Whole Genome Sequencing. The sWGS pipeline was set up in our lab by1430
Dineika Chandrananda and Chris Smith based on published methods [271], which1431
Dineika applied to whole-genome libraries I generated from these longitudinal samples.1432
• Mutation detection. I developed these criteria for detection of ctDNA at multiple loci1433
given background error rates at each locus.1434
• Calculation of mean allele fraction. Here, I suggested the use of a depth-weighted1435
mean allele fraction as a measure of quantification of ctDNA across multiple patient1436
specific mutations. This concept of aggregation/averaging of signal across multiple1437
mutations was built upon in the subsequent INVAR manuscripts.1438
3.3 Abstract1439
Circulating tumour DNA (ctDNA) is increasingly used to both genotype disease and monitor1440
tumour responses. Single-locus assays and fixed sequencing panels generate data on individ-1441
ual mutations only, resulting in molecular profiling of a limited number of mutations, and1442
with a limited overall sensitivity due to sampling error for rare mutant molecules. Patient-1443
specific approaches allow interrogation of multiple mutant loci, and also greater sensitivity1444
for ctDNA. Here, we designed patient-specific sequencing panels targeting a median of1445
~50 mutations per patient, which we applied to longitudinal plasma samples from stage1446
IV melanoma patients undergoing treatment with chemotherapy or immunotherapy. First,1447
we show discordance in mutation profiles between matched tumour and plasma samples,1448
indicating the potential utility of plasma mutation profiling alongside tumour profiling. Next,1449
we demonstrate that the limit of detection of amplicon sequencing in plasma can be improved1450
to 0.01% by aggregating signal across multiple shared and private mutations rather than1451
considering each individually. By doing so, the agreement between ctDNA and imaging1452
was improved, and allowed identification of progression 28 days earlier than serum lactate1453
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dehydrogenase, a currently used protein marker. We suggest that interrogation of multiple1454
shared and private tumour mutations in plasma can help to mitigate sampling error for tumour1455
genotyping, and can boost sensitivity for disease monitoring.1456
3.4 Introduction1457
Shared and private mutations in heterogeneous disease, and from multiple tumour regions, can1458
be detected in patient blood plasma samples as circulating tumour DNA (ctDNA) [125, 124].1459
Mutations that are shared between multiple tumour loci appear in plasma at higher mutant1460
allele fractions, as opposed to those that are private to individual lesions [125, 124]. Serial1461
measurement of ctDNA has previously been applied to non-invasively monitor melanoma1462
patients [258, 134, 172, 272], though following the initiation of chemotherapy or following1463
surgery, ctDNA concentration may decline to undetectable levels using single-locus assays,1464
often due to there simply being no mutant molecules (at the locus of interest) in the plasma1465
sample collected.1466
Patient-specific plasma sequencing approaches can enable a larger number of mutations to1467
be interrogated in plasma. Thus far, 10-32 mutations per patient have been targeted [113, 106].1468
Patient-specific approaches provide greater sensitivity for ctDNA by interrogating a larger1469
number of loci [59], and generate high-depth plasma sequencing across multiple mutations,1470
enabling the comparison of tumour and plasma mutation profiles in plasma.1471
In this study, we designed patient-specific TAm-Seq panels [29], each targeting between1472
48-65 mutations per patient, for 9 patients with stage IV melanoma. Both shared and private1473
tumour mutations were included in the panel design based on sequencing of multiple tumour1474
biopsies, which enabled assessment of mutation representation in plasma at high disease1475
burden time points, and improved detection of ctDNA overall at low disease burden time1476
points. Based on discordance between tumour and plasma mutation profiles with high-depth1477
sequencing, we suggest that a combined tumour biopsy and liquid biopsy approach may1478
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provide a more accurate genotype than a tumour biopsy alone. Furthermore, we suggest that1479
targeting multiple shared and private mutations in plasma with patient-specific panels can1480
boost sensitivity for low-burden disease by providing additional opportunities to sample rare1481
mutant molecules.1482
3.5 Results1483
3.5.1 Targeting multiple mutations reveals sampling biases in tumour1484
biopsies1485
Mutation profiles were compared between tumour and plasma, before and after treatment, for1486
9 patients with metastatic melanoma (Supplementary Figures 3.10- 3.18, page 74). Across1487
all patients, we found a Pearson correlation of 0.58 between tumour and plasma mutant1488
allele fractions (P < 2.2 x 10-16), consistent with published data [124]. Data from one patient1489
(MR1012) are shown in Fig. 3.1: for this patient, two metastatic biopsies were collected1490
from the left groin, one collected at baseline, prior to treatment initiation with dabrafenib1491
and trametinib, and another biopsy collected 190 days later at progression (Fig. 3.1A). Allele1492
fractions for 39 mutations were measured in each sample in both tumour TAm-Seq and1493
plasma TAm-Seq. Mutation loci showed a greater change in allele fraction in longitudinal1494
tumour biopsy samples compared to longitudinal plasma samples (Fig. 3.1B). The differences1495
between baseline and progression time point allele fractions can be quantified by assessing1496
the coefficient of determination values (R2) determined by linear regression (Fig. 3.1C),1497
which showed smaller differences in allele fraction relative to the overall trend in plasma as1498
compared to tumour. In addition, we observed that high-depth amplicon sequencing reduces1499
the variability in tumour allele fraction as compared to exome sequencing (Fig. 3.1C), which1500
is summarised in Supplementary Fig. 3.9. These data indicate that the mutation profiles1501
56 Targeting multiple mutations in plasma improves genotyping and monitoring
obtained from tumour mutation biopsies differ compared to plasma samples, which could be1502
due to tumour biopsy sampling error.1503
Fig. 3.1 Comparison of tumour and plasma mutations from matched samples
Panel A shows the sampling timeline for this patient: metastatic biopsies and plasma samples
were taken, 190 days’ apart, both from metastases to the left groin. This patient received
dabrafenib and trametinib during the intervening period.
Panel B shows a heat map with mutant allele fractions in tumour and plasma DNA samples
at baseline and progression. Mutations are ordered based on hierarchical clustering of allele
fractions across tumour and plasma samples.
Panel C shows baseline mutant allele fractions plotted against progression mutant allele
fractions, for tumour DNA sequenced with exome sequencing and TAm-Seq, and for plasma
DNA sequenced by TAm-Seq. A linear regression line is shown, and its adjusted R2 value is
indicated.
Tumour mutations were classified as shared if they were any mutant reads in both tumour1504
samples, otherwise the mutation was classified as private to one tumour biopsy. Patient-1505
specific mutation detection is described in Method 3.8.1. The median allele fraction of shared1506
mutations was significantly greater than that of private mutations when measured in either1507
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tumour and plasma samples (P<0.001, Welch’s Two Sample t-test, Fig. 3.2A), reflecting1508
their increased intratumour prevalence. Shared mutations showed a greater difference in1509
mutant allele fraction in plasma compared to in tumour samples, enabling greater accuracy1510
in classification of mutations as shared or private based on mutant allele fraction alone (Area1511
Under the Curve, of 0.89 ± 0.02 vs. 0.70 ± 0.02, P<0.001, Fig. 3.2B).1512
96.1% of shared tumour mutations were detected in time-matched plasma, whereas 37.5%1513
of private tumour mutations were detected in plasma (P=0.002, Wilcox test). In addition, an1514
average of 3% (1.2 mutations out of 40) were detected in plasma at a time point when they1515
were not observed in the tumour sample. The total number of detected mutations are shown in1516
Fig. 3.2C. These data were confirmed by re-analysis of data from Murtaza et al. [34], which1517
showed that plasma mutation detection sensitivity increases as the prevalence of that mutation1518
increases within the tumour bulk (Fig. 3.2D), and mutations identified in >2 metastatic biopsy1519
sites were detected in plasma with a median sensitivity of 100%. To determine a plasma1520
detection rate for mutations in the Murtaza et al. [125] study, only one tumour and plasma1521
sample pair was used, as this was the only time-matched sample pair. Mutations with >1%1522
mutant allele fraction (MAF) were classified as detected. Mutations were classified as shared1523
if they were detected in >1 tumour sites.Taken together, these data suggest the utility of1524
performing matched plasma sequencing in parallel to any tumour genotyping in order to1525
allow identification of sampling biases for private mutations of low-intratumour prevalence,1526
depicted in Fig. 3.3.1527
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Fig. 3.2 Plasma mutation representation
Panel A shows box plots of allele fractions in plasma and tumour for tumour-private and
tumour-shared mutations.
Panel B shows Receiver Operating Characteristic curves for the classification of shared and
private mutations in tumour and plasma. The Area Under the Curve values for tumour and
plasma were 0.70 ± 0.02 and 0.89 ± 0.02, respectively (P < 0.001).
Panel C shows the mean number of detected mutations per matched sample in the current
study of Stage IV melanoma patients, as compared to the data from a case study of a patient
with metastatic breast cancer. 96.1% of tumour-shared mutations were detected in time-
matched plasma, whereas 37.5% of tumour-private mutations were detected. An average of
1.2 mutations (out of 40) per patient were detected in the plasma at a time-point where these
were not detected in the tumour analysis.
Panel D contains box plots showing the detection rates for mutations present in a varying
number of metastatic sites, using data from Murtaza et al. [125]. Mutations were classified
as shared if they were present in both tumour biopsies in this study, or if they were present in
at least 5 sites in the Murtaza et al. study [125].
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Fig. 3.3 Plasma DNA analysis mitigates biased mutation detection in tumour biopsies
The clonal composition of this hypothetical patient’s disease is shown on the left, and the
time point of tumour and plasma sampling is indicated. Individual biopsies may each give a
different mutation profile due to sampling error in spatially heterogeneous disease. Matched
plasma analysis can reveal the extent of this sampling bias, identifying mutations that are
relatively under- or over-represented in plasma. By comparing the two modalities, the effect
of sampling error may be minimised.
60 Targeting multiple mutations in plasma improves genotyping and monitoring
3.5.2 Benchmarking the sensitivity of patient-specific TAm-Seq1528
Next, we assessed the sensitivity of patient-specific TAm-Seq for individual and aggregated1529
mutations for disease monitoring. We applied patient-specific TAm-Seq to a spike-in dilution1530
series, made from a patient plasma cfDNA eluate serially diluted into cfDNA from healthy1531
individuals (Method 3.7.7). Detection of patient-specific variants above background noise1532
was performed as described in Method 3.8.1. This patient had a BRAF V600E mutation,1533
which was detected in the dilution series to an allele fraction of 10-2 (Fig. 3.4), but was not1534
detected in subsequent serial dilutions.1535
When multiple mutations are targeted, signal can be aggregated by taking an average1536
allele fraction across all loci, allowing quantification of disease to 10-4 mean allele fraction1537
(Fig. 3.4). Although the individual detected mutations had allele fractions >10-3, the depth-1538
weighted average allows quantification of ctDNA despite having few mutant molecules1539
present (Method 3.8.2). Quantification of ctDNA may be achieved to 10-4, although due to1540
sampling error, the mean allele fraction deviated from the expected allele fraction by up to1541
an order of magnitude (Fig. 3.4). Aggregating signal across multiple loci is essential when1542
the level of signal is below the sampling limit of any individual locus, since the signal can1543
occur at any of the loci. 10-4 mutant allele fraction is approaching the limit of detection set1544
by the background rates of non-error-suppressed sequencing that we characterised (Fig. 3.5).1545
3.5.3 Detection rates in longitudinal clinical samples1546
First, detection of ctDNA was assessed at baseline with individual driver mutations. Using1547
either BRAF or NRAS mutations only, ctDNA was detected at baseline in 7/9 patients1548
(Fig. 3.6). Patient information is shown in Table 3.1. Across all longitudinal time points,1549
ctDNA was detected in 62 out of 104 time points (59.6%), and of the detected samples,1550
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Fig. 3.4 TAm-Seq dilution series with multiple mutations
Patient-specific TAm-Seq was performed with 49 unique amplicon pairs, sequenced to a
median depth of 66,204x. Detection of ctDNA at each locus was based on a threshold set
using control samples (Method 3.8.1). The BRAF V600E driver mutation is indicated with a
triangle, whereas all other mutations are indicated by circles. Mutations that were detected
are coloured in blue, and non-detected mutations are coloured in red and plotted along
the x-axis. + indicates the depth-weighted mean allele fraction across the patient-specific
mutations. The dashed line indicates the expected allele fraction for each dilution level.
















































Error rate per locus, split by class
Fig. 3.5 TAm-Seq background error rates by mutation class
For each mutation locus interrogated, its mutation class was determined and the error rate
per locus has been plotted with grouping by class. Background error rates by class varied
between 0.43% to 0.0052% for T/C (T>C) and G/C (G>C) mutations, respectively.
When using multiple mutations, detection at baseline increased to 100% (9/9) patients1552
(Fig. 3.7), and across all time points, ctDNA detection increased to 100 out of 104 (96.1%),1553
with a range of individual allele fractions per locus of <0.01% to 33%. Although each of1554
the mutations showed a similar overall trend, targeting multiple mutations provided a larger1555
number of opportunities for mutant fragments to be sampled, shown by different loci showing1556










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.4 Comparison of ctDNA with clinical data1558
At time points of progressive disease, average allele fraction across all mutations was1559
increasing immediately before at 15 out of 19 events (79%), non-detected at 2/19 events1560
(11%), and decreasing at 2/19 events (11%, Fig. 3.8). In contrast, when one mutation was1561
targeted, ctDNA was identified as rising in 12/19 events (63%), non-detected in 5/19 events1562
(26%), and falling in 2/19 events (11%). For the non-detected time points in patient MR1004,1563
there was clinical progression due to new lesions identified on CT, though the ctDNA level1564
was below 0.01% mutant allele fraction. For the discordant time points relative to clinical1565
data, one patient (MR1020) showed a decrease in ctDNA from 8% to 5% allele fraction at1566
the same time as clinical progression, and patient MR1032 showed a decrease in ctDNA1567
of 0.9% to 0.7% ctDNA at the same time as clinical progression. These data suggest that1568
small decreases in allele fraction might still occur at progression. A larger cohort may allow1569
better characterisation of small changes, or broader genomic sequencing may identify loci1570
that were in fact rising in mutant allele fraction.1571







































































































































































































































































































































































































































































































































Following treatment with targeted therapies (either vemurafenib or dabrabrafenib/trame-1572
tinib combined), ctDNA declined initially in all patients, reaching a minimum ctDNA level1573
after a median of 62.5 days (Fig. 3.8). When ctDNA subsequently increased, driver mutations1574
showed the highest allele fractions (Fig. 3.7), consistent with BRAF amplification being a1575
known mechanism of reactivation of the MAPK pathway [273] (Supplementary Fig. 3.19).1576
Serum lactate dehydrogenase (LDH) is a melanoma tumour marker in advanced disease,1577
with an upper limit of normal of 250IU/L. LDH concentrations were measured for each1578
patient longitudinally. Compared to LDH, ctDNA was identified as rising a median of 281579
days earlier (IQR 0-36 days, Fig. 3.8), as measured from the date of the sample where the1580
rise was evident (with no subsequent declines in ctDNA prior to the date of the LDH rising1581
above the limit of normal). LDH plots are shown in Supplementary Fig. 3.20.1582
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3.6 Discussion1583
In this study, we show that targeting multiple shared and private mutations in plasma may1584
have utility for both tumour genotyping and disease monitoring. We suggest that when1585
genotyping patients with heterogeneous disease, it may be advantageous to also sequence1586
their ctDNA at the same mutation loci in order to mitigate sampling error effects in the1587
tumour biopsy. In addition, we demonstrate the sensitivity benefit of targeting multiple1588
mutations in parallel to overcome sampling error for rare mutant molecules in plasma.1589
In our data, baseline and progression samples were temporally separated, and thus clonal1590
evolution may influence comparisons between mutant allele fractions, such as in Fig. 3.1C.1591
We sought to control for temporal changes by analysing multi-region sequencing studies1592
from patients with advanced [46, 125] and localised cancers [149, 150]. We found that1593
although tumour-based genomic profiles may vary based on the individual biopsy analysed,1594
the biases affecting plasma sampling appear constant (Fig. 3.2). Mutations were observed1595
in either the tumour and plasma samples that were not observed in the other sample type,1596
at that time point. We conclude that a combined tumour and plasma genotyping approach1597
may provide a more accurate tumour profile than either sample type alone. In this analysis,1598
although patient-specific primer pairs had to be designed in order to verify tumour mutations1599
in plasma, in future, it may be possible to use untargeted approaches such as plasma exome or1600
whole-genome sequencing at high depth to generate equivalent data, if costs were to decline1601
sufficiently.1602
Furthermore, targeting additional shared and private mutations in addition to the driver1603
mutation, such as BRAF, provides more opportunities for rare mutant molecules to be1604
sampled. By considering signal across multiple patient-specific loci, the limit of detection1605
was improved to 0.01% average mutant allele fraction, approaching the theoretical limit1606
of detection set by the background error rates of TAm-Seq (Fig.3.19). We found that a1607
patient-specific approach allows more accurate tracking of disease relative to imaging, and1608
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was rising 28 days prior to LDH. Although ctDNA changes either preceded or tracked1609
progression events in most cases (79%), there were some discordant events, potentially due1610
to RECIST scoring a progression event when a new lesion is identified while the overall1611
burden of disease was decreasing. In 11% of events, ctDNA was non-detected, and thus1612
the analytical sensitivity of this method was insufficient to accurately assess the change in1613
ctDNA mutant allele fraction.1614
Patient-specific amplicon sequencing is being increasingly performed [113, 117]. As1615
tumour and plasma sequencing costs decline, patient-specific plasma analysis for tumour1616
profiling and detection of low levels of ctDNA may have increasing utility in both clinical1617
and research settings.1618
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3.7 Experimental Methods1619
3.7.1 Patient cohort1620
We evaluated tumour biopsy and plasma samples from nine patients with metastatic melanoma1621
who were enrolled in the MelResist study (REC number 11/NE/0312) before and after treat-1622
ment with targeted therapies and/or immunotherapy. MelResist is a translational study of1623
response and resistance mechanisms to systemic therapies of melanoma. Table 3.1 shows1624
clinical information for each of the patients analysed.1625
Patient Baseline tumour site Progression tumour site Treatment during in-
terim
MR1002 L trunk, posterior L trunk, posterior Vemurafenib
MR1004 L posterior ear L supraclavicular fossa Ipilimumab, Pazopanib
MR1006 R thigh R thigh Vemurafenib, Pan-RAF
inhibitor (MLN2480)
MR1010 R trunk, anterior L trunk, posterior Vemurafenib
MR1012 L external iliac lymph
node
L external iliac lymph
node
Dabrafenib/trametinib
MR1014 R forearm R cheek Vemurafenib
MR1020 L axilla L axilla Vemurafenib
MR1022 R chest wall R chest wall Dabrafenib/trametinib
MR1032 L upper limb, anterior L upper limb, anterior Pan RAF Inhibitor
(MLN2480)
Table 3.1 Tumour sites and treatments for each patient
For each of the 9 patients in this cohort, their baseline and progression tumour biopsy sites,
and treatments received, are shown.
3.7.2 Sample processing1626
Blood samples were collected in S-Monovette 9mL EDTA tubes and inverted 8-10 times.1627
For plasma collection, samples were centrifuged at 1600g for 10 minutes within an hour of1628
the blood draw, and then an additional centrifugation of 20,000g for 10 minutes was carried1629
out. Plasma samples were stored at -80°C.1630
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3.7.3 Fresh frozen tumour, buffy coat and plasma DNA extraction1631
Up to 30mg of each fresh frozen tissue biopsy sample was combined with 600µL RLT buffer1632
(Qiagen), then placed in a Precellys CD14 tube (Bertin Technologies) and homogenised at1633
6500 rpm for two bursts of 20 seconds separated by 5 seconds. DNA was extracted using1634
the AllPrep extraction kit (Qiagen) as per the manufacturer’s protocol. Genomic DNA was1635
extracted from 10 mL whole blood using the Gentra Puregene Blood Kit (Qiagen) as per1636
the manufacturer’s protocol. Cell-free DNA was extracted from 2mL plasma using the1637
QIAsymphony (Qiagen) according to the manufacturer’s protocol.1638
Digital PCR was carried out using a Fluidigm BiomarkTM HD, run with 55 cycles of1639
PCR using a hot-start polymerase. To quantify the cfDNA concentration of each sample,1640
digital PCR was carried out using Taq-man probes for the housekeeping gene RPP30, and1641
XenT, labelled with ROX and FAM, respectively.1642
3.7.4 Exome sequencing1643
Library preparation of 5µg genomic DNA, and sequencing and variant calling were performed1644
as described by Varela et al. [274], using the Agilent SureSelectXT Human All Exon 50Mb1645
bait set. Eight samples were multiplexed per pool and each pool loaded on to two lanes of an1646
Illumina HiSeq 2000, giving an average 8GB of unique mapped reads per sample with an1647
average of 80% of base pairs covered by >20 reads.1648
3.7.5 Amplicon sequencing1649
Tagged amplicon sequencing (TAm-Seq) was performed as previously described [29]. Panels1650
were designed based on point mutations identified in either the baseline or progression tissue1651
biopsies that had a depth of 10 reads or more. For each patient, a mean of 40 mutations1652
(range 33-55) were selected for TAm-Seq. BRAF and NRAS hotspot mutations were included1653
in each panel where they were detected in that patient, plus additional shared and private1654
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mutations spanning a range of allele fractions. Samples were sequenced in duplicate to a1655
mean depth of 32,000x on a HiSeq 2500. A depth-weighted average mutant allele fraction1656
was calculated for each data point.1657
3.7.6 Shallow Whole Genome Sequencing1658
Libraries generated using the Rubicon ThruPLEX protocol were pooled at equimolar concen-1659
tration then sequenced on a HiSeq 4000 to achieve a target coverage of 0.5-1x per library.1660
Reads were de-multiplexed, mapped, and primer-dimers were removed in silico. Copy1661
number was estimated using HMMcopy with the default settings [271], which first counts1662
the number of reads in bins of equal genomic length, corrects based on local GC content,1663
segments and classifies by copy number profile using a Hidden Markov Model.1664
3.7.7 Dilution series1665
To assess the limit of detection of TAm-Seq with a patient-specific approach, we generated a1666
serial dilution of a sample with a high level of ctDNA, serially diluted in extracted cfDNA1667
from a healthy individual (Seralabs). Extracted plasma cfDNA from patient MR1022 at their1668
final time point was used for this dilution series. The concentration of each of the eluates1669
was determined using digital PCR, then the samples were equalised in concentration using1670
water. The patient sample was diluted 5-fold serially for a total of 6 dilutions (5x to 15,625x1671
dilutions).1672
3.8 Bioinformatics and Statistical Methods1673
3.8.1 Mutation detection1674
To determine whether mutations are significantly above background noise, detection was1675
performed per locus against a panel of 31 healthy control samples, as follows:1676
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• At each interrogated locus, the background mutant allele fraction (AF) was determined1677
as the depth-weighted mean AF in control samples.1678
• For each primer pair, the mean + 4 standard deviation threshold was calculated in a1679
panel of control samples to give an expected false positive rate of 0.00006. Plasma1680
samples were classified as positive if any primer pairs crossed this threshold.1681
• When these thresholds were applied to the same control samples, a false-positive rate1682
of 0.0066 was observed.1683
3.8.2 Calculation of mean allele fraction1684
After loci were classified as detected/non-detected, non-detected loci were set as having an1685
allele fraction of zero for the calculation of mean allele fraction, then a depth-weighted mean1686
allele fraction was calculated across all patient-specific loci.1687
3.8.3 Receiver Operating Curve (ROC) analysis1688
easyROC [275] was used to fit ROC curves and determine the Area Under the Curve (AUC)1689
and standard error of the AUC.1690
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3.9 Supplementary Figures1691
*	
Sample type vs. adjusted R-squared value 
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Fig. 3.9 Box plots of R2 values between two samples sequenced with either TAm-Seq
or exome sequencing
Box plots show the adjusted R2 values based on the linear model fitted to the baseline vs.
progression mutant allele fraction data from Figures S1-S9. Two patients were excluded
from this analysis because their median plasma ctDNA mutant allele fraction was below
0.5% (using amplicon sequencing). Between baseline and progression time points, mutant
allele fractions in plasma showed a significantly higher R2 value than tumour sequencing
(P<0.05; one-sided Wilcoxon rank sum test).
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Fig. 3.10 Tumour and plasma mutation profiles - MR1002
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.























































































MR1004 mutation profile comparison
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Fig. 3.11 Tumour and plasma mutation profiles - MR1004
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.
























































































MR1006 mutation profile comparison
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Fig. 3.12 Tumour and plasma mutation profiles - MR1006
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.
















































































MR1010 mutation profile comparison
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Fig. 3.13 Tumour and plasma mutation profiles - MR1010
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.








































































MR1012 mutation profile comparison
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Fig. 3.14 Tumour and plasma mutation profiles - MR1012
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.













































































MR1014 mutation profile comparison
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Fig. 3.15 Tumour and plasma mutation profiles - MR1014
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.















































































MR1020 mutation profile comparison
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Fig. 3.16 Tumour and plasma mutation profiles - MR1020
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.

































































MR1022 mutation profile comparison
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Fig. 3.17 Tumour and plasma mutation profiles - MR1022
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.


















































































MR1032 mutation profile comparison
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Fig. 3.18 Tumour and plasma mutation profiles - MR1032
Panel A shows a heat map of mutant allele fractions for each patient-specific locus at matched
time points. Panel B compares mutant allele fractions between time points for each method.
Panel C shows a matrix of pairwise comparisons of mutant allele fraction. In panels B and
C, tumour mutations were classified as shared if they were detected in both tumour samples
(blue), or private if detected in only one (red), based on amplicon sequencing.
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Fig. 3.19 BRAF amplification in tumour and plasma - patient MR1004
Shallow WGS was used to assess copy number profile for patient MR1004 in both tumour
and plasma samples. Log2 ratios are shown for each bin. Bins were segmented and called as
described in Method 3.7.6. Blue indicates a called amplified segment, and yellow indicates a
deleted segment.
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LDH concentration over time
Fig. 3.20 Serum lactate dehydrogenase concentration over time
Serum LDH concentrations (IU/L) are plotted over time, and treatments are indicated by
shaded boxes. The upper limit of normal (250 IU/L) is shown with a horizontal line.

Chapter 41692
Monitoring ctDNA to parts per million1693
by integration of variant reads1694
4.1 Attribution1695
I developed the INVAR pipeline with Katrin Heider; all decisions on Figures included in1696
the manuscript were agreed by both Katrin and I following discussion, then approved by1697
Nitzan. This chapter is adapted from a manuscript we resubmitted in July 2018 (full citation1698
in Section 6.2).1699
I should emphasise that the INVAR project certainly was a two-person job (at least), as1700
it required us to carry out wet lab, dry lab, pipeline development tasks, and paper writing -1701
often in parallel. Our joint first co-authorship on the INVAR manuscript reflects this, and I1702
trust that the university will allow Katrin to use her fair share of our manuscript in her thesis.1703
I will detail our specific intellectual and experimental contributions below.1704
First, to summarise our contributions to this pipeline, the number of commits per person1705
to the Bitbucket repository are shown in Table 4.1. Once the data were processed with this1706
pipeline, Katrin and I proceeded to explore the data. The commits for this exploratory work,1707
data visualisation and summarisation for the paper are shown in Table 4.2.1708





Table 4.1 Bitbucket commits for the INVAR pipeline
Table of commits to the INVAR Bitbucket repository. Katrin Heider is another PhD student
in the lab (2015-19), working on custom capture sequencing for NSCLC. Eyal Fisher is a
mathematics MPhil student who carried out a 3-month rotation in our lab (during Spring
2018), who we consulted with to develop methods that we implemented in the pipeline. James
Morris is a bioinformatician in the lab who mentored us from a bioinformatics standpoint
throughout, and helped us troubleshoot errors in the pipeline.
Jonathan Wan 316
Katrin Heider 152
Table 4.2 Bitbucket commits for data exploration
Commits to the repository where we plotted all the figures for the INVAR paper. We jointly
ran all samples through the pipeline, and following data being output, we visualised the data
in this repository.
4.1.1 Methods line-by-line contribution1709
• Methods 4.6.1, 4.6.2 – Patient cohort. Sample and clinical information collection1710
and plasma sample processing were performed by the respective study co-ordination1711
teams.1712
• Methods 4.6.3 - 4.6.5 – Tumour and plasma DNA extraction, quantification and1713
library preparation. I performed these wet lab steps for the MELR (stage IV1714
melanoma) and AVAST-M (stage II-III resected melanoma) tumour and plasma sam-1715
ples, and Katrin did the same for the LUCID (stage I-IIIA NSCLC pre-surgery) samples1716
in parallel. These steps were performed with the aim of generated individualised cap-1717
ture sequencing data for each of our cohorts, suggested by Nitzan.1718
• Method 4.6.6 – Custom hybrid-capture panel design and sequencing of plasma.1719
Katrin and I independently generated custom hybrid-capture baitsets for each of our1720
cohorts, again suggested by Nitzan.1721
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• Methods 4.6.7, 4.6.8 – Exome and WGS of plasma with INVAR. After we demon-1722
strated that the INVAR method could be applied to custom capture sequencing data,1723
Katrin and I agreed that it in theory could be run on any deep sequencing data with1724
patient-specific mutations. Thus, I explored its use on exome and WGS data from1725
MELR plasma samples using plasma WES/WGS data I had previously generated.1726
To confirm the sensitivity of this approach, Katrin did the wet lab work to generate1727
additional plasma exome sequencing libraries.1728
• Method 4.6.9 – Experimental spike-in dilution series. I generated a spike-in dilution1729
series to test the sensitivity of using thousands of mutations as opposed to 50 mutations1730
which I had previously tested in the individualised TAm-Seq work. I applied the1731
sequencing panel designed in Method 4.6.6 to these dilution series.1732
• Method 4.6.10 – Imaging. Andrew Gill and Ferdia Gallagher analysed volumetric1733
CT imaging at time points matching with plasma sample data.1734
• Method 4.7.1 – Generation of patient-specific mutation lists. Tumour mutation1735
calling was performed using our in house pipeline, developed by our Bioinformatics1736
core. I ran the pipeline with some slight modifications for MELR and AVAST-M.1737
Katrin ran the pipeline on LUCID samples. We agreed on the filters jointly through1738
discussion and exploration of the data.1739
• Method 4.7.2 – Data processing and error-suppression. I modified our sequencing1740
data pipeline to take ThruPLEX Tag-Seq data, which has specific requirements for1741
pre-processing prior to read collapsing. After comparing error rates and proportions1742
of data retained, we opted for a family size of 2 (Fig. 4.28), similar to Newman et al.1743
[111]. Katrin and I jointly ran samples through the pipeline, and Katrin wrote scripts1744
to run multiple cohorts of samples at once.1745
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• Method 4.7.2 – Concatenation of data across time points. Nitzan suggested the1746
possibility of concatenating sequencing data to leverage signal across multiple time1747
points, which I implemented with the code shown.1748
• Method 4.7.3 – Data filtering. I suggested and implemented these filters. In addition,1749
instead of assessing background error rates by mutation class, I increased the resolution1750
into error rates by annotating each mutation with its trinucleotide context. Katrin and I1751
jointly explored this data on our respective cohorts and jointly reached the conclusion1752
that error rates should be evaluated by trinucleotide context. We changed the threshold1753
for identifying a noisy locus from  3 control samples to requiring signal in at least1754
10% of control samples.1755
• Method 4.7.4 – Feature annotation. Trinucleotide context-based error rates were1756
favoured over mutation class error rate, as I showed, and Katrin confirmed, variability1757
in error rate between different trinucleotide contexts within the same class. (Fig. 4.6).1758
For annotation with fragment size, Dineika Chandrananda had previously written a1759
script to obtain the fragment length of reads from a BAM file, which I adapted with1760
assistance from James Morris and incorporated in the pipeline.1761
• Method 4.7.5 – Patient-specific outlier suppression. I conceived and developed1762
this approach to identify ctDNA signal at a locus that is not consistent with all other1763
patient-specific loci. Katrin confirmed the utility of the approach on her cohort.1764
• Method 4.7.6 – Statistical model for detection, estimation of read length distribu-1765
tion and calculation of IMAF. All mathematical equations and their definitions were1766
written by Eyal Fisher (Mathematics MPhil rotation student) based on our discussions1767
of the problem and my previous approaches (data not shown). I wrote the explanatory1768
text around the equations. We worked together to integrate his code into the pipeline,1769
and I explored the resulting data. Katrin and I performed troubleshooting of the code.1770
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– Tumour allele fraction weighting. Katrin and I independently demonstrated1771
the potential utility of tumour allele fraction weighting from exploratory data1772
analysis in each of our cohorts. These findings were consistent with previous1773
studies on tumour heterogeneity [124]. We agreed that we should incorporate1774
this into the method, and so I outlined the problem to Eyal. Thus, Eyal wrote1775
an equation to incorporate tumour allele fraction (AFi) when calculating INVAR1776
likelihood ratios.1777
– Fragment size weighting. The Mouliere et al. [276] paper demonstrated the1778
potential sensitivity benefit of leveraging fragment sizes of ctDNA. However,1779
size-selection can cause drop out of rare mutant alleles when ctDNA levels are1780
very low, as is the case here. Therefore, Katrin and I discussed and agreed that1781
a size-weighting-based approach would be appropriate to boost signal where1782
possible, but retain all signal. We proposed this extension of the inclusion of size1783
to Eyal. I updated the pipeline’s code so that the format of the data would be1784
compatible with his size-weighting script.1785
– GLRT. Eyal selected an appropriate test to generate an output value based on1786
exploratory analyses on our samples and on in silico data.1787
• Method 4.7.7 - Estimation of the read length distribution. In order to perform1788
weighting by size, a reference size distribution is needed. Eyal highlighted the need1789
for this, and the need to smooth the distribution. I generated the data in an appropriate1790
format, and tested the effect of different levels of smoothing (Fig. 4.35).1791
• Method 4.7.8 – Calculation of IMAF. All equations and definitions in this section1792
were written by Eyal. I wrote the explanatory text following discussion with Eyal.1793
• Method 4.7.9 – Detection based on classification of INVAR scores. I wrote the1794
code in the pipeline to apply a ROC-based cut-off for INVAR score.1795
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• Method 4.7.10 – Calculation of informative reads. The concept of ‘informative1796
reads’ as a quantifier of sensitivity based on the total number of patient-specific reads1797
on target was suggested by Nitzan.1798
• Method 4.7.11 – Survival analysis. Kaplan-Meier analysis was performed by our1799
trial statistician (Andrea Marshall). We were blinded to patient outcomes. I provided1800
Andrea with ctDNA values and detection status for all samples in order for her to do1801
this.1802
• Method 4.7.12 – Estimated detection rates with fewer IR. I outlined the problem1803
to Eyal and he kindly provided us with an equation to calculate the 95% confidence1804
interval of a sample’s allele fraction given that zero mutant reads were detected in n IR.1805
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4.2 Summary1806
Circulating tumour DNA (ctDNA) is increasingly used to monitor tumour responses1807
[59, 151]. In patients with low disease burden, ctDNA detection rates are low due to1808
the presence of few or no copies of any individual mutation in each sample [129, 117].1809
Sensitivity may be increased by collecting larger plasma volumes, but this is not1810
feasible in practice. Here we demonstrate that sensitivity can be greatly enhanced1811
by analysing a large number of mutations via sequencing. Although cancers have1812
thousands of mutations in their genome [234], previously published work measured1813
only individual or up to 32 tumour-specific mutations in plasma [29, 59, 106, 117]. We1814
sequenced in plasma 102-104 mutated loci per patient, using custom capture panels,1815
whole exome or shallow (low-coverage) whole genome sequencing (WES/WGS).1816
We developed an analytical method for INtegration of VAriant Reads (INVAR) that1817
aggregates reads carrying tumour mutations, and uses a statistical model to assign1818
confidence to error-suppressed reads based on mutation context, fragment length1819
and tumour representation. We applied this algorithm to 143 plasma samples from1820
47 patients with stage II-IV melanoma, 19 patients with stage I-IIIA non-small cell1821
lung cancer (NSCLC), and 26 healthy individuals. ctDNA was detected to 1 mutant1822
molecule per million, and tumour volumes of ~1cm3. INVAR detected ctDNA in 66%1823
of patients with stage I-II NSCLC. In patients with stage II-III melanoma who relapsed1824
after resection, ctDNA was detected within 6 months of surgery and prior to relapse in1825
50% of cases. INVAR can enhance detection of ctDNA in samples with limited input1826
or sequencing coverage. Using WGS (0.6x) and WES data, ctDNA was detected to1827
concentrations of 10-4 by integrating data from thousands of mutant loci. As tumour1828
sequencing becomes more widespread, this method has potential to enhance detection1829
of minimal residual disease, and to enable routine cancer monitoring using low-depth1830
sequencing and from low-volume blood samples, which might be self-collected.1831
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4.3 Introduction1832
In patients with early-stage cancer [129], or patients at all stages undergoing treatment1833
[59], ctDNA concentrations can be low and may often result in false-negatives due to1834
sampling error, even for an assay with perfect analytical performance [59] (Fig.4.1).1835
Sequencing errors can further limit detection. To improve sensitivity, studies have1836
analysed larger volumes of plasma from multiple blood tubes [170, 185], and/or used1837
sequencing panels covering 18-507 genes (2 kb – 2 Mb of the genome) [117, 170,1838
203, 277, 278]. Analysis in plasma of up to 32 patient-specific mutations (identified1839
beforehand via tissue analysis) achieved detection to levels of 1 mutant molecule per1840
25,000 copies in a patient with NSCLC [106]. ctDNA was detected in <50% for1841
patients with stage I NSCLC [117, 203] and in only 13% of lung adenocarcinoma1842
cases [117]. In early-stage patients who underwent surgery and later relapsed, ctDNA1843
was detected after surgery in approximately 50% of breast or colorectal cancer patients1844

















Fig. 4.1 Targeting multiple mutations overcomes sampling error
Even with perfect analytical performance, a single-locus assay can fail to detect low ctDNA
levels due to random sampling of DNA fragments. This can be overcome by using multi-
plexed assays on the same sample.
To obtain information from a large number of mutations per patient, we sequenced1846
plasma DNA using custom capture panels, WES or WGS. In analysing sequencing1847
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data, ctDNA detection algorithms have previously relied on identification of individual1848
mutations [117, 170, 203], which uses limited information inefficiently: any signal1849
that does not pass a mutation calling threshold is discarded and lost. Studies have1850
highlighted the potential advantages of aggregating signal across multiple loci to detect1851
DNA from transplanted organs [7] or diluted tumour DNA [106], but this has not been1852
applied to monitor cancer in plasma. To efficiently use sequencing information from1853
plasma we developed INVAR. INVAR uses prior information from tumour sequencing1854
to guide analysis and aggregate signal across 102-104 loci which are known to be1855
mutated in the patient’s cancer. It considers biological and technical features of ctDNA1856
sequencing including trinucleotide error rate, ctDNA fragment length patterns and the1857
allele fraction of each mutation in the patient’s tumour (Fig. 4.2).1858
To identify patient-specific mutations, we performed tumour sequencing of 45 patients1859
with stage II-IV melanoma and 19 patients with stage I-IIIA NSCLC. After mutation1860
calling (Method 4.7.1), we generated patient-specific mutation lists (Supplementary1861
Figs. 4.26, 4.27 and Table 4.3), consisting of a median of 625 mutations per patient1862
with melanoma (IQR 411-1076) and 388 per patient with stage I-IIIA NSCLC (IQR1863
230–600). These lists were used as input for INVAR, together with plasma DNA1864
sequencing data generated using custom capture sequencing panels (2,301x mean1865
depth), WES (290x) and shallow WGS (sWGS, 0.6x, Fig. 4.3, Table 4.4).1866
The detection of ctDNA is limited by the amount of DNA analysed, which we evaluate1867
as the number of haploid genomes analysed (hGA), equivalent to the average dedupli-1868
cated sequencing coverage. In methods such as sWGS, DNA analysed is often <1 hGA1869
(less than 1x coverage), and although this is often generated from nanogram amounts1870
of DNA, it could in principle be generated from picograms of DNA. The number of1871
Informative Reads (IR) covering tumour-mutated loci are equal (on average) to the1872
number of hGA multiplied by the number of mutations analysed (Fig. 4.4, defined1873
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Plasma DNA from 
same patient
Plasma DNA from 
other individuals
ACGGCTACACGATCGACTTGTCGACTCAATGCGTAGCTA
Informative reads Control reads
Informative Reads
  (covering loci known to be
    mutated in this patient)
Tumour DNA mutation signal
Reads from other individuals
Background errors
ACGGCTACGCGATCGACTAGTCGACTCAATGAGTAGCTA
Fig. 4.2 INtegration of VAriant Reads concept
To overcome sampling error, signal was aggregated across hundreds to thousands of mutations.
Here we classify samples (rather than mutations) as being significantly positive for ctDNA,
or non-detected. Reads from a patient’s sample that overlap loci in the patient-specific
mutation list are indicated as ‘patient-specific’, whereas reads overlapping the same loci in
other patients are indicated as ‘non-patient-specific’. INVAR also incorporates additional




















Fig. 4.3 Experimental outline of study
Tumour sequencing was performed to identify patient-specific mutations, which are targeted
for high-depth sequencing data in matched plasma. In this study, custom capture sequencing,
exome and whole-genome sequencing were used on plasma samples.
in Method 4.7.10). For example, 105 IR may be generated from 10,000 hGA and 101874
mutated loci (deep sequencing of a narrow panel) or from 10 hGA across 10,000 loci1875
(wide coverage of limited input). In a sample with ctDNA mutant allele fraction of1876
10-5, observing a single mutant read across 105 IR would have a probability of 0.26 due1877
to binomial sampling statistics, but this increases to 0.96 with 5 x 105 IR, highlighting1878
the relationship between molecules sampled and the maximum sensitivity achievable.1879











Blood volume required 50 - 100 µL 1 - 10 mL 102 -103 mL




















































Fig. 4.4 Working points for ctDNA analysis
Illustration of the range of possible working points for ctDNA analysis using INVAR. Current
methods often focus on analysis of ~10ng of DNA (300-3,000 haploid copies of the genome)
across 1 to 30-50 mutations per patient. This results in ~10,000 informative reads (IR,
equivalent to hGA x targeted loci), leading to frequently encountered detection limits of
0.01%-0.1% [203, 117]. Increasing the number of hGA and the number of mutations targeted
result in a larger number of IR, and therefore, greater sensitivity.
We utilised integration of variant reads (INVAR) to explore the possible working points of
sensitivity that can be achieved using 103-104 mutations. We applied this method to samples
with both conventional levels of input mass (obtainable from millilitres of blood, red box)
and from limited input (~10 hGA, blue shaded box). Theoretically, high sensitivity can
be achieved through sampling larger volumes of blood, but often this may be unfeasible
in cancer patients. The shaded boxes show different possible working points for ctDNA
analysis. LOD, limit of detection; IR, informative reads; ng, nanogram; mL, millilitre.
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4.4 Results1880
4.4.1 Development of the INVAR algorithm1881
Error-suppression1882
Increasing the number of informative reads addresses sampling error. To reduce1883
the likelihood of false positive detection, the background error must be below the1884
reciprocal of IR. As part of the INVAR workflow (Fig. 4.2), we reduced background1885
error rates through the following: (i) by read-collapsing based on endogenous or1886
exogenous unique molecular identifiers (UMIs) [112], (ii) excluding signal that was1887
not supported by both forward and reverse reads, (iii) using a bespoke error model that1888
assesses error rates for different mutation contexts from data outside patient-specific1889
mutation lists, and (iv) excluding outlying signal from individual loci that were not1890
consistent with the distribution of signals from other loci in that sample (Supplementary1891
Fig. 4.32, Method 4.7.5). Together, these methods resulted in a combined reduction of1892
background error by 131-fold on average across trinucleotide contexts (Figs. 4.5, 4.6).1893























Read collapsing + + + + +
Locus noise filter + + +
Both F + R read + + +
Outlier-suppression +
Fig. 4.5 Reduction of error rates following error-suppression methods
Each mutation was required to be observed in both mates of a paired-end sequencing read,
and the given locus must be characterised as low-noise in control samples (Method 4.7.3).

























































































































































































Fig. 4.6 Error rates by trinucleotide context and mutation class following data filtering
Mismatch rates per trinucleotide context were determined (Method 4.7.4). Error rates
varied by more than an order of magnitude within the same mutation class, highlighting the
importance to assess loci with respect to their trinucleotide context.
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Signal-enrichment1894
Previous studies have shown relationships between tumour allele fraction and plasma1895
allele fraction [124, 125], and have shown size differences between mutant and wild-1896
type cfDNA fragments [65, 198]. To effectively use sequencing information, INVAR1897
enriches for ctDNA signal through probability weighting based on ctDNA fragment1898
sizes (Figs. 4.7) and each mutation’s allele fraction in tumour sequencing data (Fig. 4.8,1899
Method 4.7.6). After weighting, a significance level is generated for each of the loci1900
in the patient-specific mutation list, which are combined into an aggregate likelihood1901
function. The likelihood is converted to the INVAR score through comparison to the1902
cumulative distribution of likelihoods for control samples, such that the INVAR score1903
represents the estimated specificity level (1 minus the false positive rate) at which a1904
sample would be ‘detected’ with this score (Method 4.7.9). An integrated mutant allele1905
fraction (IMAF) is determined using a maximum likelihood estimator (Method 4.7.8).1906
102 Monitoring ctDNA to parts per million by integration of variant reads
Fig. 4.7 Fragment size profiles and enrichment ratios
Left panel, for each cohort, size profiles were generated for mutant and wildtype fragments.
The proportion of data per bin is shown. Wild-type data are shown in red, and mutant data
are shown in blue. The size of a nucleosome (166bp) is indicated with a dashed line, as is the
di-nucleosome (332bp).
Right panel, for each size range, the ratio between mutant and wild-type fragments for each
of the three cohorts was determined. This ratio between mutant and wild-type fragments for
a given size range indicates the extent of mutant fragment enrichment per bin. Size ranges











































Fig. 4.8 Tumour allele fractions of loci observed in plasma
Tumour allele fractions were compared between loci with vs. without detected signal in
plasma, showing that loci with signal in plasma have a significantly higher tumour allele
fraction in patient samples. There was no significant increase in tumour allele fraction when
the same analysis was performed on non-patient-specific samples, i.e. in patient samples but
at loci not belonging to that patient. Student’s t-test was performed. NS, not significant; ***,
p < 0.0001.































Fig. 4.9 Detection rate of mutations by tumour allele fraction
Using error-suppressed data, tumour loci were grouped into bins of 0.01 mutant allele
fraction, and the proportion of loci observed in plasma was determined for different levels of
a dilution series. The dilution level of the spike-in dilution series is indicated by each colour.
At each dilution level, there is a positive correlation between the tumour allele fraction and
proportion of loci observed in plasma.
4.4.2 Analytical performance of the INVAR algorithm1907
Dilution series1908
We evaluated the analytical performance of INVAR by analysis of sequencing from a1909
custom capture panel, in a dilution series of plasma from one melanoma patient, for1910
whom we had identified 5,073 mutations through exome sequencing (Method 4.6.9),1911
diluted into plasma from healthy control volunteers. Without error-suppression, the1912
lowest dilution detected with INVAR score >0.92 (equivalent to a specificity, calculated1913
in Method 4.7.6) had an IMAF of 10-4. Following error-suppression and size-weighting,1914
samples diluted in healthy control cfDNA down to an expected IMAF of 1 x 10-6 (11915
part per million, ppm) were detected with an INVAR score >0.92. Of 3 replicates1916
diluted to 1 ppm, two were detected with IMAF values of 9.2 ppm and 0.47 ppm. The1917
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correlation between IMAF and the expected mutant fraction was of 0.99 (Pearson’s r,1918
P = 4.2 x 10-12, Fig. 4.10).1919
We downsampled the sequencing data in silico to include only subsets of the patient-1920
specific mutation list (Method 4.6.9), which confirmed that a larger number of muta-1921












































Fig. 4.10 Spike-in dilution experiment of 5,073 patient-specific mutations to test the
sensitivity of INVAR
In non-error-suppressed data with INVAR, samples with allele fractions at or above 10-4
were detected. Using error-suppressed data with INVAR, ctDNA was detected in replicates
for all dilutions above 10-6, and in 2 of 3 replicates at the expected ctDNA concentration of 1
x 10-6. The dashed line indicates the allele fractions expected for every sample based on the
dilution factor.
Application on exome and WGS data1923
To test the ability to detect low levels of ctDNA with other types of sequencing data,1924
we also applied INVAR to WES data (median depth 238x) and sWGS data (median1925
depth 0.6x) generated from samples with IMAF down to 10-4. In exome sequencing1926



















Fig. 4.11 Sensitivity analysis with varying numbers of mutations
The number of loci analysed was downsampled in silico to between 1 to 5,000 mutations with
the highest observed mutant allele fraction in tissue (Method 4.6.9). With 5,000 mutations,
ctDNA was detected at 10-6 with 50% sensitivity.
data, ctDNA was detected in all samples (down to IMAF of 10-4) and the IMAF values1927
between custom capture and exome sequencing showed a correlation of 0.96 (Pearson’s1928
r, P = 9 x 10-12, Fig. 4.12). When WGS data was used, samples with ctDNA mutant1929
allele fractions down to 10-4 measured by custom capture were detected, although they1930
were observed at higher allele fractions due to the limited number of IR achieved using1931
sWGS.1932
These data show that the INVAR algorithm can be applied flexibly to data that is not1933
custom capture. Any sequencing data with reads overlying patient-specific sites may1934
be used, either by capture based or untargeted methods. By using 0.6x WGS for this1935
analysis, many of the loci have zero reads due to the low depth, but signal may still be1936





































































Fig. 4.12 Generalisation of INVAR to exome and sWGS
In addition to designing custom sequencing panels, we tested the application of exome and
low-coverage whole genome sequencing to a subset of samples with IMAF down to 10-4,
achieving detection in 100% of samples undergoing whole exome sequencing. Correlation in
IMAF between exome and custom capture was 0.96 (Pearson’s r, P = 1.3 x 10-11). Using
low-coverage whole genome sequencing, we detected and quantified ctDNA down to IMAFs
below 10-2.
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4.4.3 Quantification to parts per million in clinical samples1938
We applied INVAR to sequencing data generated using custom capture panels from1939
160 plasma samples from 47 stage II-IV melanoma patients and 19 plasma samples1940
from 19 stage I-IIIA NSCLC patients. We analysed a median of 625 mutations per1941
patient with melanoma and 388 per patient with stage I-IIIA NSCLC, resulting in up1942
to 2.9 x 106 IR per sample (median 1.7 x 105 IR), thus analysing orders of magnitude1943
more cell-free DNA fragments compared to methods that analyse individual or few1944
loci. Each sample analysed in this section is plotted in 2-dimensional space based on1945
the number of mutations and haploid genomes analysed in Supplementary Fig. 4.36.1946
We detected ctDNA levels ranging from 0.98 x 10-6 to 0.57 (Fig. 4.13, Tables 4.4, 4.5),1947
confirming a dynamic range of nearly 6 orders of magnitude, and detection of trace1948
levels of ctDNA in plasma samples from cancer patients to the ppm range, from a1949
median of 1638 copies of the genome (5.46 ng of DNA; Table 4.4). ctDNA was thus1950
confidently detected by INVAR in samples containing as little as 49 femtograms of1951
tumour DNA (0.007 of the amount of DNA in a single tumour cell). Given the limited1952
input, these ctDNA levels would be below the 95% limit of detection for a perfect1953
single-locus assay in 34% of the cases, which is indicated by the presence of a filled1954
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4.4.4 Comparison against clinical markers in advanced melanoma1956
Next, we compared the IMAF assessed by INVAR to other metrics for ctDNA levels1957
and other clinical markers in patients with unresectable stage IV melanoma. We1958
compared IMAF to the variant allele fraction (VAF) for ctDNA that was determined1959
by amplicon sequencing of an individual mutation, showing a Pearson’s correlation1960
of 0.85, (Fig. 4.14). Amplicon sequencing of BRAF or NRAS alone detected ctDNA1961
in 73% of longitudinal samples, with a minimum detected VAF of 0.01%, whereas1962
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Fig. 4.14 Comparison of INVAR IMAF values against amplicon sequencing
Amplicon sequencing was performed on a subset of samples with TAm-Seq [29], targeting
one mutation per patient, either a BRAF or NRAS mutation. A Pearson correlation of 0.85
was observed between the two methods.
IMAF was compared to tumour volume from CT imaging (Table 4.6,Method 4.6.10)1965
and to serum lactate dehydrogenase (LDH), a routinely used clinical biomarker for1966
melanoma. For one patient treated with vemurafenib, ctDNA was detected at IMAF as1967
low as 1.1 ppm, and the corresponding tumour volume was 1.3 cm3 (Fig. 4.15). We1968
found a correlation between IMAF and imaging of 0.8 (Pearson’s r, P = 6.7 x 10-10,1969
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Fig. 4.16), and a correlation of 0.82 between IMAF and LDH (Pearson’s r, P = 4 x1970
10-13, Fig. 4.17). Compared to other studies [111, 117], INVAR showed a steeper1971






































Fig. 4.15 INVAR monitors disease to parts per million and 1.3cm3
The shaded red box indicates the working point of INVAR using millilitres of plasma. ctDNA
was detected to 1.1 ppm during treatment with anti-BRAF targeted therapy, when disease
volume was on the order of 1cm3. ctDNA IMAF and tumour volume in cm3 are plotted over
time. Treatments are indicated by shaded boxes. ND, not detected.






























































































Fig. 4.16 Comparison between ctDNA and tumour volume in this study and others
ctDNA IMAF values were compared against tumour volume measurements by CT. These
data were also compared against previous publications measuring multiple mutations per





































































Fig. 4.17 Correlation between serum lactate dehydrogenase with IMAF in advanced
stage melanoma patients
A Pearson correlation score of 0.46 was observed between serum LDH and IMAF (P =
0.0058). A dashed line is drawn at 250 IU/L, the upper limit of normal for LDH. A smoothed
line was fitted to the data.
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4.4.5 Detection of stage I-IIIA NSCLC1974
We tested ctDNA detection by INVAR in plasma samples collected pre-treatment1975
from 19 patients with newly diagnosed stage I-IIIA NSCLC (consisting of 11, 6 and 21976
patients with stage I/II/IIIA). In two samples, ctDNA was not detected, but fewer than1977
2 x 104 IR were analysed due to a small number of mutations identified in WES of1978
matched tissue (59 and 93 in each case) and these were considered as non-evaluable1979
and discarded due to limited effective sensitivity (Method 4.7.9). Of the 17 evaluable1980
patients, the median number of IR was 5.6 x 104 (IQR 3.5-9.6 x 104). ctDNA was1981
detected in 12 out of 17 patients, including 2/5 patients with stage IA, 3/5 patients with1982
stage IB, 5/5 patients with stage II and 2/2 patients with stages III (Table 4.7). We1983
performed receiver operating characteristic (ROC) analysis to test different thresholds1984
of INVAR score to define detection in these patient and control samples (including both1985
plasma samples from healthy volunteers, and data from patients across non-matched1986
mutation lists, Method 4.7.9). The area under the curve (AUC) values were 0.72, 0.831987
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Fig. 4.18 ROC analysis of stage I-IIIA NSCLC cohort
ROC analysis was perfomed on the INVAR scores generated from stage I-IIIA NSCLC
patient samples. AUC values of 0.72, 0.83 and 0.995 were achieved for stage I (dotted line),
stage I-IIIA (dashed line) and stages II-IIIA (solid line), respectively. The ground truth was
defined by analysing a set of healthy individuals alongside the NSCLC patient samples.
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4.4.6 Detection of ctDNA post-surgery in stage II-III melanoma1989
To test INVAR in the residual disease setting, we analysed samples from 38 pa-1990
tients with resected stage II-III melanoma recruited in the UK AVAST-M trial (IS-1991
RCTN81261306, Table 4.8), collected up to 6 months after surgery with curative intent.1992
We interrogated a median of 1.65 x 105 IR (range 0.62 x 105 to 3.23 x 105) and detected1993
ctDNA (with INVAR score >0.93) to a minimum IMAF of 0.98 ppm. Of the evaluable1994
patients (n = 33, Method 4.7.9), ctDNA was detected in 50% of stage II-III patients1995
who later recurred, and was associated with a significantly shorter disease-free interval1996
(4.5 months vs. median not reached with 5 years’ follow-up; Hazard ratio (HR) = 3.69;1997
95% CI 1.44-9.46, P = 0.007; Fig. 4.19) and overall survival (2.6 years vs. median not1998
reached, Fig. 4.20). Using this method, the sensitivity of ctDNA to predict recurrence1999
was 50%, in contrast to previous analysis of plasma from 161 patients from the same2000
trial with resected BRAF or NRAS-mutant melanoma, where ctDNA was detected in2001
15.6% of patients who later relapsed using a single-locus digital PCR assay targeting2002
the respective BRAF/NRAS mutations [266].2003
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Fig. 4.19 Kaplan-Meier analysis of stage II–III melanoma patients for disease-free in-
terval
Kaplan-Meier analysis was performed based on ctDNA detection using INVAR. Disease-free
interval was significantly poorer in patients with ctDNA detected within 6 months following
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Fig. 4.20 Kaplan-Meier analysis of stage II–III melanoma patients for overall survival
Patients with detected ctDNA had a significantly poorer overall survival (P = 0.02, Cox
proportional hazards model). The median survival for patients with detected ctDNA was 2.6
years (95% CI 1.1-5.3) vs. median not reached (95% CI 3.1 – median not reached).
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4.4.7 Estimation of detection rates with varying IR2004
Using IMAF values from the clinical samples, we estimated the expected detection2005
rates for different cohorts of patients with fewer IR, and fitted a linear model (R22006
= 0.95). In stage IV melanoma patients prior to treatment, we detected ctDNA in2007
100% of cases with 105 IR (Fig. 4.21). In patients with stage IV melanoma undergoing2008
treatment, where ctDNA levels are lower, an extrapolation of the linear fit predicted 1062009
IR would enable detection of ctDNA in nearly all samples (Supplementary Fig. 4.39).2010
In patients with early-stage NSCLC, a linear extrapolation predicted that it may be2011
possible to detect ctDNA in nearly all patients if ~106 IR were sequenced for each2012
sample. In contrast, for stage II-III melanoma patients who undergo surgery, even2013
analysis of 107 IR is predicted to result in detection of ctDNA within 6 months of2014
surgery in only ~60% of patients who would relapse. Such depth of analysis may be2015
currently impractical based on sequencing costs and the amount of input DNA required2016
(Fig. 4.21).2017
4.4.8 Application of INVAR in limited input samples2018
Sensitive monitoring using sWGS data2019
We explored the applicability of INVAR to other scenarios, including low-input or low-2020
depth sequencing from plasma samples of cancer patients. High-sensitivity detection2021
of ctDNA from such sequencing data could potentially enable a generic and widely2022
applicable monitoring assay, and could also be applied to analyse minuscule blood2023
volumes, such as can be obtained from a pin-prick or dried blood spot (Fig. 4.22). We2024
showed that libraries can be generated from individual genome copies (Supplementary2025
Fig. 4.40) to demonstrate the feasibility of generating data from blood spots. Next,2026
we applied INVAR to sWGS data (0.6x coverage) from longitudinal samples from2027
4.4 Results 117

































Fig. 4.21 Estimated the detection rates of ctDNA for different IR sequenced
We observe a linear relationship (R2 = 0.95) between the number of IR and detection rate in
the baseline samples of the stage IV melanoma cohort (blue). ctDNA was detected in 100%
of these samples with 105 IR. Detection of ctDNA in follow-up samples required a larger
number of IR (Supplementary Fig. 4.39). In stage I-IIIA NSCLC at diagnosis (green) and
stage II-III melanoma post-surgery (red), linear relationships were observed between IR and
detection rates, and the predicted rates of detection of ctDNA were extrapolated.
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patients with stage IV melanoma, where ctDNA was quantified down to an IMAF2028
of 10-4 (Fig. 4.23). Analysis of 0.6 genomes (0.6 hGA) could hypothetically be2029
obtained from a sequencing library prepared from ~1-2 genome copies (after losses2030
from library preparation and sequencing), equivalent to the DNA from ~2µL plasma2031
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Fig. 4.22 Number of hGA vs. mutations targeted - low IR setting
Samples were either downsampled in silico to 10 hGA, or libraries were sequenced with 0.6x
WGS, equivalent to 0.6 hGA. 10 hGA were chosen to simulate the deduplicated sequencing
coverage obtainable from a single droplet of blood or blood spot (volume = 75µL, plasma
content = 55%, cfDNA concentration = 1-5ng/mL, library preparation efficiency = 30%,
giving 4-20 hGA per droplet/blood spot). The dark blue shaded box indicates the working
point achieved by INVAR with low input. The light blue shaded box indicates the potential
for monitoring using sWGS.
Detection and monitoring from 10 genome copies in silico2033
Theoretically, one blood drop may yield up to 60 genome copies, assuming a droplet2034
volume of 75µL, plasma content of 55%, cfDNA concentration of 1-5ng/mL [279];2035
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Fig. 4.23 Longitudinal monitoring of ctDNA by applying INVAR to sWGS
For 6 patients with >500 mutations, sWGS data was generated and deduplicated. The solid
lines and circles indicate low-depth IMAF values for each time point from sWGS. Filled
circles indicate detection at INVAR score >0.99. For samples with lower INVAR score,
the 95% confidence intervals of the ctDNA level are shown based on the number of IR
interrogated. ND, not detected, indicating the maximal likely IMAF with 95% confidence
intervals based on the number of IR sequenced.
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coverage. We therefore downsampled plasma sequencing data from stage IV melanoma2037
patients in silico to 10 hGA, to simulate the analysis of cfDNA from a droplet of blood.2038
We detected ctDNA in 90% of cases to concentrations of 10-4 (Fig. 4.24), and used2039




















Fig. 4.24 Assessment of sensitivity with 10 hGA with a spike-in dilution series
For 6 patients with >500 mutations, deduplicated sWGS data were generated. The same spike-
in dilution series (Method 4.6.9) was downsampled to 10 hGA, and sensitivity for detecting
ctDNA at estimated specificity (INVAR score) of 0.97 using INVAR was determined.
Different cancer types have different rates of mutations across the genome [234]. These2042
would result in varying numbers of IR in data from plasma cfDNA sequencing. With2043
WGS data available for each patient’s tumour and WGS data from 10 hGA of cell-free2044
DNA (obtainable from two blood droplets or spots), INVAR could theoretically detect2045
ctDNA at levels ranging from 4 to 330 ppm (Fig. 4.25). Previous work has shown2046
the feasibility of detecting fetal DNA in cell-free DNA samples collected prenatally2047
on dried blood spots [280, 281]. Given the sensitivity of detection we have shown2048
using INVAR analysis, it may in future be possible to monitor cancer by analysis of2049
DNA collected on dried blood spots to detect low concentrations of ctDNA, potentially2050
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4.5 Discussion2052
In summary, we described an algorithm that can achieve high levels of sensitivity2053
by integration of variant reads across hundreds to thousands of mutated loci. We2054
demonstrated ctDNA detection to parts per million, 1-2 orders of magnitude lower than2055
previous data [117, 170, 203, 277, 282]. In addition, this method enables the detection2056
of low concentrations of ctDNA in limited input samples, potentially even from a2057
few drops of blood. We showed that the INVAR algorithm can be applied to plasma2058
sequencing data from custom capture panels, exome sequencing and WGS. Leveraging2059
information from tumour sequencing, INVAR enables monitoring of ctDNA levels2060
from sWGS data with greater sensitivity than previously-described methods based2061
on copy-number analysis [114, 115]. As tumour sequencing becomes increasingly2062
implemented in personalised oncology, these data may be leveraged with INVAR to2063
enhance ctDNA monitoring, through limited plasma volumes and to greater levels of2064
sensitivity.2065
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4.6 Experimental Methods2066
4.6.1 Patient cohort2067
Samples were collected from patients enrolled on the MelResist (REC 11/NE/0312),2068
AVAST-M (ISRCTN81261306)30 and LUCID (REC 14/WM/1072) studies. MelResist2069
is a translational study of response and resistance mechanisms to systemic therapies2070
of melanoma, including BRAF targeted therapy and immunotherapy, in patients with2071
stage IV melanoma. AVAST-M is a randomised control trial which assessed the2072
efficacy of bevacizumab in patients with stage IIB-III melanoma at risk of relapse2073
following surgery; only patients from the observation arm were selected for this2074
analysis. LUCID is a prospective and observational study of stage I-IIIB non-small cell2075
lung cancer patients (NSCLC) who are planning to undergo radical treatment (surgery2076
or radiotherapy +/- chemotherapy) with curative intent. All studies were coordinated2077
by the Cambridge Cancer Trials Unit-Cancer Theme, and demographics and clinical2078
outcomes were collected prospectively.2079
4.6.2 Sample collection and processing2080
For patients with stage I-III melanoma or NSCLC, formalin-fixed, paraffin-embedded2081
tumour blocks and matched buffy coat samples were obtained. Fresh frozen tumour2082
biopsies prior to treatment were collected from patients with stage IV cutaneous2083
melanoma. For patients on the AVAST-M study, plasma samples were collected2084
within 12 weeks of tumour resection, with a subsequent sample after 3 months, where2085
available. Patients on the LUCID study had one plasma and matched buffy coat sample2086
taken pre-surgery. Longitudinal samples were collected during treatment of patients2087
with stage IV melanoma as part of the MelResist study. Peripheral blood samples were2088
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collected at each clinic visit in S-Monovette 9mL EDTA tubes. For plasma collection,2089
samples were centrifuged at 1600 g for 10 minutes within an hour of the blood draw,2090
and then an additional centrifugation of 20,000 g for 10 minutes was carried out. All2091
aliquots were stored at -80°C.2092
4.6.3 Tissue and plasma extraction2093
FFPE samples were sectioned into up to 8 µm sections, and one H&E stained slide2094
was generated, which was outlined for tumour regions by a histopathologist. Marked2095
tumour regions were macrodissected, and DNA extraction was performed using the2096
QIAamp DNA FFPE Tissue Kit using the standard protocol, except with incubation at2097
56°C overnight and 500 rpm agitation on a heat block. DNA was eluted twice using2098
20 µL ATE buffer each time with centrifugation at full speed. Following extraction,2099
DNA repair was performed using the NEBNext FFPE DNA Repair Mix as per the2100
manufacturer’s protocol.2101
Fresh frozen tissue biopsies were first homogenised prior to DNA extraction, which2102
was performed as follows: up to 30 mg of each fresh frozen tissue biopsy sample2103
was combined with 600 µL RLT buffer, then placed in a Precellys CD14 tube (Bertin2104
Technologies) and homogenised at 6,500 rpm for two bursts of 20 seconds separated by2105
5 seconds. Subsequently, the Qiagen AllPrep extraction kit as per the manufacturer’s2106
protocol.2107
Genomic DNA was extracted from up to 1 mL whole blood or buffy coat using the2108
Gentra Puregene Blood Kit (Qiagen) as per the manufacturer’s protocol. Samples2109
were eluted in two rounds of 70 µL buffer AE and incubated for 3 minutes before2110
centrifugation. Up to 4mL of plasma was extracted using the QIAsymphony (Qiagen)2111
with a QIAamp protocol. DNA was eluted in 90 µ l elution buffer and stored at -80°C.2112
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Plasma samples were extracted using the QIAsymphony instrument (Qiagen) using a2113
2-4mL QIAamp protocol. For each QIAsymphony batch, 24 samples were extracted,2114
which included a healthy individual control sample (Seralab).2115
4.6.4 DNA quantification2116
Following extraction of fresh frozen, FFPE and genomic DNA eluted DNA concen-2117
tration was quantified using a Qubit fluorimeter with a dsDNA broad range assay2118
(ThermoFisher Scientific). To quantify cfDNA concentration of plasma DNA eluates,2119
digital PCR was carried out using a Biomark HD (Fluidigm) using a Taq-man probe2120
for the housekeeping gene RPP30 (Sigma Aldrich). 55 PCR cycles were used. The2121
RPP30 assay was 65 bp in length. The estimated number of RPP30 DNA copies per2122
µl of eluate was used to determine the cfDNA concentration in the original sample.2123
4.6.5 Library preparation2124
Tumour2125
FFPE tumour tissue DNA samples (up to 150 ng) and buffy coat DNA samples (75 ng)2126
were sheared to a length of 150, using the Covaris LE 220 (Covaris, Massachusetts,2127
USA). The standard Covaris protocol for a final fragment length of 150bp and an input2128
volume of 15µl using the 8 microTUBE-15 AFA Beads Strip V2 was used. After2129
the shearing, the fragmentation pattern was verified using a Bioanalyser (Agilent).2130
Sequencing libraries were prepared using the ThruPLEX DNA-seq kit (Rubicon).2131
100ng and 50ng sheared tumour and buffy coat DNA were used, respectively, and the2132
protocol was carried out according to the manufacturer’s instructions. The number of2133
amplification cycles was varied during library preparation according to the manufac-2134
turer’s recommendations. Fresh frozen tumour biopsies and matched buffy coat library2135
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preparation was performed as described by Varela et al. [274] using the SureSelectXT2136
Human All Exon 50 Mb (Agilent) bait set. Samples were multiplexed and sequenced2137
with a HiSeq 2000 (Illumina).2138
Library concentration was determined using qPCR with the Illumina/ROX low Library2139
Quantification kit (Roche). Library fragment sizes were determined using a Bioanalyser2140
(Agilent). After library preparation, exome capture was performed with The TruSeq2141
Exome Library Kit (Illumina), using a 45Mbp exome baitset. Three libraries were2142
multiplexed in one capture reaction and 250ng of each library was used as input. For2143
compatibility with ThruPLEX libraries, the protocol was altered by adding 1µl of i52144
and i7 TruSeq HT xGen universal blocking oligos (IDT) during each hybridisation2145
step. To compensate for the increased hybridisation volume, the volume of CT3 buffer2146
was adjusted to 51 µ l. Two rounds of hybridisations were carried out, each lasting for2147
24 hours. Library QC was performed using qPCR and Bioanalyser, as above. Samples2148
were multiplexed and sequenced with a HiSeq 4000 (Illumina).2149
Plasma2150
cfDNA samples were vacuum concentrated at 30°C using a SpeedVac (ThemoFisher)2151
prior to library preparation where required. Library preparation for plasma cfDNA2152
was performed using the Rubicon ThruPLEX Tag-Seq kit. The number of PCR am-2153
plification cycles during the ThruPLEX protocol was varied between 7-15 cycles, as2154
recommended by the manufacturer. Following amplification and sample barcoding, li-2155
braries were purified using Ampure XT beads (Beckman Coulter) at a 1:1 ratio. Library2156
concentration was determined using the Illumina/ROX low Library Quantification kit2157
(Roche). Library fragment sizes were determined using a Bioanalyser (Agilent).2158
For the stage IV melanoma cohort, library preparation and sequencing was run in2159
duplicate to assess the technical reproducibility of the experimental and computational2160
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method, showing a correlation between IMAF values generated by the INVAR pipeline2161
of 0.97 (Pearson’s r, P < 2.2 x 10-16). For the early-stage cohorts, input cfDNA material2162
was not split and was instead prepared and sequenced as a single sample per time point.2163
4.6.6 Custom hybrid-capture panel design and sequencing of plasma2164
Following tumour mutation calling (Method 4.7.1), custom hybrid-capture sequencing2165
panels were designed using Agilent SureDesign software. Between 5 and 20 patients2166
were grouped together per panel in this implementation. Baits were designed with 4-5x2167
density and balanced boosting for melanoma patients and 1x density and balanced2168
boosting for lung cancer patients. 95.5% of the variants had baits successfully designed;2169
bait design was not reattempted for loci that had failed. Custom panels ranged in size2170
between 1.26-2.14 Mb with 120 bp RNA baits, designed based on patient-specific2171
mutation lists generated by mutation calling (Fig. 4.26, Method 4.7.1). Individualised2172
capture was performed on 213 libraries (Table 4.4).2173
Libraries were captured either in single or 3-plex (to a total of 1000 ng capture input)2174
using the Agilent SureSelectXT protocol, with the addition of i5 and i7 blocking oligos2175
(IDT) as recommended by the manufacturer for compatibility with ThruPLEX libraries2176
[283]. Custom Agilent SureSelectXT baits and 13 cycles of post-capture amplification2177
were used. Post-capture libraries were purified with Ampure XT beads at a 1:1.8 ratio,2178
then were quantified and library fragment size was determined using a Bioanalyser2179
(Agilent).2180
4.6.7 Exome capture sequencing of plasma2181
For exome sequencing of plasma, the Illumina TruSeq Exome capture protocol was2182
followed. Libraries generated using the Rubicon ThruPLEX protocol (as above) were2183
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pooled in 3-plex, with 250ng input for each library. Libraries underwent two rounds of2184
hybridisation and capture in accordance with the protocol, with the addition of i5 and2185
i7 blocking oigos (IDT) as recommended by the manufacturer for compatibility with2186
ThruPLEX libraries [283]. Following target enrichment, products were amplified with2187
8 rounds of PCR and purified using AMPure beads prior to QC.2188
4.6.8 Low-depth whole-genome sequencing of plasma2189
For WGS, 30 libraries were sequenced per lane of HiSeq 4000, achieving a median2190
of 0.6x deduplicated coverage per sample. For these libraries, since the number of2191
informative reads (IR) would limit sensitivity before background errors would become2192
limiting, we used error-suppression with family size 1 for this particular setting. Error2193
rates per trinucleotide were compared between WGS and custom hybrid-capture2194
sequencing data for family size 1 data, showing a Pearson r of 0.91.2195
WGS data underwent pre-INVAR data processing, as described in Methods 4.7.22196
and 4.7.3, except the minimum depth at a locus was set to 1, and patient-specific2197
outlier-suppression was not used because loci with signal vs. loci without signal will2198
only show allele fractions of 0 or 1, given an average depth of 0.6x.2199
4.6.9 Experimental spike-in dilution series2200
Plasma DNA from one patient with a total of 5,073 patient-specific variants was serially2201
diluted 10-fold in a pool of plasma cfDNA from 11 healthy individuals (Seralab) to2202
give a dilution series spanning 1-100,000x. Library preparation was performed, as2203
described in Method 4.6.5, with 50ng input per dilution. The healthy control cfDNA2204
pools were included as control samples for the determination of locus error rate to2205
identify and exclude potential SNP loci.2206
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To assess the sensitivity of INVAR with smaller panel sizes, the spike-in dilution series2207
was downsampled to between 1 and 5,000 patient-specific loci. Given the relationship2208
between tumour allele fraction and plasma mutation representation (Fig. 4.8), any2209
smaller panel for INVAR should be based on clonal mutations with highest priority,2210
with lower allele fractions included only if plasma sequencing data is sufficiently broad.2211
Thus, we iteratively sampled the data with replacement from each of the dilution2212
series sequencing libraries (with 50 iterations), then selected the top N mutations. The2213
locus with the highest mutant allele fraction was the BRAF V600E mutation. After2214
downsampling the number of loci, outlier-suppression (Method 4.7.5) was repeated on2215
all samples except for the single BRAF V600E locus data.2216
4.6.10 Imaging2217
CT imaging was acquired as part of the standard of care for each patient of the stage2218
IV melanoma cohort and were examined retrospectively. Slice thickness was 5 mm2219
in all cases. All lesions with a largest diameter greater than 5 mm were outlined2220
slice by slice on the CT images by an experienced operator, under the guidance of a2221
radiologist, using custom software written in MATLAB (Mathworks, Natick, MA).2222
The outlines were subsequently imported into LIFEx software in NifTI format for2223
processing. Tumour volume was then reported by LIFEx as an output parameter from2224
its texture based processing module.2225
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4.7 Bioinformatics and Statistical Methods2226
4.7.1 Generation of patient-specific mutation lists2227
We generated patient-specific mutation lists for 64 patients with stage II-IV melanoma2228
and stage I-IIIA lung cancer. A median of 625 (IQR 411-1076) and 388 (IQR 230-2229
600) patient-specific mutations were identified per patient with melanoma and lung2230
cancer, respectively (Figs. 4.26, 4.27, Table 4.3). These mutation lists were used both2231
to design custom capture sequencing panels, and as input for the INVAR algorithm2232
(Method 4.7.6).2233
For fresh frozen tumour biopsies, mutation calling was performed as described by2234
Varela et al. [274]. For FFPE tumour biopsies, mutation calling was performed with2235
Mutect2 with the default settings: –cosmic v77/cosmic.vcf and –dbsnp v147/dbsnp.vcf.2236
To maximise the number of mutations retained, variants achieving Mutect2 pass2237
(LUCID and AVAST-M samples) OR tumour LOD > 5.3 were retained (AVAST-M2238
samples), with the additional filters:2239
– Buffy coat mutant allele fraction equals zero2240
– Mutation not in homologous region2241
– Mutation not at a multiallelic locus2242
– 1000 Genomes ALL and EUR frequency equals zero2243
– A minimum tumour depth of 5.2244
– For FFPE data in the melanoma cohort, the filter for C/A errors proposed by2245
Costello et al. [284] was applied to suppress C/A artefacts arising from library2246
preparation of FFPE samples.2247



















































































Fig. 4.26 Individualised sequencing panel mutation profiles
The number of somatic mutations per patient is shown, coloured by cancer type. Patients are
ordered by increasing number of mutations per mutation list.
Stage IV melanoma
Stage II-III melanoma

































































































































Fig. 4.27 Tumour mutation profiles by trinucleotide context
Mutation counts by trinucleotide context, coloured by mutation class. The allele fraction
distribution is shown for each cohort. The Stage I-IIIA NSCLC and stage II-III melanoma
cohorts were called from FFPE material, and the stage IV melanoma cohort was called from
fresh frozen tumour material.
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4.7.2 Data processing and error-suppression2248
Cutadapt v1.9.1 was used to remove known 5’ and 3’ adaptor sequences specified2249
in a separate FASTA of adaptor sequences. Trimmed FASTQ files were aligned to2250
the UCSC hg19 genome using BWA-mem v0.7.13 with a seed length of 19. Error-2251
suppression was carried out on ThruPLEX Tag-seq library BAM files using CONNOR2252
[285]. The consensus frequency threshold -f was set as 0.9 (90% consensus), and the2253
minimum family size threshold -s was varied between 2 and 5 for characterisation of2254
error rates (Fig. 4.28). For custom capture and exome sequencing data, a minimum2255





















































































Fig. 4.28 Background error rates with and without error-suppression
Error suppression was performed using CONNOR [285] with different minimum family
size requirement settings, ranging from 1 to 5. To assess background error rate, 10 bp
either side of patient-specific loci were used, excluding the patient-specific locus itself
(‘near-target’). Background error rates were calculated by aggregating all non-reference
bases across all bases considered. Left panel, error suppressed and non-error suppressed
background error rates. Right panel, overall background error rates resulting from different
family size requirements, and proportion of read families retained with each setting.
To leverage signal across multiple time points, error-suppressed BAM files can be2257
combined using ‘samtools view -ubS - | samtools sort -‘ prior to further data processing.2258
In the early-stage melanoma cohort (AVAST-M), where samples were available at2259
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both 3 and 6 month time points post-surgery, BAM files were run through the INVAR2260
pipeline both individually (Table 4.4) and after merging (Figs. 4.19, 4.20).2261
4.7.3 Data filtering2262
The INVAR pipeline takes error-suppressed BAM files, a BED file of patient-specific2263
loci, and a CSV file indicating the tumour allele fraction of each mutation and which2264
patient it belongs to. It is optimised for a cluster running Slurm. The workflow is2265
shown in Fig. 4.29. Briefly, the pipeline assesses wild-type and mutant reads at patient-2266
specific loci in all samples, and this data is annotated with trinucleotide error rate,2267
locus error rate, which patient the mutation belongs to, tumour allele fraction, fragment2268
size, presence in both F and R reads, and whether the signal at that locus is an outlier2269
relative to all other patient-specific loci in that sample (Method 4.7.5). Following2270
data annotation, signal is aggregated across all patient-specific loci in that sample2271
to generate both an INVAR score, equivalent to a specificity (Method 4.7.6) and an2272
integrated mutant allele fraction (IMAF), which is the estimate of ctDNA level based2273
on the INVAR algorithm (Method 4.7.8).2274
SAMtools mpileup 1.3.1 was used at patient-specific loci based on a BED file of2275
muations, with the following settings: –ff UNMAP, –q 40 (mapping quality), –Q 202276
(base quality), –x, –d 10,000, then multiallelic calls were split using BCFtools 1.3.1.2277
Next, all TSV files were annotated with 1,000 Genomes SNP data, COSMIC data, and2278
trinucleotide context using a custom Python script. Output files are then concatenated,2279
compressed, and read into R. First, based on prior knowledge from tumour sequencing2280
data, all loci were annotated per patient with being either: patient-specific (present in2281
patient’s tumour) or non-patient-specific (not present in patient’s tumour, or individual2282
does not have cancer). Since each non-patient-specific sample contains the loci from2283
multiple patients, every non-patient-specific sample may control for all other patients2284
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Fig. 4.29 Overview of the INVAR workflow
INVAR utilises plasma sequencing data and requires a list of patient-specific mutations,
which may be derived from tumour or plasma sequencing. Filters are applied to sequencing
data, then the data is split into: patient-specific (locus belonging to that patient), non-patient-
specific (locus not belonging to that patient), and near-target (bases within 10 bp of all
patient-specific loci). Patient-specific and non-patient-specific data are then annotated with
features that influence the probability of observing a real mutation. Outlier-suppression
is applied to identify mutant signal inconsistent with the overall level of patient-specific
signal. Next, signal is aggregated across all loci, taking into account annotated features, to
generate an INVAR score per sample. Based on non-patient-specific samples, an INVAR
score threshold is determined based on ROC analysis for each cohort.
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analysed with the same sequencing panel or method (excluding loci that are shared2285
between individuals). Next, the following filters were applied to both patient-specific2286
and non-patient-specific data:2287
– Data points were excluded if MQSB < 0.01 (mapping quality / strand bias).2288
– Multi-allelic sites were identified, and were blacklisted if 3 different alternate2289
alleles were observed with error-suppressed read families in the dataset. Loci2290
with 2 separate alternate alleles observed in the dataset were only excluded if2291
there were more than 2 error-suppressed reads of the minor alternate allele.2292
– Loci were blacklisted on the basis of strand bias if they showed a ratio between2293
F and R mutant reads <0.1 or >10, with mutant signal in at least three separate2294
samples.2295
– Loci that showed mutant signal in >10% of the control samples were excluded2296
(Fig. 4.30). When determining the error rate per locus, all other patients who2297
were genotyped as negative for that mutation may serve as controls for the patient2298
of interest, since 99.8% of mutations are private to each patient.2299
– Mutation signal had to be represented in both the F and R read of that read2300
pair (Fig. 4.31). This both serves to reduce sequencing error and causes a size-2301
selection for fragments, retaining fragments <300bp as PE150 sequencing was2302
performed (only mutant signal in the overlapping region of the F and R read can2303
be retained). The resulting error-suppression is analogous to tools that merge2304
paired-end reads [286].2305
The effects of combining each of these filters on the background error rate are shown2306
in Fig. 4.31.2307
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Blacklisted loci = 3.77%
Fig. 4.30 Allele fraction distribution of loci removed by the locus-noise filter
For each patient-specific locus, the error rate was determined in all other patient samples.
Loci were blacklisted if they showed signal in >10% of control samples, or had an overall
allele fraction of >1% in control samples. The distribution of allele fractions of blacklisted
and non-blacklisted loci that had non-zero allele fraction are shown.
4.7.4 Feature annotation2308
After data filtering, data was annotated with both locus-specific error rate and trinu-2309
cleotide error rate. Locus-specific error rate is calculated as the background error rate2310
at that locus in control samples for the patients-specific mutation. Since the estimation2311
of locus-specific error rate is limited by the number of control samples and cfDNA2312
molecules at that locus, we also assessed trinucleotide error rate. Trinucleotide error2313
rates were determined from the region up to 10bp either side of every patient-specific2314
loci (excluding patient-specific loci), and data was pooled across all similar trinu-2315
cleotide contexts. After pooling data in this manner, a median of 3.0 x 108 informative2316
reads (or deduplicated reads) per trinucleotide context were analysed. Trinucleotide2317
error rate was calculated as a mismatch rate for each specific mutation context. If a2318
trinucleotide context had zero mutant deduplicated reads, the error rate was set to the2319
reciprocal of the number of IR/deduplicated reads in that context.2320










































































































































































































































































































Fig. 4.31 Effect of each noise filter on background-error rate
For each trinucleotide, background error rates are plotted before and after each background
error filter, i.e. requiring signal in both reads, and a locus noise filter (Method 4.7.3). Each
filter produced a separate effect: requiring signal to be present in both forward and reverse
reads only reduced error rates of trinucleotides with error < 5 x 10-5.
In addition, each data point was annotated with the cfDNA fragment size of that read2321
using a custom Python script. Then, to eliminate outlier signal that is not consistent with2322
the remainder of that patient’s loci, we performed patient-specific outlier suppression2323
(Method 4.7.5, below).2324
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4.7.5 Patient-specific outlier-suppression2325
Patient-specific sequencing data consists of informative reads at multiple known patient-2326
specific loci, providing the opportunity to compare mutant allele fractions across loci as2327
a means of error-suppression. The distribution of signal across loci potentially allows2328
for the identification of noisy loci not consistent with the overall signal distribution.2329
Each locus was tested for the probability of having observed mutant reads given the2330
average signal across all loci (Figs. 4.32, 4.33). Loci observed with significantly greater2331
signal than the remainder of the loci might be due to noise at that locus, contamination,2332
or a mis-genotyped SNP locus. The possibility of a mis-genotyped SNP becomes2333
increasingly likely when a large number of mutation loci are targeted by INVAR.2334
For each sample, the IMAF was determined across all loci passing pre-INVAR data2335
processing filters with mutant allele fraction at that locus of <0.25; loci with signal2336
>0.25 mutant allele fraction were not included in the calculation because (i) in the2337
residual disease setting, loci would not be expected to have such high mutant allele2338
fractions (unless they are mis-genotyped SNPs), and (ii) if the true IMAF of a sample2339
is >0.25, when a large number of loci are tested, they will show a distribution of2340
allele fractions such that detection is supported by having many low allele fraction2341
loci with signal. Based on the ctDNA level of the sample, the binomial probability2342
of observing each individual locus given the IMAF of that sample was calculated.2343
Loci with a Bonferroni corrected P-value <0.05 (corrected for the number of loci2344
interrogated) were excluded in that sample, thereby suppressing outliers. As a result of2345
outlier-suppression, background noise was reduced 2.3-fold in control samples, while2346
retaining 94.7% of signal in patient samples (Fig. 4.33).2347





































































































































































































































































Fig. 4.32 Effect of outlier-suppression on mutant signal
Effect of outlier-suppression in early-stage NSCLC cohort. Loci observed with significantly
greater signal than the remainder of the loci of that patient might be due to noise at that locus,









































Fig. 4.33 Summary of effect of outlier-suppression on all three cohorts
Following patient-specific outlier-suppression, background noise was reduced 2.3-fold in
control samples, while retaining 94.7% of signal in patient samples.
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4.7.6 Statistical model for detection2348
We developed a statistical method to model the number of mutant reads at multiple2349
patient-specific loci, incorporating prior information available from patient-specific2350
sequencing, such as the background error of that trinucleotide context, the tumour2351
allele fraction at that locus, and fragment length. This approach aggregates signal2352
across multiple patient-specific mutations after error-suppression (Method 4.7.2). In2353
this model, we test the significance of the number of mutant reads at each locus given2354
the trinucleotide error rate of that context. Trinucleotide error rates were used instead2355
of locus-specific error rates in order to determine an accurate estimation of background2356
error rates to 10-7 (Fig. 4.6). Locus-specific error rates were previously used to identify2357
loci with recurrent signal in control samples (Method 4.7.3).2358
Tumour allele fractions and trinucleotide error rates were considered as follows: Denote2359
AFi as the tumour mutant allele fraction at locus i, ei as the background error in the2360
context of locus i, and let p be the integrated mutant allele fraction of a sample (IMAF,2361
estimated using an expectation maximisation algorithm in Method 4.7.8). A random2362
read at locus i can be observed to be mutant either if it arose from a mutant molecule, or2363
an incorrectly sequenced wild type DNA molecule; this event occurs with probability2364
qi:2365
qi = AFi · (1  ei) · p+(1 AFi) · ei · p+ ei · (1  p)
Testing for the presence of ctDNA is now equivalent to testing the statistical hypothesis2366
H0 : p = 0. Assuming the number of observed mutant reads is independent between2367
loci, the following likelihood function can be produced:2368








qiMi j(1 qi)1 Mi j ,
where Mi j is the indicator for mutation in read j of locus i, and Ri is the number of reads2369
in locus i. The above method allows weighting of signal by tumour allele fraction,2370
which we confirm influences plasma mutation representation in patient samples with2371
early stage and advanced disease (Fig. 4.8), and in the spike-in dilution series from2372
one patient (Fig. 4.9, Method 4.6.9).2373
Each sequencing read provides fragment size information, which may be used to2374
separate mutant from wild-type molecules and produce an enrichment in ctDNA2375
(Fig. 4.7). Probability weighing was preferred over size selection to avoid allelic2376
loss at ultra-low allele fractions, suggested by Fan et al. [208] in the non-invasive2377
prenatal testing setting. Therefore, read length information can also be incorporated2378
into the likelihood. The read length distribution of mutant and wild-type fragments2379
was estimated in Methods 4.7.7. This approach is in contrast to size-selection and2380
may be considered as a size-weighting step alongside tumour AF weighting that was2381
performed above. Fragment sizes for each sequencing read may be incorporated to the2382
INVAR algorithm. To do so, let Li j be the length of read i of locus j. The likelihood2383








P(Mi j,Li j|e,AF, p).
Assuming that given the source of the read (mutant or wild-type DNA), the read length,2385
and mutation status are independent, we can factor the likelihood as follows:2386






















eimi j · (1  ei)1 mi j · p0(li j) · (1  p)+g
mi j
i · (1 gi)
1 mi j · p1(li j) · p,
where zi j is the indicator that read j of locus i came from ctDNA, pk(li j) =P(li j|zi j = k),2387
and gi = AFi · (1  ei)+(1 AFi) · ei. The above method weights the signal based on2388
both fragment length of mutant and wild-type reads, though in this implementation of2389
INVAR, we set the weight of all wild-type size bins to be equal, thereby neglecting2390
size information from wild-type reads. Lastly, a score is generated for each sample2391
through aggregation of signal across all patient-specific loci in that sample using the2392
Generalized Likelihood Ratio test (GLRT). The GLRT directly compares the likelihood2393
under the null hypothesis against the likelihood under the maximum likelihood estimate2394





The higher the value of the likelihood ratio, the greater evidence for ctDNA presence in2396
a sample. Classification of samples was performed based on comparison of likelihood2397
ratios between patient and control samples (Method 4.7.9).2398
4.7.7 Estimation of the read length distribution2399
Size-weighting with INVAR depends on first having a known distribution of sizes of2400
mutant and wild-type reads against which to perform weighting. In order to estimate2401
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the read length distribution with the greatest accuracy, we used all wild type and mutant2402
reads from healthy samples and patients from each of the cohorts, and used kernel2403
density estimation to smooth the respective probabilities.2404
The size distributions and enrichment ratios per bin for each of the studied cohorts are2405
shown in Fig. 4.7. We demonstrated that the early stage cohorts were not significantly2406
different in size profile, whereas the advanced melanoma cohort had a significantly2407
greater proportion of di-nucleosomal fragments despite downsampling of data to a2408
similar number of reads (Fig. 4.34). Thus, data from both early stage cohorts were2409
pooled to generate a prior distribution of the size of mutant and wild-type fragments,2410
























































































Fig. 4.34 Comparison of mutant fragment distribution between cohorts
Fragment size distributions were compared using a two-tailed Wilcoxon rank test. Data
were first downsampled to the same number of reads. Stage IV melanoma patients show
a significantly longer mutant size profile compared to the early stage cohorts. NS, not
significant; *** = P < 0.0001.
To estimate the probability that a read is of length l, given that the cell of origin of2412
wild type, P(L = l|z = 0), we used all of the wild-type reads from each pooled data set.2413































Fig. 4.35 Effect of smoothing size profile data
In order to weight fragment sizes, mutant and wild-type size profiles were characterised and
smoothed to varying extents (Methods 4.7.7). For each level of smoothing, the distribution
of mutant and wild-type fragment sizes is shown.
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For both of the data sets, we used the R function "density", with a Gaussian kernel, to2414
smooth the estimated probabilities, and obtained a density estimate f̂ (l|Z = z). Finally,2415
to estimate P(L = l|Z = z), we integrated the respective density: P(L = l|Z = z) =2416
R l+0.5
l 0.5 f̂ (t|Z = z)dt.2417
Smoothing the size distribution estimates is important in data sets where data is sparse2418
to avoid assigning too large a weight to any given mutant fragment.2419
4.7.8 Calculation of IMAF2420
In this section we derive an Expectation Maximization (EM) algorithm to estimate2421
IMAF (integrated mutant allele fraction). If we treat the tumor of origin zi j, as a latent2422
variable, and assume that is known, the joint likelihood of Z, M (Mi j is the indicator2423
for a mutation in read j of locus i), L (Li j is the length of read i of locus j), AF (AFi is2424










eimi j · (1  ei)1 mi j · p0(li j) · (1  p)
⇤1 zi j ·
⇥
gmi ji · (1 gi)
1 mi j · p1(li j) · p
⇤zi j
(4.1)
We can now use EM to find a maximum likelihood estimate for p, and taking the2427
expectation of the likelihood with respect to zi j. The log-likelihood is linear in zi j,2428
so taking the expectation of the likelihood amounts simply to replacing the Zi j with2429
their expectation at stage l, zli j = E(zi j|mi j, li j, pl), where pl is the best estimate of p at2430
iteration l. An estimate for pl is obtained by taking the derivative with respect to pl2431
and equating it to zero:2432









The above is simply the expected proportion of reads from ctDNA at stage l.2433
Bayes’ theorem can be used to compute zli j:2434
zli j =P(zi j = 1|mi j, li j, pl)=
P(mi j|zi j = 1) · p1(li j) · p
P(mi j|zi j = 1) · p1(li j) · p+P(mi j|zi j = 0) · p0(li j) · (1  p)
.
By substituting the respective probabilities we obtain:2435
zli j =
gmi ji (1 gi)1 mi j p1(li j)p
gmi ji (1 gi)1 mi j p1(li j)p+ e
mi j
i (1  ei)1 mi j p0(li j)(1  p)
The algorithm proceeds by alternating the maximization of p, and taking the expecta-2436
tion of the zi js.2437
4.7.9 Detection classification based on INVAR scores2438
For each sample, the likelihood ratio (LR) was determined, as above. To accurately2439
assess the background LR distribution, reads from each control sample were iteratively2440
resampled with replacement and the GLRT script run. To convert each LR into an2441
INVAR score for each sample, the proportion of controls with an equal or lower LR2442
was calculated, making the INVAR score analogous to a specificity value.2443
Using control samples, the cut-off for INVAR score was determined using ROC2444
analysis using the ‘OptimalCutpoints’ package in R [287] . To minimise the risk of any2445
patient-specific contamination of signal at non-patient-specific control loci (through2446
de novo mutations overlapping with patient-specific sites), only patient samples with2447
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patient-specific IMAF <1% were used as controls for determination of the cut-point.2448
ROC analysis gave INVAR score thresholds varying between 0.92-1.00 for the above2449
cohorts, which are provided in Table 4.5. Samples with INVAR scores greater than2450
their respective threshold were classified as detected.2451
4.7.10 Calculation of informative reads (IR)2452
The number of informative reads (IR) for a sample is the product of the number of2453
mutation targeted (i.e. length of the mutation list) and the number of haploid genomes2454
analysed by sequencing (hGA, equivalent to the deduplicated coverage following read-2455
collapsing). Thus, the limit of detection for every sample can be calculated based on2456
1/IR (with adjustment for sampling mutant molecules based on binomial probabilities).2457
For non-detected samples, the 1/IR value provides an estimate for the upper limit2458
of ctDNA in that sample; this allows quantification of samples even if no mutant2459
molecules are present, and is utilised in Fig. 4.23 to demonstrate quantification to 10-42460
using sWGS data. Also, samples with limited sensitivity can be identified and classified2461
as a ‘low-sensitivity’ or ‘non-evaluable’ group, where the INVAR algorithm is limited2462
by the number of IR. In this study, we aimed to quantify ctDNA with sensitivity2463
greater than other methods, and so we classified samples with non-detected ctDNA2464
with <20,000 IR as low-sensitivity and thus non-evaluable. Across the cohorts in this2465
study, 7 patients were non-evaluable with these criteria.2466
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4.7.11 Survival analysis for resected stage II-III melanoma cohort2467
Disease-free interval (DFI), and overall survival were calculated from the date of2468
randomisation of the AVAST-M trial to the date of first recurrence or date of death,2469
respectively [266]. Kaplan-Meier analysis was used to generate survival curves for2470
differences between DFI and OS in patients with detected ctDNA vs. non-detected2471
levels and compared using a Cox proportional hazards model to obtain hazard ratios2472
and 95% CIs.2473
4.7.12 Estimated detection rates with fewer informative reads2474
Based on the IMAFs of detected samples, detection rates can be estimated where fewer2475
IR were achieved with a perfectly sensitive assay. For a given number of IR, the value2476
of p that would be detected with 95% sensitivity can be determined as follows:2477
p = 1  elog(1-0.95)/IR
Thus, for each entry in a vector of IR values (102, 103 . . . 107), the detection rates for2478
cancer were calculated per cohort, and are plotted in Fig. 4.21. The maximum value2479
of the vector of IR values was set to be larger than the maximum number of IR per2480
sample in that cohort, rounded to the nearest order of magnitude. For the stage II-III2481
melanoma patients, detection was defined as the sensitivity for patients who relapsed2482
within 5 years. Linear regression was used to calculate R2 values for each cohort.2483
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Stage II-III melanoma (post-surgery)
Stage I-IIIA NSCLC
Stage IV melanoma
Fig. 4.36 Number of hGA vs. mutations targeted in the conventional input setting
The shaded red box indicates the working point of INVAR using millilitres of plasma.
Samples are coloured by cohort. Dashed diagonal lines indicate the number of IR achieved for
a given number of hGA and targeted loci. hGA, haploid genomes analysed; IR, informative
reads.
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Heatmap of each mutation
Fig. 4.37 Heatmap of individual mutations over time
For each patient with stage IV melanoma, a heatmap showing their mutations over time is
plotted. Each line represents one patient-specific mutation. Mutations are either filled or not
filled, based on the mutation being observed in plasma or not observed, respectively. The
effect of sampling error for individual mutations at low levels of ctDNA can be observed.
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Multiple mutations - INVAR
Data type
Fig. 4.38 Comparison of INVAR IMAF against amplicon sequencing mutant allele frac-
tion in advanced stage melanoma patients
Amplicon sequencing was performed on a subset of samples with TAm-Seq [29], targeting
one mutation per patient, either a BRAF or NRAS mutation. A Pearson correlation of 0.85
was observed between the two methods.
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Fig. 4.39 Detection rate with varying IR in melanoma pre- and post-treatment initiation
We estimated the detection rates of ctDNA for different levels of IR (Method 4.7.12). We
observe a linear relationship (R2 = 0.95) between the number of IR and detection rate in the
baseline samples of the stage IV melanoma cohort (blue). ctDNA was detected in 100% of
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Fig. 4.40 Library preparation from individual genome copies
Preparation of DNA libraries from restricted inputs. Libraries were prepared from diluted
samples ranging from 3 – 500 haploid genome copies. Cycle threshold values were compared
to non-template control (red).
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Fig. 4.41 Monitoring stage IV melanoma patients using data downsampled in silico to
10 hGA
ctDNA was monitored to 2 x 10-4 IMAF using 10 hGA, which is equivalent to 10 genome




































































































































































































Table 4.4 Details of libraries sequenced (truncated)
This table lists all the patient plasma DNA sequencing datasets analysed by INVAR. For each sample/analysis, this indicates sample
details, QC metrics following sequencing, and ctDNA IMAF values following the application of the INVAR algorithm. Samples were
non-evaluable if they had no ctDNA signal and <20,000 IR due to the limited sensitivity achieved (Method ??). The table has been
truncated to show the data structure; the full table is available upon request. IR, informative reads (see Methods); LR, likelihood
ratio; IMAF, integrated mutant allele fraction; INVAR score, output of INVAR algorithm based on evidence for ctDNA, scaled to be
equivalent to specificity.
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Table 4.5 INVAR score thresholds
This table gives details on each of the cohorts, the experimental method performed to generate
data, and the INVAR score threshold used (determined by ROC analysis, Method 4.7.9).
Minimum family size setting was used in read-collapsing (Method 4.7.2).
Table 4.6 Tumour volume data
This table shows the CT imaging data for stage IV melanoma patients, processed according
to Methods 4.6.10.
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Table 4.7 Detection summary for stage I-IIIA NSCLC cohort
Detection and median IMAF values are shown by stage for the stage I-IIIA NSCLC cohort.
Totals for the whole NSCLC cohort are shown in the bottom row. IR, informative reads;
IMAF, integrated mutant allele fraction.
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Table 4.8 Summary of patient characteristics in the stage II-III melanoma cohort




In this thesis, I describe an approach I developed in collaboration with my colleagues2505
(listed in the attribution sections throughout) for enhanced detection and monitoring2506
of ctDNA. Given a patient-specific mutation list, INVAR aggregates signal across a2507
large number of loci, and weights signal based on characteristics of patient-specific2508
ctDNA sequencing data. We demonstrate that this method is not limited to custom2509
capture data, but may also be applied to WES and WGS data. The INVAR algorithm2510
(Chapter 4) builds upon our understanding of mutation representation in plasma and2511
patient-specific sequencing generated by amplicon sequencing (Chapter 3).2512
This thesis focuses on patient-specific sequencing data, where between 101-104 known2513
tumour-mutated loci were interrogated using plasma sequencing. When interrogating2514
multiple mutations, signal may be considered either at each individual locus, or signal2515
may be aggregated across all loci (taking into account the differences in error rate and2516
other characteristics between loci). Initially, amplicon sequencing (TAm-Seq) was2517
used to target up to 62 mutations per patient, then we moved towards using broader2518
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sequencing methods (i.e. custom-capture sequencing, WES and WGS) in order to2519
generate plasma sequencing data at up to 5,036 patient-specific mutations. At the same2520
time as moving to capture sequencing, in order to reduce background error rates, we2521
used molecularly barcoded library preparation kits (whole-genome amplification kits).2522
The differences between the sequencing data are shown in Table 5.1.2523
By combining both error-suppression and a large number of mutations with a novel2524
analytical method using hybrid-capture data, we improved sensitivity for ctDNA from2525
conventional levels of 0.01% mutant allele fraction to 0.0001% (1 ppm). This approach2526
utilised the learning from our TAm-Seq work which showed the benefit of targeting2527
multiple mutations, and that private mutations are represented less well in the plasma.2528
Moving to non-amplicon-based sequencing methods allowed exploratory analyses into2529
the relationship between fragment size and mutation detection, which has previously2530
been studied [198, 65]. Together, these learning points were combined and formalised2531
as the INtegration of VAriant Reads algorithm, a method for sensitive detection and2532
quantification of ctDNA in a sample using a list of patient-specific mutations. Aside2533
from demonstrating 1-2 orders of magnitude greater sensitivity in plasma than previous2534
studies [106], we also showed that by targeting a large number of loci, samples with2535
limited input DNA (and limited sequencing, i.e. sWGS) can be leveraged for sensitive2536
detection to 0.01%, again orders of magnitude of more sensitive than copy-number-2537
based analyses of sWGS data [115].2538
5.2 Patient-specific amplicon sequencing2539
Patient-specific amplicon sequencing panels for 9 patients with stage IV melanoma2540
were designed based on tumour exome sequencing of metastatic tumour biopsies.2541
Suzanne Murphy and I performed amplicon sequencing on longitudinal plasma samples2542




Number of mutations 10-100 102-104 >102-104




Samples per lane of
HiSeq4000 (to achieve
⇠1,000x depth)
>300 ⇠5-10† 1–30 (0.5-15x depth)
Table 5.1 Properties of sequencing data generated
In this thesis, amplicon, hybrid-capture and whole-genome sequencing data were generated
and analysed with patient-specific detection algorithms.
*Error-suppression by read-collapsing can only be performed with WGS data if the library
input mass is restricted, thereby allowing families of sufficient size to be generated.
†Dependent on off-target rate of the capture kit.
from those patients and re-sequenced the tumour DNA eluates with the same method2543
to confirm the allele fractions of those mutations. These data allowed two separate2544
analyses: in Section 3.5.1, we performed comparisons of mutation profiles between2545
matched plasma and tumour samples in order to assess mutation representation in2546
plasma; and in Section 3.5.2, we analysed the longitudinal ctDNA profiles for these2547
patients, assessing the sensitivity of amplicon sequencing with individual and multiple2548
mutations.2549
5.2.1 Tumour vs. plasma comparison2550
In Chapter 3, Amplicon sequencing of matched tumour and plasma samples allowed2551
comparisons between mutation profiles with >10,000x depth per locus. This analy-2552
sis highlighted that while longitudinal metastatic tumour biopsies showed variable2553
mutation profiles, mutation profiles of longitudinal plasma samples from the same2554
patients showed a lesser degree of change over time. Of course, these samples are2555
temporally separated and are thus subject to clonal evolution. However, sampling error2556
164 Discussion
may confound such analyses. Therefore, we suggest that combined analysis of tumour2557
samples and matched plasma samples would be most informative in order to interpret2558
tumour mutation profile data. One possible future approach could be to correct tumour2559
allele fractions by plasma allele fractions, i.e. weighting tumour mutation profiles by2560
their representation in plasma.2561
However, this analysis is currently limited, at present, by not knowing the ground truth2562
as to whether: (a) the plasma mutation profiles are truly representative of the tumour,2563
and the tumour biopsy is subject to sampling error, or (b) the tumour biopsies are2564
accurate, but the factors affecting release of ctDNA vary such that mutation profiles2565
in plasma remain relatively constant between samples. In future, comparing each2566
of the mutation profiles against FFPE tumour mutation profiles would provide an2567
additional sample against which to compare. Alternatively, instead of trying to show2568
which sample type is more ‘true’, we can accept that both are confounded each in their2569
own ways. Thus, it might be appropriate to generate mutation profiles that consist2570
of the product the mutation profiles of the tumour and plasma. This approach would2571
effectively assign equal weight to tumour and plasma samples, and might overcome2572
some of the sampling biases from each, allowing for more accurate monitoring of2573
clonal evolution. The mutation detection approach in each of the sample types would2574
still remain separate, in case tumour samples and cfDNA samples show different error2575
profiles.2576
5.2.2 Sensitivity analysis from multiple mutations2577
After comparing time points where we had matched tumour and plasma samples, we2578
then analysed longitudinal plasma samples using the same method of patient-specific2579
TAm-Seq. In this analysis, we showed preliminary evidence for the sensitivity benefit2580
of targeting multiple mutations to overcome sampling error, using both a dilution2581
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series of patient plasma cfDNA (Fig. 3.4) and clinical samples (Fig. 3.7). By targeting2582
multiple patient-specific loci, we detected and quantified ctDNA to a mean mutant2583
allele fraction of 0.01%, over an order of magnitude lower than what was shown in the2584
original TAm-Seq study [29]. This level of sensitivity is approaching the theoretical2585
limit of detection given the background error rates of this method, indicating that to2586
improve detection rates further, background error rates must be suppressed.2587
We did not attempt to improve background error rates of TAm-Seq in this study. This2588
could have been performed experimentally, for example, by adapting the experimental2589
protocol to include molecular barcodes through ligation prior to the rest of the TAm-2590
Seq workflow (the published depicted in Fig. 5.1). Alternatively, error-suppression2591
to a lesser degree could be achieved (with the existing data) through generating the2592
consensus sequence between the forward and reverse mates from a paired-end read,2593
with a tool such as ‘Paired-End reAd mergeR’ [286], as was applied to the Abbosh et2594
al. amplicon sequencing study [117]. Paired-end read merging is particularly suited2595
to amplicon sequencing of cfDNA data because of the short fragment size of cfDNA,2596
combined with the even smaller amplicon size (~90bp), since any fragment shorter than2597
150bp would be read entirely in both directions (using PE150 sequencing). Despite2598
not implementing PEAR in any of the methods in this thesis, the concept of error-2599
suppression based on F and R mates was later used in the INVAR algorithm since any2600
mutant signal was required to be present in both reads of the pair (Method 4.7.3).2601
To improve the sensitivity of TAm-Seq would require both molecular barcodes and a2602
larger number of mutations to be targeted. However, the number of mutations targetable2603
with TAm-Seq is limited since during the pre-amplification step, if too many primer2604
pairs are multiplexed, they may form primer-dimers, or show reduced efficiency of2605
amplification [288].2606
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Fig. 5.1 TAm-Seq outline
Dilute or degraded cfDNA is pre-amplified by PCR to amplify rare events. Each amplicon
of interest then undergoes a single-plex PCR in order to achieve similar coverage across
PCR amplicons. Next, a barcoding PCR is carried out, where sample barcodes and Illumina
adaptors are added. Molecular barcodes would need to be annealed to each individual
molecule, then a limited PCR amplification is performed prior to the pre-amplification step.
Taken from [29].
5.3 Patient-specific capture sequencing2607
In order to target a larger number of loci than was possible with TAm-Seq, we next2608
considered patient-specific hybrid-capture approaches, which can target megabases2609
of the genome. Balancing of bait concentrations is handled by the manufacturer, so2610
that validation of individual baits does not have to be performed again in our lab. In2611
addition, we could leverage existing molecularly barcoded library preparation kits to2612
reduce error rates. Lastly, capture sequencing data also retains greater information on2613
the starting fragment, such as the fragment size and its start and end position.2614
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Starting with the same patient-specific mutations lists generated for the 9 stage IV2615
melanoma patients in Chapter 3, we generated a custom sequencing panel where all2616
mutations passing relaxed QC filters were included (Method 4.7.1). We aimed to2617
maximise the number of mutations targeted, since we initially wanted to explore the2618
factors that influence the representation of a given mutation in plasma. This relaxed2619
filtering strategy still persists in our design of custom capture panels, since we can now2620
assign weight to mutation signals based on the confidence of the tumour call rather2621
than restricting the mutation list and losing the signal permanently.2622
We designed custom sequencing panels using Agilent SureDesign software and Agilent2623
SureSelectXT capture kits (Method 4.6.6). We generated sequencing data with 1,000-2624
2,000x depth at each of the patient-specific loci of interest; these depth values will2625
undoubtably rise as sequencers with greater output become available, and as kits with2626
lower off-target rates are used. Eventually, if sequencing becomes cheap enough, WES2627
or WGS approaches would allow the panel design step to be avoided altogether, as we2628
suggest in Fig. 4.12. However, saturating levels of sequencing for WGS are currently2629
too costly, and so patient-specific panels will give deeper sequencing at loci of interest2630
for the foreseeable future.2631
5.3.1 Overcoming limited data for background-error estimation2632
One of the challenges of patients-specific sequencing data is that of generating adequate2633
control data for every patient-specific locus. For fixed sequencing panels, the same2634
panel can be run on many samples to accurately characterise differences between2635
mutations, though this process must be repeated for each new patient-specific panel.2636
Therefore, we opted to assess background error rates not only per locus, but also per2637
trinucleotide context, based on findings that each mutation class has its own error2638
rate [106]. This allowed identification of the noisiest loci (based on locus-specific2639
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noise), and for loci with zero background error in control samples, we leveraged the2640
background error rate of that context. Of course, greater granularity in error rates could2641
be obtained by assessment of contexts of >3nt (e.g. 5nt context), though the compute2642
required increases rapidly with each additional base pair in the context.2643
5.3.2 Reduction of background noise further2644
Aside from using molecular barcoding for error-suppression, we developed additional2645
filtering steps to reduce error further. Firstly, We required signal to be present in2646
both F and R mates of the paired end read. This served the dual purpose of reducing2647
background error rates (Fig. 4.5), and also excludes long cfDNA fragments from the2648
analysis (since fragments >300bp simply cannot have any overlapping reads using2649
PE150 sequencing). This effectively acts as a size-selection step, which may enhance2650
detection of the early-stage cancer samples, since their mutant signal arose entirely2651
from fragments less than 200bp. In advanced disease, we observed mutant signal in2652
fragments of length indicative of dinucleosomal cfDNA; these fragments would be2653
lost, but ctDNA levels were sufficiently high such that detection was still supported by2654
short fragments.2655
In addition, we also developed a method of outlier-suppression for loci that showed2656
signal greatly above the rest of the patient-specific loci in that sample (Method 4.7.5).2657
This was based on the observation in our data that at the lowest levels of ctDNA,2658
sampling error is expected, and that signal should only ever look like individual2659
molecules at individual loci, and should not be multiple mutant reads all at one locus2660
when all other loci are negative. This approach is only possible when a patient-specific2661
mutation list of 100 to >1000 mutations is available, because it relies on identifying2662
loci that are different in allele fraction to the remainder. We find that in our data, noise2663
is reduced to ~50% while >90% of signal in patient samples is retained.2664
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5.3.3 Signal-weighting2665
In order to detect the lowest levels of ctDNA, it is important to maximise the number2666
of informative reads (IR, collapsed reads overlying patient-specific mutation loci,2667
Fig. 4.4), since the limit of detection achievable is related to the reciprocal of IR. Thus,2668
instead of using hard thresholds on fragment size or tumour allele fraction, which2669
would result in increases in observed ctDNA signal (but could cause loss of the signal2670
entirely, as shown by Fan et al. [208]), we instead opted for an approach of weighting2671
signal by tumour allele fraction (Fig 4.8) and fragment size (Fig. 4.7).2672
Tumour loci were weighted based on tumour allele fraction, which varies between2673
0 and 1, and thus provides a straightforward approach for weighting based on the2674
product of the signal and the tumour allele fraction. However, it may not always be the2675
case that a higher allele fraction mutation should be assigned greater confidence than2676
those with lower allele fraction, since the number of mutant reads supporting the call,2677
the mutation context etc. should also be considered. Thus, in future, it may be more2678
appropriate to use a probability given by the mutation caller to perform weighting. For2679
example, Mutect2 outputs a ’LOD score’, which is a log-odds score for the confidence2680
in the mutation based on the number of mutant reads given the depth at that locus and2681
the error rate [289]. However, in order to utilise LOD scores in the current INVAR2682
code, each value would have to be translated to values between 0 and 1, as LOD scores2683
can range between <10 to 1 x 106 [290].2684
Signal was further enhanced based on fragment size profiles, since it is known that2685
short fragments are more likely to be tumour-derived [65]. Previous analyses have2686
used size-selection approaches [199], though hard cut-offs for signal may result in true2687
mutant signal being lost [208]. Therefore, we opted for a weighting-based approach2688
in order to retain such signal by assigning weight based on what we know about the2689
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enrichment ratio for ctDNA for a given fragment size. However, the current challenges2690
of this weighting-based approach are as follows:2691
– Firstly, size-weights are assigned based on all the size data available for that2692
cancer type and stage. Although the size profile is smoothed to compensate for2693
limited data (Method 4.7.7), any deviation from the ground truth confounds the2694
analysis.2695
– Currently, size-weighting is performed per sample relative to the fragment size2696
profile of that cohort (Method 4.7.6). Although the size profile is smoothed, there2697
is still some data in the profile that is from that same sample, meaning that the2698
size-weighting is partially circular. This should be addressed with a leave-one-out2699
style of analysis whereby the sample is weighted based on the size profiles of all2700
other samples only. This would take longer to compute since the fragment size2701
profile of the n 1 cohort would be recalculated each time.2702
5.3.4 Biological limitations of sensitive detection2703
Based on the INVAR method of aggregation and weighting of signal, we were able to2704
quantify ctDNA to parts per million (Fig. 4.13) in early- and advanced-stage disease.2705
Quantification to parts per million was made possible by sequencing millions of infor-2706
mative reads (IR), which was only possible by knowing tumour mutations in advance.2707
To boost sensitivity further, the number of IR will have to increase correspondingly.2708
For example, in order to reach 107 IR, 104 loci would need to be identified (only WGS2709
can achieve this), and 3,000x deduplicated coverage (or haploid genomes analysed,2710
hGA) needs to be reached (Fig. 4.4).2711
We suggest that 107-108 IR is the upper limit of the sensitivity of INVAR. The error2712
rate is not the limiting factor, since background error rates down to 10-12 can be reached2713
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through duplex sequencing [99, 106]. Instead, the expected number of mutations per2714
whole genome of a cancer [234] and the volume of blood possible to draw at once2715
becomes limiting. In this study, melanoma and NSCLC patient samples were used in2716
order to maximise the number of detected mutations per exome, and thereby maximise2717
the sensitivity achieved with this approach. To achieve adequate sensitivity in cancer2718
types such as renal cancer or ovarian (which have low mutation rates) would require2719
tumour WGS to be performed since tumour WES would detect an insufficient number2720
of mutations to reach the levels of sensitivity described in this thesis. Furthermore,2721
the maximum blood volume that it is feasible to take at once in clinic (<30-50mL)2722
places a hard limit on sensitivity. Larger volumes may be taken using methods such as2723
plasmapheresis, though this may be impractical and difficult to scale for routine use.2724
Alternatively, larger volumes may be taken if patients were to have blood sampling on2725
consecutive days, but again this may not be practical or acceptable for patients.2726
It is possible that we are approaching the maximum possible sensitivity of ctDNA-2727
based analyses, and that further improvements would require a multi-modal approach2728
whereby other nucleic acids or proteins are targeted in addition to ctDNA. This has2729
been borne out by recent developments, which have shown that platelet RNA can be2730
used to accurately classify both early and advanced stage cancer patients [221]. In2731
addition, a combined protein and ctDNA-based approach showed improved detection2732
relative to ctDNA alone [291]. The ideal combination of tests would utilise every part2733
of the blood sample with minimal waste, thereby maximising the sensitivity achieved2734
from the fewest blood tubes possible.2735
5.3.5 Application of INVAR to limited-input samples2736
By targeting a large number of mutations, INVAR can aggregate signal across loci2737
when there are few hGA. Low hGA can arise from low input DNA, or low sequencing2738
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depth, or both, since the number of error-suppressed families generated is a function2739
of input DNA mass and the extent of oversequencing. We show that ctDNA can be2740
quantified to 10-4 from sWGS data (equivalent to 0.6 hGA), and similarly detect ctDNA2741
to 10-4 in custom capture sequencing data that was downsampled to 10hGA. Since2742
10hGA may be obtained from the volume of plasma from a drop of blood, we suggest2743
that INVAR might enable monitoring using limited blood volumes. This would allow2744
pin-prick diagnostics, and potentially could allow self-collection of blood by patients2745
onto card, which may be later extracted in a centralised laboratory.2746
So far, we have shown that given >0.6 hGA, the INVAR algorithm can quantify disease2747
to 10-4. However, we have not yet proven whether >0.6 hGA can be obtained from a2748
blood drop. Theoretically, one blood drop may yield up to 60 genome copies, assuming2749
a droplet volume of 75µL, plasma content of 55%, and cfDNA concentration of 1-2750
5ng/mL [279]; with a library preparation efficiency of 30%, this may yield 4-20 hGA.2751
Thus, to address this, we will perform DNA extraction from dried blood spots and will2752
apply INVAR. We will start with dried blood spots, rather than miniscule volumes of2753
blood, since blood spots can be easily stored on Whatman FTA (filter paper) cards at2754
ambient temperature for at least 11 years [292], and can be easily shipped. Dealing2755
with miniscule blood volumes would require the use of specialised collection devices2756
[293], which may enable multiple potential applications, but are less readily available2757
than filter paper cards, and would cost more to manufacture and ship.2758
For these future blood spot experiments, I expect that there will be dilution of signal2759
caused by white blood cell lysis and release of genomic DNA (gDNA). Thus, we2760
will start by analysis of high ctDNA samples in order to quantify any potential drop2761
in ctDNA IMAF due to this dilution effect. At the same time, we will characterise2762
the fragment size profile of these samples to try identify any potential differences in2763
size profile between cfDNA and fragmented gDNA, which could indicate whether an2764
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in vitro or in silico size-selection are warranted, in order to exclude as many gDNA2765
fragments as possible.2766
5.4 Conclusion2767
INVAR can be applied to reach sensitivity to parts per million, or can allow monitoring2768
with limited input amounts down to the levels of sensitivity that are commonly applied2769
today by other methods. INVAR depends on the availability of previous mutation lists2770
from the patient’s cancer sequencing (demonstrated here from tumour sequencing,2771
but this can be obtained at higher costs from plasma sequencing when ctDNA levels2772
are high). Thus, this approach addresses a specific clinical context and need, i.e. for2773
sensitive monitoring following surgery or initation of immunotherapy, where tumour2774
mutation information is available.2775
Patients increasingly undergo broader and deeper tumour sequencing, either to identify2776
actionable mutations [294, 295], to assess tumour mutation burden for immunother-2777
apies [294], or in large clinical or genomic studies where WGS is being performed2778
[296]. We suggest that as sequencing costs decline further, INVAR-like algorithms2779
could have increasing applicability and utility for sensitive monitoring either from2780
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Vladimír Palička. Carrier molecules and extraction of circulating tumor DNA3148
for next generation sequencing in colorectal cancer. Acta Medica, 59(2):54–58,3149
2016.3150
References 187
[71] Marie-Theres Gansauge and Matthias Meyer. Single-stranded DNA library3151
preparation for the sequencing of ancient or damaged DNA. Nature Protocols,3152
8(4):737–48, 2013.3153
[72] Philip Burnham, Min Seong Kim, Sean Agbor-Enoh, Helen Luikart, Hannah A3154
Valantine, Kiran K Khush, and Iwijn De Vlaminck. Single-stranded DNA library3155
preparation uncovers the origin and diversity of ultrashort cell-free DNA in3156
plasma. Scientific Reports, 6(February):27859, 6 2016.3157
[73] S. V. Kostyuk, E. M. Malinovskaya, a. V. Ermakov, T. D. Smirnova, L. V.3158
Kameneva, O. V. Chvartatskaya, P. a. Loseva, E. S. Ershova, L. N. Lyubchenko,3159
and N. N. Veiko. Fragments of cell-free DNA increase transcription in human3160
mesenchymal stem cells, activate TLR-dependent signal pathway, and suppress3161
apoptosis. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry,3162
6(1):68–74, 2012.3163
[74] Sachiko Nishimoto, Daiju Fukuda, Yasutomi Higashikuni, Kimie Tanaka,3164
Yoichiro Hirata, Chie Murata, Fukiko Sato, Masahiro Bando, Shusuke Yagi,3165
Takeshi Soeki, Tetsuya Hayashi, Issei Imoto, Joo-Ri Kim-Kaneyama, Fukiko3166
Sato, Masahiro Bando, Shusuke Yagi, Takeshi Soeki, Tetsuya Hayashi, Issei3167
Imoto, Hiroshi Sakaue, Michio Shimabukuro, and Masataka Sata. Obesity-3168
induced DNA released from adipocytes stimulates chronic adipose tissue in-3169
flammation and insulin resistance. Science Advances, 2(March):1–12, 2016.3170
[75] Jerker Porath and Stanley M Gartler. Cellular Uptake of Deoxyribonucleic Acid3171
by Human Tissue Culture Cells. Nature, 184(4697):1505–1506, 11 1959.3172
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